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Abstract 
Background: The introduction of highly active antiretroviral therapies (HAART) in 
1996 to treat patients living with the human immunodeficiency virus type 1 (HIV-1), 
led to dramatic improvements in their mortality and morbidity. However, high levels 
of adherence to HAART regimens are required and due to the very nature of HIV-1: 
its high replicative capacity and lack of a proof reading mechanism, drug resistance 
mutations emerge, which impact on the ability of the drugs to suppress the patient’s 
circulating viruses.  Genotypic resistance testing can determine whether mutations 
have developed which confer resistance to specific antiretrovirals (ARV) and thus 
enhance clinical care.   
Methods: A clinical cohort database was developed to host the demographic, 
treatment and resistance mutation data for patients living with HIV-1 across the 
United Kingdom (UK) who had a genotypic resistance test (tests) conducted as part 
of their clinical care.  These data were pooled and interrogated to determine the 
evolution and dynamics of resistance in targeted sub-groups of patients including 
treatment-naïve patients; treatment-experienced patients and their potential 
susceptibility to new ARV drugs; and the evolution of new subtype profiles within the 
clinical cohort and the impact of this on clinical outcomes. The over-riding aim of 
each of the studies was to improve the clinical care of patients with HIV-1 infection 
in the UK.  
Results: In the treatment-naïve patient cohort (n=380), a resistance prevalence rate 
of 16.5% was determined. In the treatment-experienced cohort (n=1,786), the 
resistance prevalence rate was 68.1%.  Of those treatment-experienced, 91.3% 
would be susceptible to the new ARV Etravirine (ETV) and 89.7% to Darunavir 
(DRV).  In the subtype patient cohort (n=1,642), an increase in the prevalence of 
pure and recombinant non-B subtypes over time was demonstrated and 
characterised, as well as the identification of polymorphisms specific to non-B 
subtypes compared to subtype B.       
Conclusions: The resistance prevalence rate of >10.0% in the treatment-naïve 
patient cohort supported the need to conduct genotypic resistance tests for all 
treatment-naïve patients with HIV-1 infection before commencement of HAART in 
order to ensure the patient was starting on the optimal first-line treatment regimen 
to control their virus.  National and European guidelines were subsequently 
amended to reflect this requirement.  The treatment-experienced patient cohort 
analyses confirmed the resistance mutations circulating within the treated HIV-1 
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community which are the source of transmitted resistance to the treatment-naïve 
patients.  Further analyses of the treatment-experienced cohort suggested two new 
ARVs which were due to be licenced for use with HIV-1 patients would be 
“theoretically susceptible”, providing further treatment options for these patients with 
resistance mutations.  The subtype patient cohort work determined that subtype 
characterisation should be introduced as part of clinical care due to the impact of 
non-B subtypes on the success of genotypic resistance testing, and the different 
mutational pathways which might occur, leading to resistance in different subtypes.  
All these studies provided data and evidence of current issues which impacted on 
the clinical care of patients living with HIV-1 in the UK and influenced changes in 
guidelines on how best to manage and improve patient care. 
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in the cohort, using the TRUGENE® resistance guidelines (Genelibrarian version 
current at time of testing) showed a broad range of mutations. 
Appendix 2_Table 9.1b: Frequencies of specific reverse transcriptase (RT) 
mutations found in the cohort, using the TRUGENE® resistance guidelines 
(Genelibrarian version current at time of testing) showed a broad range of 
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Appendix 3_Table 10.1a: Demographics, protease (PR) and/ or reverse 
transcriptase (RT) mutations and drug class impacted (non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors 
(NRTIs), protease inhibitors (PIs)) in patients in 2001: three out of the four patients 
had evidence of resistance (R) to the NNRTI drug class. 
Appendix 3_Table 10.1b: Demographics, protease (PR) and/ or reverse 
transcriptase (RT) mutations and drug class impacted (non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors 
(NRTIs), protease inhibitors (PIs)) in patients in 2002: the majority of the patients 
identified with drug resistance mutations were from the Greater London area 
(14/15 patients); presented with mutations to the NNRTI drug class (12/15 
patients) and one patient had resistance mutations which impacted all three drugs 
classes. 
Appendix 3_Table 9.1c: Demographics, protease (PR) and/ or reverse 
transcriptase (RT) mutations and drug class impacted (non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors 
(NRTIs), protease inhibitors (PIs)) in patients in 2003: the majority of the patients 
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Appendix 3_Table 9.1d: Demographics, protease (PR) and/ or reverse 
transcriptase (RT) mutations and drug class impacted (non-nucleoside reverse 
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mutations to the other drugs classes (4/13 had NRTI resistance mutations, 4/13 
had PI mutations and 5/13 had NNRTI mutations). 
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Graph 4.1a: Non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
associated mutations and prevalence of resistance over the study (and 
presentation as primary HIV-1 infection (PHI), chronic-naive (CN) or pregnant and 
treatment-naïve).  K103N was the most prevalent of the NNRTI mutations 
impacting use of the whole of the NNRTI drug class.  V179D mutation was the 
next most frequent mutation which translated as possible resistance to all of the 
NNRTIs. 
Graph 4.1b: Nucleoside reverse transcriptase inhibitors (NRTIs), associated 
mutations and prevalence of resistance over the years (and presentation as 
primary HIV-1 infection (PHI), chronic-naive (CN) or pregnant and treatment-
naïve).  The graph depicts low frequencies of NRTI mutations with treatment 
options within this drug class available to the majority of the patients with these 
mutations.  However, for the patient with four NRTI resistance mutations 
(K70R+M184V+T215Y+K219E) the accumulation of these mutations impacts a 
number of the specific drugs available within this class. 
Graph 4.1c: Protease inhibitors (PIs), associated mutations and prevalence of 
resistance over the years (and presentation as primary HIV-1 infection (PHI), 
chronic-naive (CN) or pregnant and treatment-naïve). The graph depicts low 
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Graph 5.1: Percentage of patients, per year, identified with major mutations 
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class, two drugs classes or all three drugs classes. The graph also shows the 
frequency of minor protease inhibitor (PI) mutations over the years with a clear 
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(major nucleoside reverse transcriptase inhibitors (NRTI) mutations) from 1996 to 
2006.  Pattern shows suboptimal treatment in 1996-1997 (stavudine 
(d4T)/zidovudine (ZDV)). From 1998 onwards, the prevalence of the NRTI 
mutations decreased as highly active antiretroviral therapy (HAART) was 
successful in suppressing replicating virus. 
Graph 5.2b: Prevalence of other major nucleoside reverse transcriptase inhibitors 
(NRTI) mutations (contd.) from 1996 to 2006.  The frequency of these NRTI 
mutations was generally lower (<10.0%) compared with the prevalence of the 
thymidine analogue mutations (TAMs) and M184V illustrated above. 
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Graph 5.5b: For 298 treatment-experienced patients (pt’s) with more than 
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Chapter 1: Introduction 
Emergence of a new virus 
In 1981, a new syndrome was reported in previously healthy, young, 
homosexual men in Los Angeles (LA) and New York City (NYC) with cases of 
Pneumocystis jiroveci (carinii) pneumonia (PCP) and/or Kaposi’s sarcoma (KS), 
(Centers for Disease Control and Prevention in America (CDC) 1981a; CDC 
1981b; CDC 1982; Masur et al 1981).  Previously, such infections were 
uncommon and only seen in people whose immune systems were 
immunocompromised.  The first cases of PCP reported in LA were accompanied 
by an editorial surmising ‘the fact that these patients were all homosexuals 
suggests an association between some aspect of a homosexual lifestyle or 
disease acquired through sexual contact…in this population’ (CDC 1981a).   
On realisation of an increase in reporting of such cases to the CDC, as well as 
an increase in the incidence of requests for controlled pentamidine to treat PCP, 
the CDC formed a Task Force on KS and opportunistic infections (KS/OI) to 
determine what was happening in the community (CDC Task Force on KS/OI 
1982).  Initially, members of the Task Force (Epidemic Intelligence Service 
Officers) interviewed the men with these syndromes and theorised these likely 
occurred as a result of immune suppression due to sexually transmitted 
diseases, immunosuppression associated with poppers or a sexually 
transmitted agent, or immune overload.  The Task Force conducted a case-
control study to try and determine possible causes of the KS/OI syndromes.  The 
case participants were all men who had sex with men (MSM) with evidence of 
PCP and/or KS, and the control participants were healthy MSM, matched by 
age, race and city of residence (Jaffe et al 1983; Rogers et al 1983).  Analysis 
of the data suggested increased sexual activity, with multiple partners, was a 
mitigating factor.   
This new syndrome was generally referred to by the CDC as KS/OI, with others 
calling it ‘gay compromise syndrome’ (Brennan et al 1981) or ‘gay-related 
immune deficiency’ (GRID, CDC 1982).   It quickly became evident however that 
these uncommon infections were not just related to a ‘homosexual lifestyle’, with 
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cases identified in injecting drug users ((IDUs), Masur et al 1981), haemophiliacs 
(CDC 1982a), those who had received blood transfusions and blood products 
(CDC 1982c), mother-to-child transmission (CDC 1982d) and likely 
heterosexual transmission (CDC 1983).  The term acquired immune deficiency 
syndrome (AIDS) was universally adopted, with the CDC publishing an official 
definition in September 1982 (CDC 1982b).   
In 1983, the Institute Pasteur in France reported they had isolated a new virus, 
which might be the cause of AIDS, which they termed lymphadenopathy-
associated virus (LAV), (Barre-Sinoussi et al 1983).  Meanwhile, a group of 
scientists from the National Cancer Institute in America (NCI) announced they 
had isolated a virus which caused AIDS, and named it ‘human T-cell 
lymphotropic virus type 3’ (HTLV-III), (Gallo et al 1984).  Another group from San 
Francisco reported on AIDS-associated retroviruses as the cause of AIDS (Levy 
et al 1984).  It became evident from detailed sequencing that LAV, HTLV-III and 
AIDS-associated retroviruses were the same virus; these multiple 
nomenclatures were rationalised in 1986 by the International Committee on the 
Taxonomy of Viruses who appointed the unifying name human 
immunodeficiency virus (HIV), (Coffin et al 1986).   
A scientific dispute ensued between the Institute Pasteur research group in 
France (led by Professor Luc Montagnier) and the American research group at 
the NCI (led by Dr Robert Gallo) as to which group was the first to isolate HIV 
(LAV/HTLV-III) as the virus which caused AIDS, as well as to design and 
develop a commercial blood test that screened for antibodies to HIV.  An 
agreement of the ‘chronology of AIDS research’ was published in 1987 with a 
supporting statement from both the Montagnier and Gallo research groups and 
it was deemed that the blood test would be regarded as a ‘joint invention’ (Gallo 
and Montagnier 1987; Palca 1987). 
In 1986, a second HIV virus was identified and characterised by the Institute 
Pasteur with the original virus named HIV type 1 (HIV-1) and this new virus HIV 
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type 2 (HIV-2), (Clavel et al 1986).  HIV-1 is the most common and prolific of the 
viruses and is more prevalent worldwide.  HIV-2, although genetically similar but 
distinct from HIV-1, is associated with West Africa and countries which have 
colonial links with West Africa (Clavel et al 1986).  HIV-1 will be the focus of this 
research thesis. 
The human immunodeficiency virus type 1 (HIV-1) 
HIV-1 was classified as a member of the Lentivirus genus which is part of the 
family of Retroviridae (retroviruses).   
Figure 1.1: HIV-1 virions (Figure used with kind permission from Prof Clive Loveday and adapted by 
myself).
A HIV-1 virion (as depicted in Figure 1.1) has an outer bilipid envelope with the 
glycoproteins (gp) gp120 and gp41 implanted.  Within the envelope, the viruses’ 
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genetic message is carried within a protective nucleocapsid protein (p24) as two 
identical copies of positive single stranded ribonucleic acid (RNA), and the 
nucleocapsid also contains enzymes which assist the replication process, 
including reverse transcriptase (RT), protease (PR) and integrase (IN).  All 
species that are potential hosts for retroviruses store their genetic information as 
double stranded deoxyribonucleic acid (DNA).  For HIV-1 to successfully 
parasitize the host it needs to generate a DNA copy of its genetic message: the 
RT enzyme, found within the nucleocapsid, reverse transcribes the retroviral 
positive RNA to double stranded proviral DNA in the host cell. 
The HIV-1 genome (the central core of a virus which contains the genetic 
message) i.e. viral RNA, is composed of at least nine different genes (as 
illustrated in Figure 1.2). The three structural genes: group-specific antigen 
(gag), polymerase (pol) and envelope (env), are the three open reading frames 
for HIV-1 and contain the information that is needed, and has the potential to 
make proteins, for building new virions.   
The gag gene encodes the proteins which form the viral core (p24 the capsid 
(CA), p17 the matrix (MA), p7 the nucleocapsid (NC), and p6).  All four proteins 
are found in mature viral core particles (Erickson 2001).  The pol gene encodes 
the essential enzymes RT, PR, IN and ribonuclease H (RNase H) which are vital 
proteins/enzymes central to the HIV-1 replication process.  The env gene 
encodes the glycoprotein gp160 and this is further cleaved into gp120 and gp41. 
The other six genes: viral protein R (vpr), viral infectivity factor (vif), viral protein 
unique (vpu), regulator of expression of virion particles (rev), trans-activator of 
transcription (tat) and negative regulatory factor (nef), (Gallo et al 1988); are 
accessory genes which encode for proteins that control the ability of HIV-1 to 
infect a cell, produce new copies of virus, or cause disease.  At each end of the 
viral genome are long terminal repeat sequences (LTRs) which contain binding 
sites which promote and enhance viral expression.  
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Figure 1.2: The genetic structure of HIV-1 (Erickson 2001). The genome 
consists of three open reading frames: group-specific antigen (gag), polymerase 
(pol) and envelope (env) genes with long terminal repeat sequences (LTRs) at 
each end and six further accessory genes: viral protein R (vpr), viral infectivity 
factor (vif), viral protein unique (vpu), regulator of expression of virion particles 
(rev), trans-activator of transcription (tat) and negative regulatory factor (nef). 
The pol gene, in particular the PR and RT enzymes which are targets of 
antiretroviral drugs, are of importance in this thesis. 
Replication of HIV-1 
The primary target of HIV-1 infection are CD4 (helper) lymphocyte cells.  To 
infect the CD4 lymphocyte, HIV-1 binds primarily to the CD4 receptor via the env 
protein gp120 (Figure 1.3a-c).  This primary binding initiates the involvement of 
one of two co-receptors (Berger 1999), either C-C chemokine receptor type 5 
(CCR5) or C-X-C chemokine receptor type 4 (CXCR4) (Figure 1.3d), which 
initiates unfolding of the gp41 protein for membrane binding (Figure 1.3e).  There 
then follows fusion of viral and CD4 lymphocyte envelopes (Figure 1.3f).  The 
membranes fuse and the nucleocapsid enters the host cytoplasm: radio 
microimaging indicates that the viral components move in the cytoplasm through 
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the endoplasmic reticulum (ER), (Kadiu and Gendelman 2011), and the two 
single stranded RNA are released.  The RT enzyme transcribes the single 
positive viral RNA into a single negative DNA copy and finally into double 
stranded proviral DNA.  The DNA circularises and enters the host CD4 
lymphocyte nucleus and is integrated into the genome of the host cell by the IN 
enzyme.  New virus production uses existing cellular transcription mechanism; 
the proviral DNA is transcribed into multiple messenger RNA (mRNA), leaves 
the nucleus to the ribosomal system and is translated into viral polypeptides. The 
viral components and proteins coalesce at the host cell surface, PR enzymes 
‘cleave’ polypeptides into functional units and complete new virions are 
assembled and bud from the surface of the host cell into extracellular space. 
 
Whilst CD4 lymphocyte cells are the primary target for HIV-1 infection, the virus 
also has secondary targets for HIV-1 to continue replicating.  These include 
macrophages, CD8 lymphocyte cells and specific cells in the lungs, brain, 
gastrointestinal tract and kidneys (Wiley 1986; Erickson 2001).
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Figure 1.3: Binding of the HIV-1 envelope glycoproteins gp41 and gp120, to the CD4 lymphocyte, allowing fusion of 
the viral and cell membranes (Figure used with kind permission from Prof Clive Loveday and adapted by myself).
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Key:  
The red numbers on the figure above illustrate the target areas in the lifecycle where drug classes are available to treat HIV-1 and are 
discussed in detail (see pg 13-14).
Figure 1.4: Replication of HIV-1 virions (Figure used with kind permission from Prof Clive Loveday and adapted by myself). 
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The viral generation time of a HIV-1 virion is approximately 2.5 days, with ten 
billion virus particles produced each day (Perelson et al 1996).  The RT process 
is error prone with at least one base error per replicative cycle.  This high 
replication rate, in addition to error prone replication, gives HIV-1 the potential 
for real time evolution.  Following primary HIV-1 infection (PHI) with only one or 
two genetically distinct viruses, the above criteria result in a genetic expansion 
of viruses within one host and a year after infection (chronic infection) the 
individual will have thousands of genetically distinct, though closely related, 
virions circulating in their body (quasispecies).   
Figure 1.5: Primary HIV-1 infection (PHI) and viral quasispecies: at PHI, the viral 
load (VL) is very high but as the host’s immune system responds, the VL 
decreases over time, with the genetic diversity within the host expanding (Figure 
used with kind permission from Prof Clive Loveday).
Following PHI, the amount of HIV-1 circulating, that is the viral load (VL), is very 
high. As the specific host immune system responds, the VL will drop and 
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stabilise.  The ‘set point’, that is, the level at which the VL stabilises, is predictive 
of how the HIV-1 infection will progress (Henrard 1995; Mellors 1996). 
Transmission and stages of HIV-1 infection 
The predominant transmission pathway for HIV-1 is through unprotected sexual 
activity whereby the virus can be transmitted across the mucosal barrier of the 
vagina, vulva, penis or rectum (Mortimer and Loveday 2001).      
A number of factors increase the likelihood of sexual transmission: 
• the pathogenicity of the virus itself,
• the VL of the person infected with HIV-1: the higher the VL the increased
risk of ‘successful’ transmission,
• concurrent sexually transmitted diseases, including genital herpes;
syphilis; gonorrhoea,
• the number of sexual partners: the greater the number of sexual partners
the greater the risk of acquiring HIV-1,
• the condition of the host’s immune system.
HIV-1 can also be transmitted via sharing injecting drugs equipment; vertically 
from mother to-child; through exposure to infected blood or blood products; or 
occupational exposure from, for example, needle-stick injuries.  Transmission 
opportunities via these routes have been limited in the United Kingdom (UK) due 
to prevention systems that have been put into place including needle exchange 
schemes (introduced in 1986); the introduction of routine testing of all pregnant 
women for HIV-1 (introduced in England in 2000 and across the UK by 2003 
(Townsend et al 2006)) and screening of the blood supply (which was introduced 
as early as 1985). 
Worldwide epidemiology of HIV-1 infection 
There are currently 35.3 million (32.2-38.8 million) people living with HIV-1 
worldwide (Joint United Nations Programme on HIV/AIDS (UNAIDS) 2013).  The 
majority of the infected (25 million, 70.8%) reside in sub-Saharan Africa (23.5-
26.6 million).  There were 2.3 million (1.9-2.7 million) new infections diagnosed 
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globally in 2012, with 1.6 million (1.4-1.8 million) of these new diagnoses 
occurring in sub-Saharan Africa. 
In the UK, it was estimated that 107,800 people (101,600-115,800) were living 
with HIV-1 in 2013, with 24.0% (26,100) unaware of their positive status (Yin et 
al 2014).  There were 6,000 new HIV-1 infections diagnosed in the UK in 2013. 
Patients with HIV-1 included in the studies presented in this thesis were 
diagnosed as early as 1981 up to 2006.  To set the context as per the above, 
there were an estimated 73,000 people living with HIV-1 in the UK in 2006 with 
approximately 21,600 (29.6%) unaware of their infection (The UK Collaborative 
Group for HIV and STI Surveillance 2007).  An estimated 7,800 new infections 
were diagnosed in the UK in 2006.  Of those currently diagnosed as HIV-1 
positive in the UK (n=47,800): the predominant exposure category was MSM 
(43.0%), followed by heterosexual women (31.0%), heterosexual men (21.0%) 
and a small minority were infected as a result of being IDU (4.0%).  Of those in 
the heterosexual exposure category, 12,100/16,200 (74.7%) of women and 
5,700/9,100 (62.6%) of men were born in Africa and had since moved to the UK. 
HIV-1 group and subtype nomenclature 
HIV-1 is a genetically diverse virus and through phylogenetic analysis of 
sequence data, HIV-1 has been classified into four distinct virus groups: Group 
M (major group, De Leys et al 1990), Group O (outlier group, Charneau et al 
1994), Group N (non-M and non-O group, Simon et al 1998) and Group P 
(putative group, Plantier et al 2009).  Group M is the most predominant, with the 
majority of HIV-1 infections belonging to this group.  At the time of writing, at 
least nine genetically distinct subtypes (also termed clades) had been 
determined within Group M including: A (further divided into sub-subtypes A1 
and A2), B, C, D, F (further divided into sub-subtypes F1 and F2), G, H, J and 
K.   
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In 1995, Robertson et al identified the potential of the Group M subtypes to 
recombine, that is, they identified different sequence subtypes within the gag 
and env genes they phylogenetically analysed, indicating individuals could 
become infected with HIV-1 strains from different sequence subtypes.  These 
mixtures of different subtypes (A to K) combining their genetic material to form a 
hybrid virus became known as circulating recombinant forms (CRFs) and the 
first CRF identified, CRF01_AE, represented a putative subtype A and subtype 
E recombinant (Carr et al 1996; Gao et al 1996). 
Guidelines issued stated that new CRFs/subtypes should be designated only 
when there were three full-length genome sequences available from three 
epidemiologically unlinked patients (Robertson et al 1999).  In 1999, Robertson 
et al reported four CRFs including CRF01_AE, CRF02_AG, CRF03_AB and 
CRF04_cpx (which was a combination of three or more subtypes).  By 2015, 
sixty-eight circulating CRFs have currently been characterised (Los Alamos 
National Laboratory, 2015).  Due to the high genetic variability of HIV-1, new 
CRFs/subtypes will evolve and be detected in the future.   
Worldwide distribution of HIV-1 subtypes 
Analyses of global HIV-1 sequences (Hemelaar et al 2011) determined 
subtype C as the most predominant type (48.0%), followed by subtype A 
(12.0%), subtype B (11.0%), subtype G (5.0%), subtype D (2.0%) and any of 
subtypes F, H, J or K (<1.0%).  The CRF02_AG was prevalent in 8.0% of the 
global population with CRF01_AE in 5.0% of the population, with other 
recombinants accounting for 4.0% (Hemelaar et al 2011).   
In the first wave of the epidemic, subtype B was the most prevalent subtype 
in Western Europe and the UK and was associated with the MSM and IDU 
risk groups (Buonaguro et al 2007).  Non-B subtypes identified in Western 
Europe populations were associated with the heterosexual risk group, in 
persons endogenous to the local geographical area and those who had 
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immigrated from endemic regions, such as Africa and Asia (Buonaguro et al 
2007). 
Treatment of HIV-1 infection: antiretroviral therapy (ART) 
With increasing understanding of the structure of HIV-1 and its lifecycle, 
therapies were - and still are - developed to try and manage the circulating virus. 
Currently, there are six classes of antiretroviral drugs available which target 
different phases of the HIV-1 lifecycle and interfere with the replication process. 
Table 1.1: Target areas in the HIV-1 lifecycle where drug classes are available 
to suppress viral replication (see the red numbers on Figure 1.4, pg 8 which 
highlight the areas where the drug classes target). 
Drug class Target area of 
drug in HIV-1 
lifecycle 
Name of antiretroviral 
drug (abbreviation) 
1 Entry/fusion inhibitors  HIV-1 entry into 
CD4 lymphocyte 
cells 
• Maraviroc (MVC)*
• Enfuvirtide (T-20)
2 Nucleoside reverse 
transcriptase inhibitors 
(NRTIs)   
RT enzyme • Zidovudine (ZDV)*
• Didanosine (ddI)
• Zalcitabine (ddC)
• Stavudine (d4T)
• Lamivudine (3TC)*$
• Abacavir (ABC)*$
• Tenofovir (TDF)*$
• Emtricitabine
(FTC)*$
3 Non-nucleoside reverse 
transcriptase inhibitors 
(NNRTIs)  
RT enzyme  
(but in a different 
way to NRTIs) 
• Nevirapine (NVP)*$
• Delavirdine (DLV)
• Efavirenz (EFV)*$
• Etravirine (ETV)*
• Rilpivirine (RPV)*$
4 Integrase inhibitors  IN enzyme • Raltegravir (RAL)*$
• Elvitegravir (EVG)*$
• Dolutegravir
(DTG)*
5 HIV-1 maturation 
inhibitors   
gag protein • Bevirimat (BVM)#
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Table 1.1 (contd.): Target areas in the HIV-1 lifecycle where drug classes are 
available to suppress viral replication (see the red numbers on Figure 1.4, pg 8 
which highlight the areas where the drug classes target). 
Drug class Target area of 
drug in HIV-1 
lifecycle 
Name of antiretroviral 
drug 
(abbreviation) 
6 Protease inhibitors (PIs) PR enzyme • Saquinavir (SQV)
• Indinavir (IDV)
• Ritonavir (RTV)*
• Nelfinavir (NFV)
• Amprenavir (APV)
• Lopinavir/boosted
with RTV (LPV/r)*$
• Atazanavir (ATV) *$
• Fosamprenavir
(FPV)*$
• Tipranavir (TPV)*
• Darunavir (DRV)*$
Key: 
* currently approved for use in the UK and European Union (National AIDS Manual (NAM) 2014)
$ recommended for use by the British HIV Association (BHIVA, Williams et al 2014)
# drug in development
1 Entry/fusion inhibitors 
The CCR5 entry inhibitor MVC was designed to target the HIV-1 lifecycle at the 
first phase by blocking viral entry by binding to the transmembrane protein CCR5 
and preventing it from interacting with the V3 loop of gp120 (Figure 1.3b).  The 
fusion inhibitor T-20 was designed to bind to gp41 and prevent the shape 
changes that enable HIV-1 virions and CD4 lymphocyte cells to fuse (Figure 
1.3e+f). 
2 NRTIs  
The NRTI drug class includes nucleoside and nucleotide RT inhibitors.  These 
inhibitors were designed to target the RT enzyme and mimic the naturally 
occurring building blocks of DNA, deoxynucleosides.  Nucleoside inhibitors 
require more metabolic steps to become active against the RT than nucleotide 
inhibitors which are already monophosphorylated (Pratt 2003).  Nucleoside 
inhibitors require conversion (phosphorylation) to their triphosphate form, then 
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they can compete with the natural deoxynucleoside triphosphates for binding to 
RT.  These NRTIs compete with the natural deoxynucleoside triphosphates for 
incorporation into new viral DNA chains and as the NRTIs have a different 
structure, the naturally occurring nucleotides cannot be added on to continue the 
transcription, resulting in chain termination and thereby halting HIV-1 replication 
(Erickson 2001). 
3 NNRTIs 
The NNRTIs are structurally diverse from NRTIs: they do not compete with the 
naturally occurring nucleotides but were designed to inhibit RT by binding 
directly to a pocket of the enzyme (p66) and inhibiting the catalytic step of RT 
polymerisation (Spence et al 1995). 
4 Integrase inhibitors   
Integrase inhibitors were designed to block the IN enzyme from inserting the 
HIV-1 viral genome into the DNA of the host cell.   
5 HIV-1 maturation inhibitors  
HIV-1 maturation inhibitors were designed to disrupt and bind to the gag protein, 
preventing the cleavage of the gag protein and therefore interfering with the 
maturation of the virus, forming non-infectious, immature virions, which were 
incapable of infecting other cells (Salzwedel et al 2007).  
6 PIs 
The PIs were designed to inhibit HIV-1 replication at a later stage of the lifecycle: 
they target the PR enzyme whose role is to cleave large polyproteins into smaller 
proteins (p17, p24, p2, p7, p1 and p6) prior to virus assembly at the cell 
membrane and the PIs ‘block’ the PR enzyme from completing assembly of 
functional new virions (Calvez 2001). 
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Measuring the success of ART 
The success of these drugs are measured by virological outcomes: the drugs 
should suppress the replication of HIV-1 virions and therefore the number of 
viruses circulating.  The aim of ART is to suppress the VL of a patient so that 
they are deemed as biologically ‘undetectable’: VL tests can determine the 
number of ‘copies’ of RNA per millilitre in a patient’s plasma sample and when 
monitored, this ideally should be <50 copies per millilitre (c/mL).  Successful 
therapy therefore ‘controls’ viral replication in the host, decreasing the number 
of circulating virions and allowing the immune system to recover, resulting in an 
increase in the CD4 lymphocyte cell count.   
The history of ART (please see Figure 1.8 on pg 25 for a timeline of ART) 
The first ART was introduced in 1987 after a double-blind, placebo-controlled 
clinical trial found that for those patients living with AIDS who were treated with 
the NRTI ZDV, (commonly known at the time as Azidothymodine (AZT)); at 24 
weeks of follow-up, ZDV prolonged the life of those living with AIDS (Fischl et al 
1987).  There was general optimism in the field: before the introduction of ZDV, 
the prognosis for patients with HIV-1 was poor, with opportunistic infections and 
eventual progression to AIDS and death.  This optimism was soon shattered 
however when results from the Concorde Trial showed that symptom free 
individuals with HIV-1 who were randomised to take ZDV monotherapy 
immediately or had treatment deferred until the onset of symptoms and were 
followed-up over a three-year period; ZDV did not slow down progression to 
AIDS or improve survival (Concorde Coordinating Committee 1994).  Even 
though other NRTIs became available to treat patients with HIV-1/AIDS, 
including ddI (1991), ddC (1992), and d4T (1994), monotherapy treatment was 
sub-optimal and morbidity and mortality rates remained high and drug-resistant 
strains emerged and evolved (Larder and Kemp 1989; Larder et al 1995).   
Dual therapy with a combination of two NRTIs: ZDV+3TC (Schlomo et al 1996; 
Katlama et al 1996) or ZDV+ddI or ddC (Delta Coordinating Committee 1996; 
Hammer et al 1996) were employed to try and control HIV-1 replication and delay 
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the onset of drug resistance.  Results from these studies found that taking a 
combination of two NRTIs compared to NRTI monotherapy, significantly 
prolonged life and delayed progression to AIDS but drug resistant mutations 
were still identified at week 24 of treatment for those on dual therapy (Katlama 
et al 1996). 
In 1996, the field of treating patients with HIV-1/AIDS took a quantal leap 
forward.  New classes of ART were introduced with the PIs SQV, RTV and IDV 
introduced to the field as well as the first NNRTI NVP.  Further studies indicated 
that combining the different drugs classes, e.g. NRTIs with PIs, reduced the 
frequency of AIDS and death (Hammer et al 1997, Gulick et al 1997, Cameron 
et al 1998).  Dramatic improvements in the morbidity and mortality of patients 
with HIV-1/AIDS were witnessed, with a decrease in the incidence of 
opportunistic infections, tumours and deaths (Rubbert and Ostrowski 2003; The 
Antiretroviral Therapy Cohort Collaboration 2008).  This became known as the 
era of highly active antiretroviral therapy (HAART). 
In spite of the dramatic improvements in VL suppression, the complexity of 
HAART regimens and associated adverse effects raised new challenges in the 
clinical management of patients with HIV-1.  These HAART regimens often 
required the patient to take up to 30 tablets a day, with food, drink and time 
constraints (Hoffman 2003).  This high pill burden resulted in problems with 
adherence to the therapies and patients often experienced severe side-effects 
to the regimens. Again, the development of drug resistance mutations for 
patients taking HAART were observed. 
Resistance to ART 
As suggested above, the development of resistance mutations to ART have a 
major impact on successful treatment outcomes.  The primary goal of ART is to 
suppress HIV-1 replication so the VL remains undetectable.  If this does not 
occur and HIV-1 is able to continue replicating: alongside the RT enzyme’s error-
prone replication with at least one base error per replicative cycle, and with the 
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absence of ‘proof-reading’ mechanisms, mutations can evolve on a daily basis 
(Perelson et al 1996).  The higher the VL, the less time it takes before resistance 
mutations/viruses evolve and continue replicating (as depicted in Table 1.2). 
Table 1.2: Viral load (VL) replication and number of days before mutation arises: 
the higher the VL, the shorter the timeframe for the development of resistance 
mutations (Table used with kind permission from Prof Clive Loveday). 
VL (c/mL) Days before mutation arises 
300,000 0.1 
30,000 1 
3,000 10 
300 100 
30 1,000 
Therefore, suppressing VL is essential to decrease the opportunities for a mutant 
viral population to develop and to ensure successful treatment with ART.  
Other factors which can impact on the development of resistance mutations 
include pharmacological issues: poor absorption and poor adherence to the drug 
regimen can lead to subinhibitory drug levels, as well as the failure of the host’s 
immune system; and combined with the biological factors described above, lead 
to persistent viral replication and therefore the continued evolution of drug 
resistance and ultimately, drug failure. 
Measuring resistance to ART 
Drug resistance tests are available to measure the emergence of resistance 
mutations including genotype tests and phenotype tests. 
Genotype tests (Molecular assay) define the nucleotide sequence from which 
the PR and RT enzymes amino acid sequence can be deduced.  The sequence 
shows the genetic code of the host’s virus.  The genetic code is composed of 
four bases: adenine (A), cytosine (C), guanine (G) and thymine (T); with A 
binding with T and C with G.  These bases, combined in different sequences in 
groups of three, known as codons, encode for a specific amino acid.  The 
genotypic resistance test compares this sequence to a reference wild-type (WT), 
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detects any base changes in the codons of the PR and RT genomes and 
interprets the consequent change in amino acid translation, and hence the 
protein (enzyme) structure and function.   
Phenotypic tests (Biological assay) measure the sensitivity of a patient’s 
circulating viruses to a drug in a replicating virus system, compared with a 
reference WT virus.  When resistance mutations occur, viruses require higher 
concentrations of drug to suppress their replication: results are expressed as a 
fold change in sensitivity between the patient’s and the reference WT virus 
replication rate (Figure 1.6).  
Figure 1.6: Interpretation of phenotypic susceptibility: drug concentration able to 
inhibit virus growth in vitro to 50.0% (50.0% inhibitory concentration, IC50)
relative to a wild-type (WT) reference virus (Hirsch et al 2008). 
Genotypic and phenotypic tests have been clinically validated for use in patient 
care but genotypic tests are generally used to determine the resistance profile 
of patients with HIV-1 as they involve a quicker turnaround than phenotype tests 
and are cheaper to conduct (Torre and Tambini 2002). 
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Interpretation of genotype resistance mutations 
Interpretation of genotypic resistance mutations is complex: there are over 100 
RT and PR mutations identified that are involved in the development of HIV 
drug resistance (Calvez 2001).   These mutations interact and emerge in 
complex patterns to suggest a person is resistant to their therapy.  They 
therefore need to be analysed using computerised tools which may exist within 
the given genotyping system or may be available as a separate entity: these 
tools have the capacity to define the importance of combinations of mutations 
and the impact for clinical care. 
In addition, genotype results can be interpreted using a ‘virtual phenotype 
database’ such that the genotypic result can be compared to an extensive 
database containing a large number of genotypic and corresponding phenotypic 
results; a ‘virtual phenotype’ can then be inferred based on a known genotypic 
profile with the result given as a fold change in sensitivity to the drug. 
An independent group of clinical experts in the HIV-1 field produce a reference 
list of known mutations which are associated with clinical resistance to the 
specific drugs and drug classes (the International Antiviral Society-USA (IAS-
USA) Drug Resistance Mutations Group (formerly known as the International 
AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group)).  These 
charts are a useful reference tool to determine resistance mutations and are 
updated annually by a group of World experts, but caution must be exercised 
when using them due to the complexity of interpreting resistance mutations and 
patterns. 
Illustrated below are the IAS-USA list of mutations associated with the NRTIs 
(Figure 1.7a), the NNRTIs (Figure 1.7b) and the PIs (Figure 1.7c), (Johnson et 
al 2009).   
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Figure 1.7a: Mutations associated with resistance to the nucleoside reverse 
transcriptase inhibitors (NRTIs) as per the International Antiviral Society-USA 
(IAS-USA) Drug Resistance Mutations Group (Johnson et al 2009). 
Key: 
Amino acid abbreviations: A alanine; C cysteine; D aspartate; E glutamate; F phenylalanine; G 
glycine; H histidine; I isoleucine; K lysine; L leucine; M methionine; N asparagine; P proline; Q 
glutamine; R arginine; S serine; T threonine; V valine; W tryptophan; Y tyrosine. 
Using the first ART, ZDV to exemplify: the pink panel represents the RT gene 
and the resistance mutations M41L, D67N, K70R, L210W, T215Y/F and 
K219Q/E have been defined as conferring resistance to ZDV.   
The number in the panel (41) represents the codon position at which a mutation 
has occurred, the upper case letter above the number (M: methionine) 
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represents the WT amino acid expressed and the letter below (L: leucine) 
represents the resistant mutation associated amino acid change.  If the codon 
number is in bold, it indicates a major mutation. 
These mutations to ZDV (M41L, D67N, K70R, L210W, T215Y/F and 
K219Q/E) are known as thymidine analogue mutations (TAMs) and are 
associated with both ZDV and d4T resistance and specific TAMs impact the 
antiviral activity of the other NRTIs also. The mutations M41L and T215F/Y 
are associated with higher levels of resistance and two patterns of TAMs that 
tend to cluster together have been identified: TAM pattern 1, M41L, L210W 
and T215Y are associated with d4T resistance; TAM pattern 2, D67N, K70R, 
T215F and K219E/Q are associated with AZT resistance (Cozzi-Lepri et al 
2005).  
Figure 1.7b: Mutations associated with resistance to the non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) as per the International Antiviral 
Society-USA (IAS-USA) Drug Resistance Mutations Group (Johnson et al 
2009). 
Key: 
Amino acid abbreviations: A alanine; C cysteine; D aspartate; E glutamate; F phenylalanine; G 
glycine; H histidine; I isoleucine; K lysine; L leucine; M methionine; N asparagine; P proline; Q 
glutamine; R arginine; S serine; T threonine; V valine; W tryptophan; Y tyrosine. 
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Figure 1.7c: Mutations associated with resistance to the protease inhibitors 
(PIs) as per the International Antiviral Society-USA (IAS-USA) Drug Resistance 
Mutations Group (Johnson et al 2009). 
Key: 
Amino acid abbreviations: A alanine; C cysteine; D aspartate; E glutamate; F phenylalanine; G 
glycine; H histidine; I isoleucine; K lysine; L leucine; M methionine; N asparagine; P proline; Q 
glutamine; R arginine; S serine; T threonine; V valine; W tryptophan; Y tyrosine. 
Each ARV drug has a different genetic barrier, that is, the number of resistance 
mutations required, to attain resistance (Paredes and Clotet 2009). Some ART 
have a low genetic barrier to resistance, that is, a single mutation confers 
resistance.  For example, the K103N mutation alone confers resistance to EFV 
with the Y181C mutation conferring resistance to NVP (Figure 1.7b).  Other ART 
have a high genetic barrier to resistance, that is, a number of mutations need to 
accumulate to confer resistance e.g. resistance to the PIs (Figure 1.7c). 
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Objectives of this thesis 
Using a clinical cohort resistance database of patients infected with HIV-1 who 
had genotypic tests conducted during 1996 to 2006, a series of studies were 
devised and conducted to determine whether the clinical care of targeted sub-
groups of patients with HIV-1 could be improved with a better understanding of: 
• the evolution and dynamics of resistance mutations in treatment-naïve
patients (Chapter 4)
• the evolution and dynamics of resistance mutations in treatment-
experienced patients (Chapter 5)
• the potential susceptibility of treatment-experienced patients to new ARV
drugs (Chapter 6)
• the evolution of subtype profiles within the clinical cohort, including
treatment-naïve and treatment-experienced patients (Chapter 7).
The main objective for conducting each of these studies was to try and improve 
our knowledge and ensure that patients with HIV-1 were receiving the best 
possible clinical care with regards to resistance and established, successful 
treatment. 
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Figure 1.8: Timeline of the introduction of specific antiretroviral therapies (ART), by drug class (Figure adapted and used with kind 
permission from Prof Clive Loveday).
NRTIs: ZDV Zidovudine, ddI Didanosine, ddC Zalcitabine, d4T Stavudine, 3TC Lamivudine, ABC Abacavir, TDF Tenofovir, FTC Emtricitabine  
PIs: SQV Saquinavir, IDV Indinavir, RTV Ritonavir, NFV Nelfinavir, APV Amprenavir, LPV/r Lopinavir (boosted with RTV), ATV Atazanavir, FPV Fosamprenavir, 
TPV Tipranavir, DRV Darunavir 
NNRTIs: NVP Nevirapine, DLV Delavirdine, EFV Efavirenz, ETV Etravirine, RPV Rilpivirine  
Fusion inhibitor: T-20 Enfuvirtide  Integrase inhibitor: RAL Raltegravir, EVG Elvitegravir, DTG Dolutegravir  CCR5 entry inhibitor: MVC Maraviroc 
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The International Clinical Virology Centre (ICVC) was a small, not for profit 
charity, specialising in the development and application of molecular (and 
related) laboratory tests, to support the clinical management of patients with 
HIV-1/AIDS.  The ICVC evolved from the team that developed the first VL and 
resistance assays for HIV-1 in the World (Semple et al 1991, Kaye et al 1992, 
Semple et al 1993) and applied these tests in Medical Research Council 
(MRC), EuroSida and other international clinical trials, and in direct patient 
care.  With this experience, 39 clinical centres (District General Hospitals 
(DGH)) across the UK asked to collaborate with the ICVC, to support the 
clinical management of their patients.  It was agreed the ICVC would conduct 
the VL and genotypic resistance testing for these 39 clinical centres and that 
the ICVC’s Clinical Director would interpret each resistance report and be 
available to discuss any patients’ case management, if the clinician required 
any advice.   
The philosophy of the ICVC was to provide quality assured molecular 
technologies to enhance patient care and the understanding of viral infections.  
The ICVC Collaborative Research Group was formed and I was recruited in 
2002 as a research assistant to establish and coordinate the ICVC Clinical 
Cohort Resistance Database.  The main objective of the ICVC Clinical Cohort 
Resistance Database was to pool the resistance data generated from the 
patients at all clinical centres.  Often, the numbers of patients seen within 
these centres were relatively small and all 39 members of the ICVC 
Collaborative Research Group agreed the data should be unified to provide a 
powerful database for audit and analysis, to answer contemporary scientific 
questions related to future patient clinical care. 
Ethical approval 
All clinical centres had to attain local ethical approval from their hospital before 
they could become members of the ICVC Collaborative Research Group: 
permission had to be granted from the hospital that the patients’ samples and 
data could be used by the ICVC.  All 39 clinical centres signed an agreement 
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with the ICVC that their patients’ clinical and resistance data could be included 
in the ICVC Clinical Cohort Resistance Database, and these data pooled and 
used anonymously, to conduct cohort audits for the overall improvement of 
clinical care for patients with HIV-1.   
Each clinical centre was responsible for attaining their patients’ written 
consent that after a VL/resistance test was conducted at the ICVC, any 
residual sample could be used in future research; as well as their clinical and 
resistance data included in the ICVC Clinical Cohort Resistance Database. 
The ICVC did not share any data nor results for commercial purposes.  Each 
of the clinical centres retained overall ownership of their data and on request, 
the ICVC provided access to their data as well as transferred their data to 
other clinical databases e.g. the Brighton clinical centre requested their data 
was forwarded to the MRC. 
On completion and final submission of this thesis, the ICVC Clinical Cohort 
Resistance Database and all data will be returned to the ICVC Charitable Trust 
Headquarters which is covered by the Data Protection Registration, 
Information Commissioner’s Office (ICO): 00043047707 (current registration 
date until 06/06/2017). 
The ICVC resistance request form 
For each patients’ sample sent to the ICVC requesting a genotypic resistance 
test was conducted, the clinicians were asked to complete a corresponding 
resistance request form (Figure 2.1).  I designed and developed the ICVC 
resistance request form after a consensus meeting with the ICVC’s Clinical 
Director and the ICVC’s Laboratory Manager, as to the clinical data that would 
be most appropriate to collect.  These data would be used to assist the 
laboratory with conducting the resistance test: an indication of the VL of the 
sample to confirm a resistance test was feasible and epidemiological data to 
identify the origin of infection and hence potential genetic diversity.  These 
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data assisted the Clinical Director with the interpretation of the resistance 
report and allowed clinical cohort research to be conducted.   
Generic clinical data was requested on the ICVC resistance request form 
including the sex and date of birth of the patient; an indication of the origin of 
the infection; as well as the risk exposure group of the patient with HIV-1 
infection.  Other clinical data was request specific i.e. why the clinician 
required that a patients’ sample was tested; was the patient currently taking 
ART and if not, were they naïve to ART or in a phase of treatment interruption.  
The clinicians were asked to comment on the patients’ adherence to their ART 
regimen and also indicate the VL and CD4 counts of the sample (or 
alternatively, the most recent values). 
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Figure 2.1: The ICVC resistance request form to be completed alongside 
each patients’ sample submitted for genotypic resistance testing, to assist the 
ICVC laboratory with conducting the test, the ICVC’s Clinical Director in 
interpreting the genotype report and to allow clinical cohort research to be 
conducted. 
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To ensure I understood the processes and procedures required to produce a 
resistance report, I was afforded the opportunity to shadow the laboratory 
technicians.  These processes and procedures are briefly described below 
(Figures 2.2a-d: Steps 1-4, which were conducted by the trained laboratory 
technicians).  I was trained by the Laboratory Manager to conduct data 
analyses and assist the laboratory technicians with interpreting the bi-
directional and consensus sequences that were generated (see Figure 2.2e: 
Step 5 and Figure 2.3). 
Sample collection, separation and storage 
Whole blood samples were received at the ICVC either by Royal Mail, by 
Courier or by special delivery with a pre-arranged drop-off time (e.g. one of 
the major clinical centres used a daily taxi service to deliver their samples to 
the ICVC).  On arrival of the samples, they were transferred to ‘Lab 1’ where 
each sample was carefully removed from its packaging: laboratory staff had 
to adhere to strict universal precautions when unpacking and handling the 
samples.  Each sample was allocated a unique identifier number (RV number).  
Samples were processed and separated by centrifugation with the resultant 
plasma transferred to labelled (RV number and hospital number) Sarstedt 2mL 
sample tubes with the laboratory technician ensuring no blood was transferred 
to the tubes.  These plasma samples could either be sent straight for 
VL/resistance testing or could be stored between -60°C and -80°C until testing 
took place.  The ICVC strove to separate and store the plasma samples within 
six hours of reaching the laboratory to ensure the integrity of the sample for 
VL/resistance testing.     
Genotype resistance testing at the ICVC 
The ICVC laboratory undertook research into the application of new 
technologies that would allow the development and use of high-throughput 
genotypic resistance testing.  The TRUGENE® HIV-1 assay was utilised 
(initially Visible Genetics Inc. (1996 to 2003), Bayer HealthCare LLC (2003 to 
2007), and Siemens (2007 to current)).  The TRUGENE® HIV-1 assay is a 
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molecular approach using HIV-1 from infected human plasma for HIV-1 viral 
RNA reverse transcription; polymerase chain reaction (PCR) amplification to 
provide complementary DNA (cDNA) for sequencing; and analysis of selected 
areas of the viral genome in the PR gene (codons 10-99) and in the RT gene 
(codons 38-247), in order to determine the presence or absence of mutations 
associated with resistance to the antiretroviral drugs. 
 
The method involved a five step process: 
 
Figure 2.2a: Step 1_SAMPLE PREPARATION: The extraction of HIV-1 viral 
RNA from infected human plasma (Visible Genetics Inc. 2001).  
 
 
 
At the ICVC, this extraction process was carried out based on the QIAGEN 
QIAamp Viral RNA Mini Kit procedure (as shown above) and used the 
TruPrep™ kit with the ICVC’s extraction protocol following the procedure 
described in the QIAGEN QIAamp Viral RNA Mini Handbook (see Appendix 1 
for copy of protocol F10: ROCHE COBAS AMPLICOR HIV-1 MONITOR v1.5 
ASSAY (STANDARD)).   
 
Using the TruPrep™ kit, 140 microlitres (µL) of patient plasma (with a VL 
>1000c/mL) was required for the extraction of HIV-1 RNA.  The process 
involved:  
• viral lysis in the presence of RNA inhibitors to preserve viral HIV-1 RNA 
during the isolation process (due to the presence of ribonucleases 
(RNases), these needed to be inactivated using Buffer AVL to ensure 
the isolation of intact viral RNA containing carrier RNA (cRNA)) 
• binding of viral RNA to the membrane in the TruPrep™ column 
31
Chapter 2: Materials and Methods 
• washing of the TruPrep™ column with buffers (AW1 and AW2 to wash
away any contaminants)
• the resulting RNA eluted in a special RNase-free buffer (AVE)
• product stored in the freezer between -60°C and -80°C.
Figure 2.2b: Step 2_RT-PCR: Reverse transcription and polymerase chain 
reaction (RT-PCR) of patients’ extracted ribonucleic acid (RNA), to transcribe 
viral RNA into complementary deoxyribonucleic acid (cDNA) (Visible Genetics 
Inc. 2001). 
The process involved: 
• introducing 17µL of the patient’s HIV-1 RNA extract into PCR tubes
containing RT-PCR master mix I (comprised of RT-PCR primers,
deoxyribonucleotides (DNTPs), dithiothreitol (DTT) and RNase
inhibitors)
• heating these tubes in a thermocycler to a temperature of 90°C for two
minutes, followed by a cycle of 50°C for five minutes
• adding 14µL of RT-PCR master mix II (RT-PCR buffer, RNase inhibitor,
RT-enzyme and DNA polymerase) to the bottom of each tube
• continuing with the 50°C cycle for 55 minutes, then 94°C for two
minutes and reheating and cooling the sample through a further 38
cycles of the RT-PCR program:
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Figure 2.2c: Step 3_CLIP™: The complementary amplified deoxyribonucleic 
acid (DNA) undergoes the CLIP™ reaction to sequence both sense (positive) 
and antisense (negative) strands of this double-stranded DNA; the method 
compares the sequence of sense and antisense to determine the true 
sequence of the clinical sample (Visible Genetics Inc. 2001). 
 
 
 
The process involved: 
• setting-up a 96-well plate containing 0.2mL thin walled strip tubes (see 
below) 
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• adding 7µL of CLIP™ terminator mix to the bottom of each strip tube in
the 96-well plate
• adding 5µL of RT-PCR product into a CLIP™ tube already containing
72µL of CLIP™ master mix (water, CLIP Buffer 1 and AmpliTaq FS)
• adding 5µL from each of these CLIP™ tubes to each appropriate well
• placing the plate in the thermocycler to undergo the CLIP™ cycle
program:
• adding 14µL of well mixed ‘Stop Loading Dye’ at the end of the cycle to
each well
• denaturing the CLIP™ samples in the thermocycler for three minutes
at 85°C  to 95°C, to prevent any further reaction.
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Figure 2.2d: Step 4_ELECTROPHORESIS: The heating of the sequencing 
reactions to denature the double-stranded deoxyribonucleic acid (DNA) 
fragments into two single-strands was undertaken on a thermocycler at 95°C 
(Visible Genetics Inc. 2001). 
 
 
 
The process involved: 
• filling a double-glass, ultra-thin sequencing plate (MicroCel 500 
cassette) with polyacrylamide gel of 6.0% (SureFill®)  
• placing the cassette into a sequencer for electrophoresis (Long-Read 
Tower® sequencer) 
• adding fresh TBE buffer to the upper and lower chambers in the 
sequencer to complete the circuit 
• pre-running the sequencer at 60°C for a maximum of 5-10 minutes to 
equilibriate the buffer and electrophoretic gel 
• flushing the cassette with the buffer 
• adding 1.5µL from each well, corresponding to one patient’s sample, to 
the correct channel in the sequencing plate  
• allowing the electrophoresis to run for 30 minutes.  
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Figure 2.2e: Step 5_DATA ANALYSIS: Bi-directional CLIP™ sequences were 
produced (Protease (PR), PR II, Reverse transcriptase (RT) beginning and RT 
middle) and interpreted by the laboratory technician to ensure consistency to 
produce a consensus sequence and ultimately a resistance report (Visible 
Genetics Inc. 2001). 
The process involved: 
• downloading the bi-directional sequences which were transferred
automatically from the Towers and stored on the computer database
(GeneObject™ Database) for the PR, PR II, RT beginning and RT
middle sequences
• using the cursor to look across the reading frame to check the
consistency of the sense versus antisense peaks (upper window:
positive (sense) DNA strand, lower window: negative (antisense) DNA
strand) for good alignment, good resolution and no significant baseline
deviations
• using the dedicated software package (GeneObject™) to analyse for
consistency against the HIV-1LAV-1 reference sequence (subtype B)
and check for any insertions and/or deletions.
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Once all checks were completed, the sense and antisense sequences were 
combined and a consensus sequence was produced and stored on the 
database (GeneObject™ Database).   
 
Figure 2.3: An example of a consensus sequence of a patient’s protease (PR) 
and reverse transcriptase (RT) genotype (Figure used with kind permission from Prof Clive 
Loveday and adapted by myself). 
 
 
In the example above, at the RT amino acid position 103, there was a mixture 
evident in the peaks (C and T), indicating a mixture of mutant and WT at 
position 103. 
 
If any base changes were identified, there were three possible outcomes: 
• no change in the coded amino acid (silent polymorphism) 
• a change in the coded amino acid at a non-relevant resistance site 
(polymorphism) 
• a change in the coded amino acid at a resistance site (mutation). 
 
The consensus sequence was further checked by the laboratory technician 
who could manually change the sequence: if this occurred, it was signaled by 
the computer by a change in the case of the identifying letter (small letter 
rather than capital).  Although interpretation and analysis was dependent upon 
a number of defined rules and guidelines, the technique had a subjective 
element and the experience and skill of the laboratory technician was essential 
for the generation of high quality results.  The checked consensus sequence 
was then submitted, interpreted and formatted into a resistance report by the 
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software package (GeneLibrarian™) producing a list of mutations present 
from codons 10 to 99 in the PR and 38 to 247 in the RT (Figure 2.4). 
 
Figure 2.4: A patient’s mutational profile.  To exemplify, the Resistance 
Mutation highlighted in yellow indicates: the protease base position (PR 28), 
the wild-type (WT) codon (CTC), the amino acid position (L10I, with ‘L’ 
indicating the amino acid WT and ‘I’ the amino acid substitution conferring 
resistance), the change in the codon from the WT with the small letters 
indicating a manual change in the sequence by the laboratory technician (aTc) 
(Bayer HealthCare LLC 2003). 
  
Resistance Mutations Silent Mutations 
(at all positions) 
Polymorphisms: Coding 
changes not at resistance 
sites 
Unexpected 
Mutations at 
resistance 
sites 
 
PR 
28 (CTC) L10I (aTc) 
136 (ATG) M46L (tTg) 
187 (CTC) L63P (ccC) 
268 (TTG) L90M(aTG) 
RT 
541 (TAT) Y181Y/C (TrT) 
550 (ATG) M184I/V (rTa) 
628 (TTG) L210W (TGG) 
643 (ACC) T215Y (TAC) 
PR 
52 (CAA) Q18Q (CAG) 
97 (TTA) L33L (YTA) ** 
151 (GGA) G51G (GGG) 
280 (GGT) G94G (GGC) 
RT 
133 (GGG) G45G (GGA) 
232 (AGA) R78R (AGR) 
250 (ACT) T84T (ACC) 
289 (CCC) P97P (CCT) 
310 (AAA) K104K (AAG) 
319 (ACA) T107T (ACG) 
346 (TTT) F116F (TTY) ** 
394 (ATA) I132I (ATT) 
412 (GAG) E138E (GAR) 
418 (CCA) P140P (CCR) 
502 (TTA) L168L (CTA) 
580 (GAA) E194E (GAG) 
589 (CAG) Q197Q (CAA) 
610 (GAG) E204E (GAA) 
637 (GGA) G213G (GGG) 
658 (AAA) K220K (AAG) 
679 (TTC) F227F (TTT) ** 
709 (GAT) D237D (GAC) 
PR 
43 (ATA) I15V (GTA) 
103 (GAA) E35E/D (GAM) 
109 (AGT) S37N (AAT) 
121 (AGA) R41K/R (ARA) 
172 (CAG) Q58E (GAG) 
214 (ATA) I72V (GTA) 
RT 
127 (AAG) K43Q (CAG) 
178 (GTA) V60I (ATA) 
361 (GAT) D121Y (TAT) 
403 (ATA) I135T (ACA) 
406 (AAC) N136K/N/T 
(AMM) 
454 (GGA) G152G/X (KGA) 
484 (AGT) S162A (GCT) 
586 (GGG) G196E (GAG) 
607 (GAG) E203K (AAG) 
619 (CAA) Q207E (GAA) 
631 (AGG) R211K (AAG) 
640 (CTT) L214F (TTT) 
724 (CAG) Q242Q/L (CWG) 
733 (GTG) V245A/V (GYG) 
NONE 
   **Indicates a silent mutation at a resistance site. 
 
The effects of these mutations on the individual antiretroviral therapies were 
interpreted by the software (GuideLines Rules) to determine whether the 
mutations conferred ‘Resistance’ (the patient’s virus was no longer susceptible 
to the specific drug); ‘Possible Resistance’ (the patient’s virus may no longer 
be susceptible to the specific drug) or ‘No Evidence of Resistance’ (the 
mutations present do not confer resistance).  The software (GeneLibrarian™) 
produced a resistance report providing: a colour-coded, easy-to-read front 
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page consisting of the resistance interpretation (Figure 2.5a); the evidence 
source on which the software’s algorithm based its interpretation; and an 
indication of the strength of the evidence used to determine the interpretation 
rules (Figure 2.5b-d).     
These GuideLines Rules were updated annually, according to the Food and 
Drug Administration (FDA) regulations, by a selected panel of ‘world-
renowned HIV experts’.  The experts met once a year and considered the 
latest clinical and research resistance data, including in vivo virological 
response and in vitro phenotypic data (published or abstracted); they then 
altered the rules for the TRUGENE® GeneLibrarian™ system accordingly and 
ran dummy cases to ensure there was no ambiguity in the interpretation. The 
new database for interpretation was then circulated worldwide to everyone 
running the TRUGENE® system (http://www.medical.siemens.com).   
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Figure 2.5a: Front cover of the TRUGENE® HIV-1 resistance report providing a 
colour co-ordinated, at-a-glance resistance summary of mutations present and the 
interpreted resistance level (Resistance, Possible Resistance, No Evidence of 
Resistance) per drug class (Bayer HealthCare LLC 2003). 
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Figure 2.5b: List of specific TRUGENE® HIV-1 resistance report rules and 
Evidence Basis for the interpretation of the mutations seen and the resistance 
level assigned, per drug (nucleoside reverse transcriptase inhibitors (NRTIs) 
and non-nucleoside reverse transcriptase inhibitors (NNRTIs)) (Bayer 
HealthCare LLC 2003). 
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Figure 2.5c: List of specific TRUGENE® HIV-1 resistance report rules and 
Evidence Basis for the interpretation of the mutations seen and the resistance 
level assigned, per drug (non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) contd. and protease inhibitors (PIs)) (Bayer HealthCare LLC 2003). 
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Figure 2.5d: Definitions of the TRUGENE® HIV-1 resistance report 
Resistance Effect levels and Evidence Basis levels (Bayer HealthCare LLC 
2003). 
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Interpretation of the resistance report by the ICVC’s Clinical Director 
At the ICVC, before any resistance reports were disseminated to the 
collaborating centres, each report generated was checked and signed-out by 
the Clinical Director who would interpret the resistance report with reference 
to the clinical data provided by the clinician requesting the resistance test.  The 
collaborating centres were encouraged to contact the Clinical Director to 
discuss any of their patients’ resistance reports and future options in order to 
ensure the best clinical care for their patient. 
The ICVC Clinical Cohort Resistance Database 
Using the Statistical Package for the Social Sciences (SPSS, initially version 
12.1 for Windows through to version 22), I designed and developed the ICVC 
Clinical Cohort Resistance Database to integrate the clinical and resistance 
data for each patient.   
Before data entry, each patients’ resistance ‘package’ (request form and 
resistance report) was assigned a unique SPSS identifier.  One ‘package’ was 
entered at a time.  Clinical data provided on the request form were entered 
first: no patient names were included on the ICVC Clinical Cohort Resistance 
Database.  The patients were uniquely identified based on the SPSS identifier 
assigned to them, along with the unique sample identifier (RV number) 
assigned by the ICVC’s laboratory, and their hospital number.  If the clinician 
did not complete a field on the resistance request form, the clinical variable 
was left blank on the database.  The corresponding list of PR and RT 
resistance mutations and polymorphisms were then entered (see Figure 2.4). 
Using the clinical data provided, the resistance database provided a powerful 
tool for conducting cohort analyses.  Simple analyses could be conducted e.g. 
male/female groupings; looking at a hospital’s resistance profile over time; 
looking at a geographical region’s resistance profile over time; looking at the 
frequency of specific mutations/polymorphisms in the database.   
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The database could be interrogated, allowing more complex analyses e.g. 
using the ‘major reason for test’ and ‘drug’ variables or patients could be 
identified and grouped as treatment-naïve or treatment-experienced.  Patients 
who were classed as treatment-experienced, based on the clinical data 
provided, could be further grouped into those on their first-line treatment 
regimen, but who were failing, or those on their second or third-line treatment 
regimens.  The resistance profiles of these groups could then be compared. 
Using FASTA sequences to determine patients’ subtype 
The TRUGENE® system generated a FASTA ‘pol’ (PR and RT) sequence for 
each patients’ genotype.  This is a shorthand sequential description of the 
sequence carried out in the machine which can be easily transmitted between 
laboratory sites and online analytical tools.  
Figure 2.6: An example of a patient’s FASTA sequence as generated by the 
TRUGENE® genotype system (Figure used with kind permission from Prof Clive Loveday).  
The first line of the sequence indicated the hospital number of the patient 
(M94-0099), the unique sample identifier (RV number) assigned by the ICVC’s 
laboratory (65165), the date and time the report was generated 
(200401261109) and the nucleotides which were analysed: PR (protease) 
(10-297), RT (reverse transcriptase) (112-741).  After this, the first part of the 
sequence represented the PR nucleotides with the long list of ‘N’s’ confirming 
the transition between the PR and RT sequence.   
>M94-0099|65165|200401261109||VGI nucleotide|PR(10-297),RT(112-741)I+D0
NNNNNNNNNACTCTTTGGCAGCGACCCCTTGTCTCAATAAAAGTAGGGGGcCAgATAAA
GGAGGCTCTCTTAGACACAGGAGCAGATGATACAGTATTAGARGArATAAATTTRCCAG
GAAAATGGAAACCAAAAATGATAGGRGGAATTGGAGGTTTTATCAAAGTAAGACAGTAT
GATCAAATACTCATAGAAATTTGTGGAAAAAAGGCTATAGGTACAGTATTAGTAGGACC
TACACCTGTCAACATAATTGGAAGAAAyATGTTGACTCAGCTTGGATGCACACTAAACTT
YNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
TGTGAAGAAATGGAGAAGGAAGGAAAAATTACAAAAATWGGGCCTgAAAatCCATATAA
CACTCCAGTGTTTGCCATAAAAAAGAAGGACAGTACTAARTGGAGAAAATTAGTAGATT
TCAGGGARCTTAATAARAGAACTCAAGACTTYTGGGAAGTTCAATTAGGAATACCCCAC
CCAGCAGGGTTAAAAAAGAAAAAATCAGTGACAGTACTAGAYGTGGGAGATGCATATTT
TTCAGTTCCTTTAGATAAAGACTTCAGGAARTATACTGCATTcACcATACCTAGTATAAAC
AATGAAACACcAGGGATTAGATATCAATAYAATGTRCTTCCACAGGGATGGAAAGGATC
ACCAGCAATATTCCAGAGTAGCATGACAAAAATCTTAGAGCCCTTTAGGGCACAAAATC
CAGGAATAGTCATCTATCAATATATGGATGACTTGTATGTAGGATCTGACTTAGAAATAG
GGCAACATAGAGCAAAAATAGAAGAGTTAAGAGAACATCTATTGAAGTGGGGATTTACC
ACACCAGATAAGAAACATCAGAAAGAACCCCCATTTCTTTGGATGGGGTATGAACTCCA
TCCTGACAAATGGACAGTACAGCCTATAGAGCTGCCA
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Although the gold standard for classification of HIV-1 subtypes should be 
based on phylogenetic analysis of full-length genome sequences (Robertson 
et al 1999) in clinical practice, this is not practical.  FASTA ‘pol’ (PR and RT) 
sequences can be downloaded from GeneLibrarian™ and entered into 
subtype tools available freely on the internet to determine subtype.  Subtype 
characterisation (using five online tools to determine subtype) and 
interpretation are presented in Chapter 7: the evolution of subtype profiles in 
the clinical cohort. 
Quality control of the data 
All data analysed in this thesis were entered into the ICVC Clinical Cohort 
Resistance Database by myself.  I ensured spot-checks of the data entry 
occurred every three months and that audits of the data were conducted to 
ensure accuracy.  As data collection spanned 10 years, some of the patients 
on the database had a number of resistance reports conducted over this 
timeframe; this too was a good way of checking the clinical information 
provided, as well as the reported mutations and polymorphisms, as I could 
determine if there were any major discrepancies in the data that needed to be 
reviewed. 
In conclusion, using the ICVC Clinical Cohort Resistance Database, I 
conducted a series of clinical cohort studies to determine whether the clinical 
care of patients with HIV-1 could be improved and was responsible for: 
• forming the research idea/question
• designing how to identify sub-groups of patients in the database
• setting the inclusion/exclusion criteria
• devising the analysis plan including the clinical variables/demographics
to analyse; the relevant mutations (polymorphisms) to analyse
• interpreting and presenting the findings.
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The ICVC Clinical Cohort Resistance Database collection commenced in 
1996 and, for the purposes of this thesis, continued up to the end of 2006, 
providing ten years of continuous data collection.  The ICVC Clinical Cohort 
Resistance Database holds 3,573 entries for 2,785 patients with HIV-1 
infection, whose plasma samples were submitted for investigation of 
genotypic resistance as part of their clinical care.     
Distribution of the ICVC Collaborative Research Group 
The ICVC conducted resistance testing for a wide, geographically distributed 
group of clinics (n=39), of varying sizes, throughout the UK.  Figure 3.1 
highlights the areas across the UK which formed the ICVC Collaborative 
Research Group with the specific city/town/borough listed by geographical 
region in Table 3.1. 
Figure 3.1: Map showing the distribution of the clinical centres across the 
United Kingdom (UK) that formed the International Clinical Virology Centre 
(ICVC) Collaborative Research Group. 
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Table 3.1: Breakdown of the International Clinical Virology Centre (ICVC) 
Collaborative Research Group by geographical region and city/town/borough 
where the clinical centre was based.  The majority of the clinical centres 
were from the Greater London area (64.3%). 
Geographical region: city/town/borough where clinical 
centre based 
n % 
Scotland 
Aberdeen 
Dundee 
35 
34 
1 
1.0 
North West 
Carlisle 
Workington 
30 
20 
10 
0.8 
Wales 
Wrexham 
Rhyl 
Swansea 
Cardiff 
Newport, Gwent 
153 
5 
16 
55 
75 
2 
4.3 
East Midlands 
Lincoln 
51 
51 
1.4 
Eastern 
Great Yarmouth 
Colchester 
Chelmsford 
Hertford/Lister 
Watford 
325 
38 
84 
5 
117 
81 
9.1 
Greater London 
Barnet 
Beckenham 
Ealing 
Lewisham 
North Middlesex 
Romford 
Hampstead 
West Smithfield, City of London 
Whipps Cross 
2,299 
4 
63 
374 
115 
29 
30 
1,022 
457 
205 
64.3 
South East 
Southampton 
Isle of Wight 
Portsmouth 
Worthing 
Brighton 
Eastbourne 
St. Leonards-on-Sea 
Slough 
High Wycombe 
Aylesbury 
590 
2 
46 
258 
29 
128 
10 
4 
88 
20 
5 
16.5 
South West 
Bristol 
Gloucester 
Cheltenham 
Dorset 
Weymouth 
90 
1 
32 
28 
4 
25 
2.5 
Total 3,573 100.0 
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Of the 2,785 patients, the majority had one resistance entry only n=2,237 
(80.3%), with the complete breakdown presented in Table 3.2.  
Table 3.2: Number of resistance entries per patient in the International 
Clinical Virology Centre (ICVC) Clinical Cohort Resistance Database showed 
that the majority only had one resistance data entry in the database. 
Number of resistance entries per patient n % 
1 entry 2,237 80.3 
2 entries 382 13.7 
3 entries 114 4.1 
4 entries 34 1.2 
5 entries 14 0.5 
6 entries 4 0.1 
Total 2,785 100.0 
Resistance request form 
Table 3.3 illustrates the completion rates of the different clinical variables on 
the resistance request form.  Apart from the clinicians indicating the ‘major 
reason for requesting a genotypic resistance test’, there was less than 
100.0% completion of the fields on the resistance request forms by clinicians. 
Table 3.3: Completion of the resistance request form showed great 
variability in data provided by the clinicians requesting a genotypic resistance 
test for their patients. 
Clinical variable n=2,785 patients with HIV-1 
Available data Missing data 
n % n % 
Sex 2,276 81.7 509 18.3 
Date of Birth 2,258 81.1 527 18.9 
Origin of Infection 1,794 64.4 991 35.6 
Ethnic Origin 982 35.3 1,803 64.7 
Risk Exposure Group 1,009 36.2 1,776 63.8 
Date of Diagnosis 892 32.0 1,893 68.0 
Clinical variable n=3,573 resistance entries 
Available data Missing data 
n % n % 
Major reason for test 3,573 100.0 0 0.0 
Sample viral load 1,209 33.8 2,364 66.2 
Recent viral load 1,844 51.6 1,729 48.4 
Most recent CD4 1,951 54.6 1,622 45.4 
Current drug therapy 2,707 75.8 866 24.2 
Adherence comment 2,260 63.3 1,313 36.7 
‘Valid percentages’ were used throughout the thesis to present the clinical 
data, that is the denominators for the percentages (unless stated otherwise), 
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were based on the available data and excluded those patients where the 
data was missing. 
Epidemiological data 
The majority of patients with HIV-1 infection were male n=1,596 (70.1%) with 
680 (29.9%) females.  The age range was from 7 years to 87 years of age, 
with an overall mean age of 42 years (43 years in males, 37 years in 
females). 
The majority of the infections were of European origin n=926 (51.6%), with 
725 (40.5%) of African origin, 48 (2.7%) from Asia, 34 (1.9%) from North 
America, and the remainder had a prevalence of less than 1.0% including 
Australasia, South America, the Caribbean, the Middle East and Russia. 
From the data provided, 467 (47.6%) patients were classed as White non-
Hispanic, 432 (44.0%) as Black African, 21 (2.1%) as White Hispanic, 20 
(2.0%) as Black Afro-Caribbean, 13 (1.3%) as Asian Sub-Continent, and all 
other categories had a prevalence below 1.0% including Asian Middle 
Eastern, Asian Oriental, Black British, Burmese, Filipino, Indian, Mauritian, 
Thai, Turkish and White South African. 
The main risk exposure group was due to heterosexual contact n=560 
(55.5%), while 370 (36.7%) were classified as at risk due to MSM, 23 (2.3%) 
due to IDU, 20 (2.0%) due to mother-to-child transmission, 16 (1.6%) due to 
blood/tissue transfer, and all other exposure groups had a prevalence below 
1.0% including as a result of a sharps injury, MSM/IDU, heterosexual/IDU, 
bisexual/commercial sex/MSM/heterosexual. 
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Table 3.4: Crosstabulation showing Ethnic origin by Origin of infection by Risk exposure group.  The majority of men who have 
sex with men (MSM) cases originated in Europe (90.0%) and were of White non-Hispanic ethnicity (92.3%).  The majority of 
heterosexual cases were of African origin (81.2%) and were classed as Black African ethnicity (77.5%).  All injecting drug 
users (IDU) cases (n=19) originated in Europe and were of White non-Hispanic/White Hispanic ethnic origin. 
 
Ethnic origin Origin of 
infection 
Risk exposure group  
 
Total MSM Heterosexual IDU Blood/tissue 
transfer 
Mother-to-
child 
Other 
n % n % n % n % n % n % n 
White non-
Hispanic 
Europe 297 91.7 40 52.6 17 100.0 8 100.0 2 100.0 9 81.8 373 
Africa 6 1.9 22 28.9 0 0.0 0 0.0 0 0.0 0 0.0 28 
Asia 1 0.3 9 11.8 0 0.0 0 0.0 0 0.0 0 0.0 10 
North America 12 3.7 1 1.3 0 0.0 0 0.0 0 0.0 0 0.0 13 
Other 8 2.5 4 5.3 0 0.0 0 0.0 0 0.0 2 18.2 14 
Total 324 100.0 76 100.0 17 100.0 8 100.0 2 100.0 11 100.0 438 
White Hispanic Europe 9 64.3 1 25.0 2 100.0 0 0.0 0 0.0 1 100.0 13 
North America 1 7.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 
Other 4 28.6 3 75.0 0 0.0 0 0.0 0 0.0 0 0.0 7 
Total 14 100.0 4 100.0 2 100.0 0 0.0 0 0.0 1 100.0 21 
Asian Sub-
Continent 
Europe 1 100.0 1 12.5 0 0.0 0 0.0 0 0.0 0 0.0 2 
Africa 0 0.0 2 25.0 0 0.0 0 0.0 0 0.0 0 0.0 2 
Asia 0 0.0 5 62.5 0 0.0 1 100.0 0 0.0 0 0.0 6 
Total 1 100.0 8 100.0 0 0.0 1 100.0 0 0.0 0 0.0 10 
Black African Europe 1 50.0 6 1.5 0 0.0 0 0.0 0 0.0 0 0.0 7 
Africa 1 50.0 384 97.2 0 0.0 2 100.0 9 100.0 3 75.0 399 
Other 0 0.0 5 1.3 0 0.0 0 0.0 0 0.0 1 25.0 6 
Total 2 100.0 395 100.0 0 0.0 2 100.0 9 100.0 4 100.0 412 
Black Afro-
Caribbean 
Europe 1 100.0 4 30.8 0 0.0 0 0.0 0 0.0 0 0.0 5 
Africa 0 0.0 2 15.4 0 0.0 0 0.0 0 0.0 0 0.0 2 
North America 0 0.0 2 15.4 0 0.0 0 0.0 0 0.0 0 0.0 2 
Other 0 0.0 5 38.5 0 0.0 0 0.0 1 100.0 0 0.0 6 
Total 1 100.0 13 100.0 0 0.0 0 0.0 1 100.0 0 0.0 15 
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Table 3.4 contd.: Crosstabulation showing Ethnic origin by Origin of infection by Risk exposure group.  The majority of men 
who have sex with men (MSM) cases originated in Europe (90.0%) and were of White non-Hispanic ethnicity (92.3%).  The 
majority of heterosexual cases were of African origin (81.2%) and were classed as Black African ethnicity (77.5%).  All 
injecting drug users (IDU) cases (n=19) originated in Europe and were of White non-Hispanic/White Hispanic ethnic origin. 
 
Ethnic 
origin 
Origin of infection Risk exposure group  
 
Total MSM Heterosexual IDU Blood/tissue 
transfer 
Mother-to-
child 
Other 
n % n % n % n % n % n % n 
Other Europe 7 77.8 2 14.3 0 0.0 0 0.0 0 0.0 1 100.0 10 
 Africa 1 11.1 4 28.6 0 0.0 0 0.0 0 0.0 0 0.0 5 
 Asia 1 11.1 6 42.9 0 0.0 0 0.0 0 0.0 0 0.0 7 
 North America 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 
 Other 0 0.0 2 14.3 0 0.0 0 0.0 0 0.0 0 0.0 2 
 Total 9 100.0 14 100.0 0 0.0 0 0.0 0 0.0 1 100.0 24 
Total Total Europe 316 90.0 54 10.6 19 100.0 8 72.7 2 16.7 11 64.7 410 
 Total Africa 8 2.3 414 81.2 0 0.0 2 18.2 9 75.0 3 17.6 436 
 Total Asia 2 0.6 20 3.9 0 0.0 1 9.1 0 0.0 0 0.0 23 
 Total North America 13 3.7 3 0.6 0 0.0 0 0.0 0 0.0 0 0.0 16 
 Total Other 12 3.4 19 3.7 0 0.0 0 0.0 1 8.3 3 17.6 35 
 Total Origin of 
Infection 351 100.0 510 100.0 19 100.0 11 100.0 12 100.0 17 100.0 920 
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Sixty-three (7.1%) patients were diagnosed with HIV-1 infection in the 1980s, 
282 (31.6%) in the 1990s and 547 (61.3%) in the 2000s. 
 
Table 3.5: Year of diagnosis, by sex, for patients in the International Clinical 
Virology Centre (ICVC) Clinical Cohort Resistance Database showed female 
infection was delayed, compared to males, but showed expansion since 
1998. 
Year of diagnosis Male Female 
n % n % 
1981 1 100.0 0 0.0 
1983 2 100.0 0 0.0 
1984 5 100.0 0 0.0 
1985 13 92.9 1 7.1 
1986 5 62.5 3 37.5 
1987 11 100.0 0 0.0 
1988 6 85.7 1 14.3 
1989 10 71.4 4 28.6 
1990 13 72.2 5 27.8 
1991 9 69.2 4 30.8 
1992 22 75.9 7 24.1 
1993 24 92.3 2 7.7 
1994 21 75.0 7 25.0 
1995 24 77.4 7 22.6 
1996 26 76.5 8 23.5 
1997 21 63.6 12 36.4 
1998 15 57.7 11 42.3 
1999 33 76.7 10 23.3 
2000 20 55.6 16 44.4 
2001 37 51.4 35 48.6 
2002 77 67.5 37 32.5 
2003 56 58.3 40 41.7 
2004 29 51.8 27 48.2 
2005 37 51.4 35 48.6 
2006 47 50.0 47 50.0 
Total 564  319  
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Table 3.6: Major reasons for requesting a resistance test. 
Major reason n % 
Any resistance/extent of resistance? 1,397 39.1 
Treatment-naïve patient, newly diagnosed 591 16.5 
Viral load raised 450 12.6 
Poor response to treatment 446 12.5 
Viral load rebound 251 7.0 
Restarting therapy 123 3.4 
Primary HIV-1 infection (PHI) 112 3.1 
Pregnant 85 2.4 
Other** 118 3.3 
Total 3,573 100.0 
Key: 
** Other reasons included: treatment interruption, simplification of treatment, PCR negative, 
low CD4 count, issues with adherence, post-exposure prophylaxis (PEP) (all frequencies 
<1.0% per reason). 
Table 3.7: Sample and/or most recent viral load (VL) data.  
VL levels 
(c/mL) 
Sample VL 
(c/mL) 
Recent VL 
(c/mL) 
n Valid 
% 
n Valid 
% 
≤50 27 2.2 43 2.3 
≥51 to ≤500 59 4.9 61 3.3 
≥501 to ≤1,000 36 3.0 49 2.7 
≥1,001 to ≤5,000 211 17.5 418 22.7 
≥5,001 to ≤10,000 90 7.4 212 11.5 
≥10,001 to ≤50,000 266 22.0 457 24.8 
≥50,001 to ≤100,000 153 12.7 228 12.4 
≥100,001 to ≤250,000 185 15.3 193 10.5 
≥250,001 to ≤750,000 114 9.4 131 7.1 
≥750,001 68 5.6 52 2.8 
Total 1,209 100.0 1,844 100.0 
Table 3.8: Most recent CD4 cell count data showed that 38.3% of patients 
had CD4 counts below 200 cells/µL with a total of 67.8% of patients with a 
CD4 count ≤350 cells/µL; as per the British HIV Association (BHIVA) 
treatment guidelines (Gazzard on behalf of the BHIVA Treatment Guidelines 
Writing Group 2008), these patients should be taking ART. 
CD4 cell count (cells/µL) n % 
≤50 202 10.4 
≥51 to ≤200 544 27.9 
≥201 to ≤350 576 29.5 
≥351 to ≤500 326 16.7 
≥500 303 15.5 
Total 1,951 100.0 
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Antiretroviral therapy (ART) treatment data 
Of ART treatment data provided, 1,953 (72.2%) were treatment-experienced 
(1,575 (58.2%) were currently taking some form of ART and 378 (14.0%) 
were not currently on treatment but had previous ART experience) and 754 
(27.9%) were treatment-naïve. 
Of those currently taking ART (n=1,575), the majority were on a combination 
of three drugs (n=1,073, 68.1%).  A minority were only taking one (n=11, 
0.7%) or two (n=108, 6.9%) drugs whilst it was indicated that 20 patients 
(1.3%) were currently taking six drugs.   
Table 3.9: Adherence comment: of those patients currently taking 
antiretroviral therapy (ART), it was indicated the majority of patients (78.0%) 
had excellent/reasonable adherence to their ART regimens. 
Adherence comment n % 
Excellent 694 60.7 
Reasonable 198 17.3 
Poor 190 16.6 
Suspect/erratic/intermittent 61 5.3 
Total 1,143 100.0 
‘First failures’ 
Of those who were on treatment, 128 patients (12.9%) were currently on 
their first ART regimen and had no other treatment experience.  Of these, 27 
patients (21.1%) were currently only taking NRTIs; 97 (75.8%) were taking 
two drugs classes (71 NRTIs+NNRTIs and 26 NRTIs+PIs) whilst four 
patients (3.1%) were on a regimen including all three classes.    
‘Drug-experienced’ 
Of 859 patients currently taking ART who had specific data provided with 
regards to their previous drug experience, 254 (29.6%) had experience of 
one drug class (178 NRTIs, 40 NNRTIs, 36 PIs); 374 (43.5%) had 
experience of two drugs classes (154 NRTIs+NNRTIs, 213 NRTIs+PIs, 7 
NNRTIs+PIs) whilst 231 (26.9%) had previous treatment experience with all 
three drugs classes.  
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Of the 378 not currently on any ART but with previous treatment experience, 
59 (16.3%) had experience of one drug class (55 NRTIs, 1 NNRTIs, 3 PIs); 
216 (59.8%) had experience of two drugs classes (120 NRTIs+NNRTIs, 94 
NRTIs+PIs, 2 NNRTIs+PIs) whilst 86 (23.8%) had previous treatment 
experience with all three drugs classes. 
 
There was a wide range of drug usage for those currently taking or who had 
previously taken ART. 
 
Table 3.10: Frequencies of each of the antiretroviral drugs by current 
antiretroviral therapy (ART) usage and previous drug experience; each of the 
antiretroviral drugs showed wide use of nucleoside reverse transcriptase 
inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) and less use of the protease inhibitors (PIs). 
 
Currently on ART 
Not 
currently 
on ART 
Drug class 
Antiretroviral 
drug 
Currently 
on ART 
(n=1,575) 
Previous 
drug 
experience 
(n=859) 
Previous 
drug 
experience 
(n=378) 
n % n % n % 
NRTIs ZDV 586 37.2 567 66.0 265 70.1 
ddI 488 31.0 335 39.0 137 36.2 
ddC 29 1.8 164 19.1 44 11.7 
3TC 964 61.2 478 55.6 274 72.5 
d4T 575 36.5 373 43.3 178 47.1 
ABC 347 22.0 117 13.6 76 20.1 
TDF 279 17.7 22 2.6 32 8.5 
FTC 13 0.8 4 0.5 3 0.8 
NNRTIs NVP 398 25.3 295 34.3 141 37.3 
DLV 9 0.6 18 2.1 7 1.9 
EFV 343 21.8 194 22.5 90 23.8 
PIs SQV 123 7.8 180 20.9 65 17.2 
IDV 93 5.9 235 27.3 60 15.9 
RTV 164 10.4 215 25.0 76 20.1 
NFV 203 12.9 173 20.1 77 20.4 
APV 26 1.7 22 2.5 8 2.1 
LPV 26 1.7 7 0.8 6 1.6 
LPV/r 213 13.5 54 6.3 28 7.4 
TPV 2 0.1 - - - - 
ATV 15 1.0 2 0.2 1 0.3 
FPV 2 0.1 - - - - 
Fusion 
inhibitor T-20 8 0.5 1 0.1 - - 
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Table 3.11: Number of nucleoside reverse transcriptase inhibitors (NRTIs) in 
a patient’s regimen: including those currently taking and with previous 
experience of taking NRTIs. 
Number of NRTIs in regimen 
Currently on ART Not currently on ART 
Current drug usage 
(n=1,575) 
Previous drug 
experience (n=859) 
Previous drug 
experience (n=378) 
n % n % n % 
0 58 3.7 83 9.7 31 8.2 
1 109 6.9 127 14.8 33 8.7 
2 1,093 69.4 302 35.2 170 45.0 
3 273 17.3 142 16.5 67 17.7 
4 42 2.7 139 16.2 51 13.5 
5 - - 50 5.8 21 5.6 
6 - - 15 1.7 5 1.3 
7 - - 1 0.1 - - 
Table 3.12: Number of non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) in a patient’s regimen: including those currently taking and with 
previous experience of taking NNRTIs. 
Number of NNRTIs in regimen 
Currently on ART Not currently on ART 
Current drug usage 
(n=1,575) 
Previous drug 
experience (n=859) 
Previous drug 
experience (n=378) 
n % n % n % 
0 832 52.8 427 49.7 174 46.0 
1 736 46.7 361 42.0 179 47.4 
2 7 0.4 67 7.8 23 6.1 
3 - - 4 0.5 2 0.5 
Table 3.13: Number of protease inhibitors (PIs) in a patient’s regimen: 
including those currently taking and with previous experience of taking PIs. 
Number of PIs in regimen 
Currently on ART Not currently on ART 
Current drug usage 
(n=1,575) 
Previous drug 
experience (n=859) 
Previous drug 
experience (n=378) 
n % n % n % 
0 902 57.3 372 43.3 195 51.6 
1 487 30.9 243 28.3 102 27.0 
2 179 11.4 140 16.3 50 13.2 
3 6 0.4 67 7.8 23 6.1 
4 1 0.1 26 3.0 7 1.9 
5 - - 6 0.7 1 0.3 
6 - - 5 0.6 - - 
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Of the 3,573 entries, 2,995 (83.8%) had a full resistance report, 38 (1.1%) 
only had a PR sequence, 59 (1.7%) only had a RT sequence and 481 
(13.5%) had complete PCR failure and the samples were unable to be 
amplified. 
Review of the PCR failures 
For the successful extraction of HIV-1 RNA from a patient’s plasma sample 
and for genotypic testing to occur, it was recommended that the VL of the 
sample submitted be >1,000c/mL.  Of the PCR failures with available VL 
data, 81/374 (21.7%) had a sample/recent VL ≤1,000c/mL.  Of the samples 
submitted with origin of infection data, 181 (49.1%) were of European origin, 
with 156 (42.3%) of African origin, 12 (3.3%) were from Asia, 11 (3.0%) from 
North America, and the remainder had a prevalence of <1.0% including 
Australasia, South America and Russia.  For those from an African, Asian, 
South American and Russian origin, they may have had a non-B subtype 
and the primers used in the genotypic kit (based on subtype B) were not able 
to amplify these samples. 
Protease (PR) and reverse transcriptase (RT) mutations data 
Of the 3,092 successful resistance entries, 2,911 (94.1%) were identified as 
having PR and/or RT mutations.  One hundred and eighty-one (5.9%) had no 
evidence of resistance mutations.  Of the 2,911 entries, 2,744 (94.3%) had 
PR mutations with a minimum of one, a maximum of 12 and a mean of 2.4 
PR mutations.  With the RT mutations, 1,707 (58.6%) had such mutations 
with a minimum of one, a maximum of 13 and a mean of 3.7.  Overall, the 
minimum number of PR and/or RT mutations was 1 and the maximum was 
22, with a mean of 4.4. 
A detailed tabulation of the frequencies of specific PR and RT mutations 
found in the cohort, using the TRUGENE® resistance guidelines 
(Genelibrarian version current at time of testing) are presented in Appendix 
2. This detailed tabulation of all the research information may be of value to
other researchers in the future, and as such, has been noted here.
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Discussion 
As detailed in the overview above, the ICVC Clinical Cohort Resistance 
Database holds a wealth of data for patients with HIV-1 who have had 
resistance tests conducted as part of their clinical care.  In addition, these 
resistance results have been performed over an extended period of time, 
providing a longitudinal view of the evolution of the patients’ virus.  This data 
was used to answer the research questions posed in the following chapters 
and ultimately, to attempt to improve the clinical care of patients with HIV-1. 
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In 1996, the introduction of HAART for the treatment of HIV-1 infection 
generated a period of optimism in the HIV-1 treatment field (Chesney et al, 
1999).  Dramatic improvements in the mortality and morbidity of patients with 
HIV-1 infection were witnessed, with a decrease in the incidence of 
opportunistic infections, tumours and deaths (Rubbert and Ostrowski 2003).  
This early optimism waned however as a result of the emergence of 
resistance mutations to the antiretroviral therapies.  Resistance emerges 
when the PR and RT enzymes that the ART should be inhibiting are able to 
continue operating and aiding the replication of HIV-1, even in the presence 
of the drugs.  This high rate of error-prone replication, particularly the RT 
enzyme, allows rapid selection of mutations associated with drug resistance. 
These drug-resistant viruses are selected in the presence of sub-optimal 
therapy and may be horizontally and vertically transmitted to new hosts.   
Genotyping resistance testing is an important tool in selecting optimal 
therapy for patients on ART.  At the time this study was designed, there was 
a poor understanding in the clinical field with regards to the use of genotypic 
resistance testing with treatment-naïve patients.  Initially, international 
treatment guidelines did not advocate testing treatment-naïve patients prior 
to their first therapy; then the IAS-USA convened a panel to review 
antiretroviral drug resistance testing in adults and the implications for clinical 
management.  The panel members (who had expertise in ART drug 
resistance and in the care of patients with HIV-1) opinionated: ‘routine 
testing for certain patients e.g. treatment-naïve pregnant women and 
persons with PHI, should be considered for testing when the prevalence of 
drug resistance in that population is increased’ (Hirsch et al 1998).  In 2000, 
the same panel convened again and concluded: ‘prior to starting treatment in 
patients with established infection, the use of resistance testing should be 
considered, particularly in areas where the local prevalence of primary drug 
resistance is appreciable’ (Hirsch et al 2000).  The panel considered that if a 
population exhibited a transmitted resistance level of 10.0%, then this was a 
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trigger for concern and resistance testing for anyone who was treatment-
naïve in this population should be considered (personal communication with 
IAS-USA panel member). 
In 1999, an audit was conducted at the ICVC of consecutive treatment-naïve 
patients following genotypic resistance testing for clinical care (n=89).  These 
89 patients were compared to an ‘absolute treatment-naïve’ patient 
population sequenced in 1986 (n=7), (Loveday et al 1999).  The pre-ART 
cohort in 1986 revealed a homogeneous population of viruses in the patients 
tested whereas there was an increase in the heterogeneity in the virus 
genome in the 1999 cohort: no major PR mutations were seen and only one 
RT mutation (M41L) but there was a low prevalence of minor PR mutations 
associated with ART resistance in the later cohort.  There was a marked 
increase in genetic heterogeneity relative to the 1986 cohort which 
suggested ongoing and increasing genetic mobility of the genome due to the 
prolific replication rate and high error rate.   
Research aims 
At the time this study was conducted, the majority of HIV-1 clinics were not 
actively utilising resistance testing for their treatment-naïve patients; they 
would start their patients on ART and if the VL had not become undetectable 
in three months, then a resistance test would be requested.  Often, the 
resistance results highlighted the presence of mutations which impacted on 
the future treatment options for the patient. 
In order to determine the best possible clinical care for those identified as 
treatment-naïve in the ICVC Clinical Cohort Resistance Database, I 
investigated:  
• the evolving and transmitted drug resistance mutations in treatment-
naïve patients, prior to them starting their first ART regimen
• the prevalence of resistance over time between 2001 and the end of
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June 2004 
• the regional variability in resistance in treatment-naïve patients across
the ICVC UK cohort
• the implications of pre-existing drug mutations for patients about to
start their first-line ART regimen and how this could be managed in
the clinic.
Method 
Patient selection 
All treatment-naïve patients including PHI (infected with HIV-1 <6 months); 
chronic-naïve (CN, infected with HIV-1 for >6 months and treatment-naïve) 
and pregnant and treatment-naïve; who had a genotypic resistance test 
performed as part of their clinical care from 2001 to the end of June 2004, 
were identified on the ICVC Clinical Cohort Resistance Database.  The 
inclusion of PHI and CN patients in the study was important as it reflected 
the treatment-naïve population attending HIV-1 clinics for care i.e. the 
majority of patients were unaware of their HIV-1 infection and by the time 
they were diagnosed, they had already experienced the PHI stage and were 
now deemed as CN.   
For those whose genotypic test outcome was PCR-negative, they were 
excluded from the study.  For those who had more than one resistance test 
conducted during the time period, their earliest resistance test was included 
in the analyses. 
Determining resistance using the TRUGENE® HIV-1 Resistance Report 
Resistance was determined based on the TRUGENE® HIV-1 resistance 
reports generated for each patient as part of their clinical care.  The 
TRUGENE® algorithm was used to determine resistance in this treatment-
naïve study, and not a different interpretation tool e.g. the IAS-USA Drug 
Resistance Mutations Figures; as the TRUGENE® resistance report output 
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reflected the genotypic resistance profiles that were disseminated to the 
clinicians in the cohort and therefore the resistance patterns that were 
occurring across the UK clinics which the ICVC served. 
Results 
Patients’ demographics 
Three hundred and eighty treatment-naïve patients were sequenced 
between January 2001 and the end of June 2004: 2001 n=37, 2002 n=89, 
2003 n=167, 2004 n=87.  Seventy-six (20.0%) were PHI, 279 (73.4%) CN, 
and 25 (6.6%) pregnant and naive. 
Table 4.1: Treatment-naïve patients derived from 26 of 39 denominator 
hospitals with the majority from clinical centres within the Greater London 
geographical region (64.2%). 
Geographical region n % 
Greater London 244 64.2 
South East 83 21.8 
Eastern 27 7.1 
South West 8 2.1 
North West 8 2.1 
Wales 6 1.6 
East Midlands 4 1.1 
The majority of the patients were male (n=280, 73.7%), with a mean age of 
38.6 years, ranging from 20 to 77 years.  One hundred and twenty-five 
(50.8%) were infected through MSM, 117 (47.6%) through heterosexual 
contact, two (0.8%) through blood/tissue transfer, one (0.4%) bisexual and 
one (0.4%) IDU.   
Europe was the predominant origin of infection for 192 (58.9%) of the 
patients, Africa (n=111, 34.0%); Asia (n=6, 1.8%); North America (n=5, 
1.5%); South Africa (n=3, 0.9%); Australasia, Europe/South America (all 
n=2, 0.6%); the Caribbean, the Middle East, Asia/Europe and Africa/Europe 
(all n=1, 0.3%).   
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Two hundred and thirty (60.5%) treatment-naïve patients presented with a 
subtype B virus whilst 150 (39.5%) had a non-B subtype virus, with subtype 
C being the most predominant (n=97, 25.6%). 
Evidence of resistance to ART 
Of the 380 patients, 266 (70.0%) presented with listed mutations associated 
with ART (excluding 69 (18.2%) with L63P only).  Forty-five patients (11.8%) 
had no listed mutations.  
From the 266 patients, 44 (16.5%) were found to have at least one major 
mutation: 
• 39 were male
• mean age was 38.9 years, ranging from 28 to 68
• 11 were PHI, 31 were CN, two pregnant and naïve
• 24 were MSM, seven heterosexual
• 10 presented with non-B subtypes
• 34 derived from the Greater London region
• major mutations conferred resistance to:
- NNRTIs for 31 patients (11.7%)
- NRTIs for six patients (2.3%)
- PIs for five patients (1.9%)
- two drug classes (NNRTI and NRTI) for one patient (0.4%)
- all three drug classes for one patient (0.4%).
Resistance by year, associated demographics, mutations and drug 
class affected  
In 2001, four patients had evidence of resistance (4/37, 10.8%), 15 patients 
had resistance in 2002 (15/89, 16.9%), 12 patients in 2003 (12/167, 7.2%) 
and 13 patients to the end of June 2004 (13/87, 14.9%). 
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Table 4.2: Prevalence of resistance in primary HIV-1 infection (PHI), 
chronic-naïve (CN), pregnant and treatment-naive patients with resistance, 
by year. 
 
 2001 2002 2003 2004 Total 
n % n % n % n % n % 
PHI 1/10 10.0 7/26 26.9 1/29 3.5 2/11 18.2 11/76 14.5 
CN 3/24 12.5 8/58 13.8 9/127 7.1 11/70 15.7 31/279 11.1 
Pregnant 
& naïve 
0/3 0.0 0/5 0.0 2/11 18.2 0/6 0.0 2/25 8.0 
 
A detailed tabulation for each individual patient with resistance mutations 
detected: their associated demographic data, the specific mutations 
identified and the drug class affected, by year; are presented in Appendix 3.  
This detailed tabulation of all the research information may be of value to 
other researchers in the future, and as such, has been noted here. 
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For those with VL data available (VL of the sample tested or most recent VL level i.e. in the past three months), 
Table 4.3a broadly illustrates the VL levels associated with the cohort.  Table 4.3b presents in detail the VL of the 
patients presenting as PHI, CN, pregnant and naive, and evidence of resistance. 
Table 4.3a: Viral load and evidence of resistance. 
Resistance n Mean VL (c/mL) Range VL (c/mL) 
No resistance 297 293,799 400 – 15,000,000 
Evidence of resistance 41 236,713 5910 – 892,000 
To NNRTIs 29 248,566 5910 – 892,000 
To NRTIs 5 144,314 7570 – 329,000 
To PIs 5 296,708 7940 - >750,000 
To NNRTIs + NRTIs 1 80,700 - 
To all 3 drug classes 1 211,000 - 
Table 4.3b: Viral load (VL), evidence of resistance (R) to the non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs); and presentation as 
primary HIV-1 infection (PHI), chronic-naive (CN) or pregnant and treatment-naïve. 
Treatment-
naive 
grouping 
No resistance R to the NNRTIs R to the NRTIs R to the PIs 
n Mean 
VL 
(c/mL) 
Range 
VL 
(c/mL) 
n Mean 
VL 
(c/mL) 
Range 
VL 
(c/mL) 
n Mean 
VL 
(c/mL) 
Range 
VL 
(c/mL) 
n Mean 
VL 
(c/mL) 
Range 
VL 
(c/mL) 
PHI 59 386,016 400 – 
8,000,000 
8 238,200 29,800– 
830,000 
2 218,000 107,000– 
329,000 
1 368,000 - 
CN 218 293,936 400 – 
15,000,000 
20 220,541 5910 – 
750,000 
3 95,190 7570 – 
203,000 
4 278,885 7940 – 
750,000 
Pregnant 
and naive 
20 20,266 400 – 
158,000 
1 892,000 - - - - - - - 
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Graphs 4.1a-c highlight the resistance mutations identified, by year, by treatment-naïve grouping (PHI, CN, 
pregnant and naïve) and the impact of the resistance mutations for the drug class affected.  The two patients’ with 
multi-class resistance were included in the separate drug class graphs: Graph 4.1a shows the NNRTI data, 
Graph 4.1b shows the NRTI data and Graph 4.1c shows the PI data. 
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Graph 4.1a: Non-nucleoside reverse transcriptase inhibitors (NNRTIs), associated mutations and prevalence of 
resistance over the study (and presentation as primary HIV-1 infection (PHI), chronic-naive (CN) or pregnant and 
treatment-naïve).  K103N was the most prevalent of the NNRTI mutations impacting use of the whole of the 
NNRTI drug class.  V179D mutation was the next most frequent mutation which translated as possible resistance 
to all of the NNRTIs. 
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Graph 4.1b: Nucleoside reverse transcriptase inhibitors (NRTIs), associated mutations and prevalence of 
resistance over the years (and presentation as primary HIV-1 infection (PHI), chronic-naive (CN) or pregnant and 
treatment-naïve).  The graph depicts low frequencies of NRTI mutations with treatment options within this drug 
class available to the majority of the patients with these mutations.  However, for the patient with four NRTI 
resistance mutations (K70R+M184V+T215Y+K219E) the accumulation of these mutations impacted a number of 
the specific drugs available within this class.  
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Graph 4.1c: Protease inhibitors (PIs), associated mutations and prevalence of resistance over the years (and 
presentation as primary HIV-1 infection (PHI), chronic-naive (CN) or pregnant and treatment-naïve). The graph 
depicts low frequencies of PI mutations with other PI treatment options within this drug class available to the 
majority of the patients with these mutations.   
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To determine the persistence of the transmitted resistance mutations, the 
date of diagnosis was subtracted from the sample date to provide an 
approximation of the length of time the resistance associated mutations had 
persisted for in the patient’s circulating virus population. 
Table 4.4: The persistence of resistance associated mutations circulating in 
a patient’s virus population (sample date minus date of diagnosis) by drug 
class (non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside 
reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs)).  The 
table illustrates that some of these related mutations can persist for >12 
months. 
Resistance mutation by drug class Persistence of mutation 
(in months) 
n 
NNRTIs 
A98S <3 1 
K101E 
K101Q 
>12 <18
>6 <12
1
1
K103N <3 
>6 <12
>18 <24
>36
3
1
1 
1 
V179D 
V179E 
>6 <12
>30 <36
<3
2
1
1 
Y181C >6 <12 1 
NRTIs 
D67N >12 <18 1 
M184I >6 <12 1 
K219Q >12 <18 1 
PIs 
D30N >12 <18 1 
M46I/L >12 <18 1 
A71V >12 <18 1 
N88D >12 <18 1 
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Discussion 
The overall resistance prevalence rate in a cohort of 380 treatment-naïve 
patients with HIV-1 was 16.5%.  In patients presenting with PHI, the overall 
resistance prevalence rate was 14.5%, for CN patients it was 11.1%, and for 
women who were pregnant and treatment-naïve it was 8.0%.  Adopting the 
IAS-USA rule that if a population exhibited a transmitted resistance level of 
10.0%, resistance testing should be considered (IAS-USA panel 1998 
personal communication), all these patient classes provided evidence that all 
treatment-naïve patients should be tested for resistance at baseline.  At the 
ICVC, we presented our findings to all 39 clinical centres and advocated that 
their treatment-naïve patients, irrespective of their treatment-naïve grouping 
(PHI/CN/pregnant and naïve), should have a genotypic resistance test 
conducted before initiating treatment. 
Overall, for those patients with resistance to one drug class only, the NNRTI 
drug class was most affected with 31 patients (11.7%) presenting with 
mutations associated with resistance to this drug class (three in 2001, 12 in 
2002, 11 in 2003, five to the end of June 2004).  Resistance to NNRTIs only 
requires the development of one major mutation and the patient is said to be 
resistant to all three drugs within this class.  For example, 14 patients 
presented with a K103N(T) mutation; eight with V179D/E; two with A98S; 
one with Y181C; one with K103N+Y181C; four with K101E/Q and one with 
F227L.  For these 31 patients, the clinician would not be able to utilise the 
NNRTI drug class, even for the patients with possible resistance only, 
therefore the first treatment regimen for these patients would have included 
drugs available in the NRTI and PI classes.   
The BHIVA Treatment Guidelines (Gazzard on behalf of the BHIVA Writing 
Committee 2005) recommended initial first-line HAART regimens contained 
two NRTIs and one NNRTI (see Table 4.6).  This would not be suitable for 
these 31 patients with the mutations above and the BHIVA Guidelines next 
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recommendation was that a two NRTI and boosted PI regimen was 
considered; a combination that had more side effects.  For the two NRTIs, 
Combivir (ZDV+3TC) was the most popular combination used in the UK, 
although clinicians also had TDF+FTC or ABC+3TC combinations available, 
which both offered similar efficacy to Combivir.  The BHIVA Guidelines 
recommended that LPV, boosted by RTV (LPV/r) was used as the PI, 
although other alternative options were available if LPV/r was not a suitable 
option for a specific patient.   
 
Table 4.5: Preferred first-line antiretroviral therapy (ART) regimens from the 
British HIV Association (BHIVA) Guidelines for the treatment of HIV-infected 
adults with antiretroviral therapy: a combination of two nucleoside reverse 
transcriptase inhibitors (NRTIs) and one non-nucleoside reverse 
transcriptase inhibitor (NNRTI) was preferred (Gazzard on behalf of the 
BHIVA Writing Committee 2005). 
 
Regimen A B   C 
Preferred EFV 
LPV/r 
ZDV 
ABC 
TDF 
ddI 
3TC 
FTC 
Alternative FOS/r 
SQV/r 
  
Specific groups NVP 
ATAZ 
ATAZ/r 
  
 
Prevalence of resistance associated mutations related to the NRTI drug 
class (2.3%) and PI drug class (1.9%) remained at low levels over the years 
in this clinical cohort.  For these drug classes it was important to consider the 
resistance associated mutations on a drug by drug basis as, unlike the 
NNRTIs, the presence of one major NRTI or PI mutation did not necessarily 
translate as resistance to all drugs within the classes.   
 
In this study, six patients (2.3%) had mutations associated with the NRTI 
class, with four patients presenting in 2004.  Of the six, only one patient had 
resistance to the majority of the drugs within the class including ZDV, ddI, 
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ddC, 3TC, d4T and ABC.  Using the BHIVA treatment guidelines, this patient 
only had TDF+FTC available to use as a two NRTI backbone.  Three 
patients had resistance to ZDV only, one patient had resistance to ddC and 
possible resistance to ddI, and one had resistance to 3TC and possible 
resistance to ddC.  The clinicians for these five patients therefore had 
options available to employ as a two NRTI backbone. 
Five patients presented with PI related mutations (1.9%), with four seen in 
2004.  Two patients had a mutation affecting resistance to SQV+NFV and 
possible resistance to IDV+RTV.  One patient had possible resistance to 
IDV, RTV, APV and ATV.  Two patients had the PR mutation A71V which in 
2004 and interpreted using TRUGENE® GuideLines 8.0, translated as 
possible resistance to ATV.  However, on sign-out of the resistance report, 
the Clinical Director of the ICVC commented that the prevalence/appearance 
of this mutation should not influence the use of this drug in these patient’s 
treatment regimens.  
The presentation of PI resistance in these patients did not affect first-line 
treatment options recommended by the BHIVA Guidelines and a two NRTI 
and NNRTI initial regimen could be utilised.  However, subsequent treatment 
options may be affected by the presence of the PI mutations. 
Specific cases exemplifying clinical issues around transmitted 
resistance evolving from this study 
i) Potential for high levels of resistance being transmitted
Two patients’ resistance profiles were quite striking in this study.  The first 
patient presented as CN and had evidence of resistance to all three drugs 
classes, including resistance to the PI NFV (D30N; A71V+N88D), possible 
resistance to the NRTIs ZDV and ABC (D67N+K219Q) and possible 
resistance to all NNRTIs (K101E).  The patient was diagnosed as HIV-1 
positive in 2001 and this baseline resistance test was conducted in 
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September 2002.  His resistance profile suggested that a person with a high 
level of treatment-experience infected him and that the resistance mutations 
had persisted since he was infected.  As per the BHIVA Guidelines, the 
clinician did have options available to treat this patient including using a two 
NRTI backbone of TDF+FTC, or using ddI+3TC or ddI+FTC, which are both 
well tolerated options, but ddI does have food restrictions and there is a 
potential for long term mitochondrial toxicity.  A boosted PI, probably LPV/r, 
would complete the regimen as the NNRTI class was not available to use. 
 
The second striking resistance profile was for a patient who presented as 
pregnant and treatment-naïve.  She was found to have resistance to the 
NRTIs ddI, ddC (K65R), possible resistance to TDF (K65R) and ABC 
(K65R+Y115F), and resistance to the NNRTIs NVP, DLV (Y181C) and 
possible resistance to EFV (Y181C).  Once again, the patient’s resistance 
profile indicated that a person with quite a high level of treatment-experience 
infected her.  Another suggestion may be that she had previously taken 
some antiretroviral drugs but was not willing to divulge.  Using the BHIVA 
Guidelines, the clinician could use a two NRTI backbone of ZDV+3TC, and a 
boosted PI, probably LPV/r.  However, this patient was pregnant and the 
clinician would need to consider the suitability of these drugs for both the 
patient and her baby.  
 
ii) Demonstration of patient to patient transmission 
Whilst liaising with one of our clinical collaborators, it became evident that a 
couple of patients’ resistance profiles in the treatment-naive cohort were 
epidemiologically linked (Kinloch et al 2003).  It transpired that patient SPSS 
92 (the ‘donor’) and patient SPSS 99 (the ‘recipient’) were partners 
practicing unprotected sexual intercourse.  SPSS 92 was diagnosed as PHI 
in June 2002 whilst his partner SPSS 99 was diagnosed in September 2002.  
Their resistance profiles were similar; both presented with the major RT 
mutation K103N.  The only difference in their resistance profiles was that 
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SPSS 99 had one additional polymorphism (RT: T165T/I) to SPSS 92’s 
profile.  Sequencing of both patients’ strains showed that there was <1.0% 
difference between the two strains, suggesting a strong epidemiological link 
between the two infections.  This ‘case study’ reflected that horizontal 
transmission of the K103N resistant mutation was possible amongst a 
person who was treatment-naïve to another person who was treatment-
naive. 
iii) Importance of resistance testing at baseline
Another important case on the ICVC Clinical Cohort Resistance Database 
highlighted the importance of clinicians requesting resistance testing for their 
treatment-naïve patients before initiating therapy.  Patient SPSS 3315 was 
diagnosed with HIV-1 on 13/09/2005.  The clinician prescribed a first-line 
treatment regimen of 3TC, ABC and EFV which the patient started on 
18/10/2005.  A resistance test was requested in December 2005 as the 
patient's virus was not responding to the treatment, even though it was 
deemed his adherence was excellent.  The patient's VL was 105,552c/mL 
and his CD4 count was 31cells/µL.  The resistance report showed the patient 
had the minor PR mutation L10I and the RT mutations V106M, V179D and 
M184V.  These RT mutations translated as conferring resistance to the 
NRTIs 3TC/FTC, possible resistance to ddC, and resistance to all the 
NNRTIs (NVP, DLV and EFV).  If the clinician had requested the resistance 
test before initiation of ART, perhaps this first-line treatment failure could 
have been averted. 
This is not a straightforward issue however and the clinical situation will 
influence whether a baseline, pre-initiation of ART resistance test can be 
requested.  For example, patient SPSS 3083 was diagnosed in June 2004 
and had a VL of 172,000c/mL and a CD4 count of only two cells/µL.  The 
clinician started ART immediately as the CD4 count was so low, and could 
not wait for the results of a resistance test.  The patient was prescribed ABC, 
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3TC and NVP on 18/06/2004.  The clinician requested a resistance test on a 
sample from the patient in September 2004 as the patient had a poor 
response to the treatment regimen, even though they stated their adherence 
was excellent.  The patient's VL in September was 66,500c/mL with a CD4 
count of nine cells/µL.  The resistance test showed the patient had mutations 
which conferred resistance to 3TC (NRTI), NVP and DLV (NNRTIs) as well 
as possible resistance to ddC (NRTI) and EFV (NNRTI).  Following these 
results, the clinician requested a retrospective resistance test was conducted 
using a sample stored at the ICVC from before the patient had started on 
ART.  This retrospective analysis only highlighted the minor PR mutation 
M36I. In this case, a resistance test before initiating ART would not have 
highlighted the mutations which occurred once treatment was started.  The 
resistant variants transmitted were not identified at baseline testing: 
explanations for this include reversion of the transmitted resistant virus to 
WT and that the resistant variants were archived and only came to the 
forefront once treatment was initiated.  Another possible explanation 
includes the fact that resistance tests are unable to detect minority variants 
that comprise <20.0% of the viral population, and although techniques are 
now available to detect these minorities, they are complex and not 
appropriate for use in clinical practice (Haubrich 2005). 
 
In conclusion, this clinical study identified a significant level of transmitted 
resistance mutations circulating in the treatment-naïve population and this 
warranted the recommendation that all treatment-naïve patients (irrespective 
of whether they were PHI, CN or pregnant and naïve) should have baseline 
genotypic resistance testing conducted before the initiation of their first-line 
treatment regimens, to ensure the best possible clinical care. 
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When treatment first became available for patients with HIV-1 it was initially 
with NRTI monotherapy (Fischl et al 1987; Larder and Kemp 1989); then a 
combination of two NRTIs were used (Schlomo et al 1996; Katlama et al 
1996; Delta Coordinating Committee 1996; Hammer et al 1996); and there 
was every opportunity for HIV-1 replication to continue as the virus was able 
to mutate and evolve resistance to these drugs that were being used to 
attempt to suppress HIV-1 replication.  Even though great advances were 
seen when HAART (NRTIs + PIs +/or NNRTIs) were introduced to treat 
patients with HIV-1 (Hammer et al 1997; Gulick et al 1997; Cameron et al 
1998), the high pill burden (patients were required to take up to 30 tablets a 
day) and side-effects, often resulted in suboptimal adherence rates; HIV-1 
was able to replicate, even in the presence of low concentrations of the 
drugs, leading to the development of resistance mutations and drug failure 
(Paterson et al 2000; Dunbar et al 2000).   
The ICVC Clinical Cohort Resistance Database included a large proportion 
of patients with HIV-1 who were highly treatment-experienced and who had 
lived through the early years of the HIV-1 treatment developments leading to 
HAART.  Genotypic resistance tests were conducted for these treatment-
experienced patients and they provided an opportunity to understand the 
resistance mutations that were currently circulating within this treatment-
experienced clinical cohort and the UK community.  These mutation data 
could be used to interpret the next treatment options available for the 
patients currently failing therapy or wishing to re-start treatment.   
Research aims 
Of those identified as treatment-experienced in the ICVC Clinical Cohort 
Resistance Database, the aims were to investigate:  
• the frequency of important and specific major NRTI, NNRTI and PI
resistance mutations
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• the prevalence of these resistance mutations over time: were there
any significant differences observed in the early cohort (EC, 1996-
2000) and the late cohort (LC, 2001-2006)
• the geographical distribution of these resistance mutations across the
cohort
• the cumulative resistance profiles over time of those treatment-
experienced patients who had more than one genotypic report.
Method 
Patient selection 
All treatment-experienced patients who were currently on treatment or had 
previous treatment-experience, were eligible for inclusion.  Complete PR and 
RT sequences were required for analysis, so treatment-experienced patients 
whose genotypic analyses provided only a partial sequence (PR only (1.2%) 
or RT only (0.9%)) or were PCR-negative (16.5%) were excluded from the 
study. 
Determining resistance 
The IAS-USA Update of the Drug Resistance Mutations in HIV-1: December 
2009 list (Johnson et al 2009) was used to determine major resistance 
mutations prevalent in this study. 
NRTI mutations included: M41L, A62V, K65R, D67N, 69Insert, K70R, L74V, 
V75I, F77L, Y115F, F116Y, Q151M, M184I/V, L210W, T215F/Y, K219E/Q. 
NNRTI mutations included: V90I, A98G, L100I, K101E/H/P, K103N, 
V106A/M, V108I, E138A, V179D/F/T, Y181C/I/V, Y188C/L/H, G190A/S, 
P225H, M230L. 
PI mutations included: L10C/F/I/R/V, V11I, I13V, G16E, K20I/M/R/T/V, L24I, 
D30N, V32I, L33F/I/V, E34Q, E35G, M36I/L/V, K43T, M46I/L, I47A/V, G48V, 
I50L/V, F53L/Y, I54A/L/M/S/T/V, Q58E, D60E, I62V, L63P, I64L/M/V, H69K, 
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PI mutations included (contd.): A71I/L/T/V, G73A/C/S/T, T74P, L76V, V77I, 
V82A/F/L/S/T, N83D, I84V, I85V, N88D/S, L89V, L90M, I93L/M. 
Key:  
For those NNRTI and PR amino acid positions highlighted in bold, they were considered 
major (primary) mutations which occur first and the non-bold were minor (secondary 
mutations) that are supportive to the molecular changes which are associated with the 
primary mutations.  
 
Data analyses 
Two approaches to data analysis were adopted once it was determined, at 
patient selection, that there were a group of treatment-experienced patients 
who had more than one genotypic resistance entry available on the 
database.  Patients with one genotype resistance report were pooled and 
their data analysed together to determine the prevalence of major resistance 
mutations (and their impact on the drugs classes) by calendar year.  Patients 
with more than one genotype resistance report where reports were 
conducted in different years (1996-2006), were initially analysed as per the 
first group (i.e. reports in different years in the same patient were treated as 
independent); but a second analytical approach (Pillay et al 2005) was also 
utilised to determine the accumulation of major resistance mutations in this 
group over the time period analysed.  For example, a patient had a 
resistance report from 2000 which showed major mutations which conferred 
resistance to the NNRTI drug class.  This patient had another resistance 
report available from 2002 which showed major mutations to the NRTI and 
PI drugs classes.  Using the first approach (one resistance report per year) 
this patient would be classed as having NNRTI resistance in 2000 and 
NRTI+PI resistance in 2002.  Using the cumulative approach, this patient 
would be classed as having NNRTI resistance in 2000 and NNRTI+NRTI+PI 
resistance in 2002; once mutations have developed, even if they are not 
detected by the resistance test they have not ‘disappeared’ and no longer 
exist, but have been archived and would become the dominant virus 
population once treatment related to the archived resistance mutations was 
initiated again (Lambotte et al 2004, Pillay et al 2005). 
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Statistical analyses were conducted using SPSS (version 22).  Chi2 (χ2) 
analyses were used to test for any significant differences in the distribution of 
mutations between the EC and the LC.  Significance was assigned at the 
0.05 level (p<0.05). 
Results 
Overall, 1,786 treatment-experienced patients were eligible to take part in 
this study including 1,488 with one genotypic resistance report available and 
298 patients with more than one report available (725 reports in 298 patients 
making a total of 2,213 genotypic resistance reports altogether). 
Patients’ demographics 
Of the 1,786 treatment-experienced patients, the majority were male (968 
males, 72.6%, and the minority 366 females, 27.4%).  The mean age of the 
male patients was 44.7, ranging from 18 to 78 years while the mean female 
age was 38.9, ranging from 18 to 87 years.  Of risk exposure group data 
provided (n=469): 250 (52.1%) of patients were infected through 
heterosexual contact, 170 (35.4%) through MSM, 21 IDU (4.4%), 14 through 
blood/tissue transfer (2.9%), 11 mother-to-child (2.3%), two MSM/IDU (0.4%) 
and one sharps injury (0.2%).  Of origin of infection data provided (n=1,040): 
Europe was the predominant origin (559 patients, 53.5%) while the 
remainder were from: Africa (n=411, 39.4%); Asia (n=24, 2.3%); North 
America (n=23, 2.2%); South America (n=9, 0.9%); Australasia (n=6, 0.6%); 
Caribbean (n=4, 0.4%); South Africa (n=3, 0.3%); and the Middle East (n=1, 
0.1%). 
Evidence of resistance in the 1,488 treatment-experienced patients with 
one genotypic report available 
Of the 1,488 patients in the treatment-experienced cohort with one genotypic 
report available: 680 (45.7%) were currently on ART treatment, 213 (14.3%) 
were not currently on ART but had previous experience and 595 (40.0%) 
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were treatment-experienced but it was not indicated whether they were on a 
current ART regimen and/or had previous ART experience. 
Of the 680 currently on ART treatment, 584 (85.8%) were taking three or 
four drugs in their regimen, three (0.2%) were on one drug only, 50 (3.4%) 
were on two, 15 (1.0%) were on five drugs and seven (0.5%) were on six 
drugs.  Thirty-two different combinations were prescribed with 257 (39.0%) 
on a combination of 2 NRTIs + 1 NNRTI, 142 (21.5%) on 2 NRTIs + 1 PI, 48 
(7.3%) on 3 NRTIs, 44 (6.7%) on 2 NRTIs + 2 PIs, 39 (5.9%) on 2 NRTIs, 25 
(3.8%) on 3 NRTIs + 1 NNRTI, 18 (2.7%) on 3 NRTIs + 1 PI, 15 (2.3%) on 2 
NRTIs + 1 NNRTI + 1 PI, and 13 (2.0%) on 1 NRTI + 1 NNRTI + 1 PI.  There 
were a further 23 combinations of specific drugs within the drugs classes 
prescribed to 58 patients, all with <1.0% of patients on the combination. 
Half of the 680 currently on ART treatment also had previous treatment 
experience (n=344, 50.6%).  The mean number of previous ART drugs was 
3.9 with a minimum of one and a maximum of 15 other drugs. 
Of the 213 who were not on ART but had previous experience, the mean 
number of previous ART drugs was 4.2 with a minimum of one and a 
maximum of 12 other drugs.  All 213 patients had previous NRTI experience 
with 116 (54.5%) having previous NNRTI drugs and 109 (51.2%) previous PI 
drugs. 
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Table 5.1: Frequencies of antiretroviral drugs by current usage and previous 
experience; showed wide use of nucleoside reverse transcriptase inhibitors 
(NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 
less use of protease inhibitors (PIs). 
  Currently on ART Not currently on ART 
 
 
Drug 
class 
Antiretroviral 
drug 
Current usage 
(n=680) 
Previous 
drug 
experience 
(n=344) 
Previous drug 
experience 
(n=213) 
n % n % n % 
NRTIs ZDV 272 41.3 269 78.2 182 83.9 
ddI 190 28.8 157 45.6 93 42.9 
ddC 19 2.9 74 21.5 20 9.2 
3TC 443 67.2 204 59.3 178 82.0 
d4T 252 38.2 172 50.0 113 52.1 
ABC 132 20.0 42 12.2 38 17.5 
TDF 85 12.9 9 2.6 14 6.5 
FTC 3 0.5 1 0.3 2 0.9 
NNRTIs NVP 198 30.0 108 31.4 82 37.8 
DLV 6 0.9 9 2.6 2 0.9 
EFV 131 19.9 69 20.1 49 22.6 
PIs SQV 63 9.6 70 20.3 44 20.3 
IDV 41 6.2 96 27.9 38 17.5 
RTV 65 9.9 81 23.5 41 18.9 
NFV 91 13.8 77 22.4 44 20.3 
APV 7 1.1 9 2.6 2 0.9 
LPV/r 72 10.9 13 3.8 14 6.5 
LPV 11 1.7 3 0.9 3 1.4 
TPV 0 0.0 0 0.0 0 0.0 
ATV 3 0.5 1 0.3 1 0.5 
FPV 1 0.2 0 0.0 0 0.0 
 
Overall, 977 (65.7%) of the 1,488 patients in the treatment-experienced 
cohort with one genotypic report available presented with major resistance 
mutations which impacted one or more drug class:  
• 319 (21.5%) had major mutations which impacted one drug class 
(12.9% NRTIs; 7.1% NNRTIs; 1.5% PIs) 
• 491 (33.0%) had major mutations which impacted two drugs classes 
(21.6% NRTI+NNRTI; 10.9% NRTI+PI; 0.5% NNRTI+PI)  
• 167 (11.2%) had major mutations to all three drugs classes.   
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Four hundred and thirty-eight patients (29.4%) presented with minor PI 
mutations only and 73 (4.9%) had no mutations.   
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Graph 5.1: Percentage of patients, per year, identified with major mutations (muts) which conferred resistance to 
the antiretroviral therapies within one drug class, two drugs classes or all three drugs classes. The graph also 
shows the frequency of minor protease inhibitor (PI) mutations over the years with a clear increase from 1997 to 
2006. 
 
 
 
* 1996 not presented in the graph above as the denominator was small (n=2).
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Of the 1,488 treatment-experienced cohort with one genotypic report 
available: 525 patients (35.3%) had genotypic resistance tests conducted 
during 1996-2000 and formed the early cohort (EC) whilst 963 (64.7%) were 
tested during 2001-2006 and formed the late cohort (LC). 
Table 5.2: Comparison of the prevalence of major mutations in the early 
cohort (EC, 1996-2000) and the late cohort (LC, 2001-2006) by drug classes 
affected.  There was a decrease in the frequency of major mutations 
impacting all three drugs classes between the EC (14.9%) and LC (9.2%); 
and an overall decrease in major mutations affecting two drugs classes (EC: 
43.0%, LC 27.5%), particularly the nucleoside reverse transcriptase 
inhibitors (NRTIs) and protease inhibitors (PIs) drugs classes between the 
EC (22.5%) and LC (4.6%). 
Major mutations and 
drug class affected 
Early cohort 
(EC)  
(n=525) 
Late cohort 
(LC)  
(n=963) 
Total 
(n=1,488) 
n % n % n % 
All three drugs classes 78 14.9 89 9.2 167 11.2 
Two drugs classes 
NRTI+PI 
NNRTI+PI 
NRTI+NNRTI 
226 
118 
3 
105 
43.0 
22.5 
0.5 
20.0 
265 
44 
4 
217 
27.5 
4.6 
0.4 
22.5 
491 
162 
7 
322 
33.0 
10.9 
0.5 
21.6 
One drug class 
NRTI 
NNRTI 
PI 
117 
80 
29 
8 
22.3 
15.3 
5.5 
1.5 
202 
112 
76 
14 
21.0 
11.6 
7.9 
1.5 
319 
192 
105 
22 
21.4 
12.9 
7.1 
1.5 
Minor PI mutations only 79 15.0 359 37.3 438 29.4 
No mutations 25 4.8 48 5.0 73 4.9 
Total 525 100.0 963 100.0 1,488 100.0 
Geographical distribution of resistance mutations 
The majority of the clinical cases were from the Greater London region 
(n=1,011, 67.9%) with 203 (13.6%) from the South East, 89 (6.0%) seen in 
both the Eastern region and Wales, 35 (2.4%) from the South West, 23 
(1.5%) from Scotland, 22 (1.5%) from the East Midlands and 16 (1.1%) from 
the North West region. 
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Table 5.3: Major mutations and drug class affected as per the Geographical regions where the 39 clinical centres 
were based.  Major mutations were identified across all regions, impacting all three drugs classes. 
 
 
 
 
 
 
 
 
 
 
Major mutations and 
drug class affected 
Geographical regions where the clinical centres were based 
Scotland North West Wales 
East 
Midlands Eastern 
Greater 
London South East 
South 
West 
n % n % n % n % n % n % n % n % 
All three drugs classes 2 8.7 5 31.3 18 20.2 1 4.5 3 3.4 117 11.6 19 9.4 2 5.7 
Two drugs classes 10 43.5 3 18.8 42 47.2 5 22.7 12 13.5 327 32.3 80 39.4 12 34.3 
NRTI+PI 5 21.7 0 0.0 15 16.9 1 4.5 2 2.2 109 10.8 27 13.3 3 8.6 
NNRTI+PI 0 0.0 0 0.0 2 2.2 0 0.0 0 0.0 5 0.5 0 0.0 0 0.0 
NRTI+NNRTI 5 21.7 3 18.8 25 28.1 4 18.2 10 11.3 213 21.0 53 26.1 9 25.7 
One drug class 4 17.4 3 18.8 16 18.0 6 27.3 15 16.9 221 21.9 52 25.6 2 5.7 
NRTI 3 13.0 3 18.8 5 5.6 3 13.6 7 7.9 133 13.2 37 18.2 1 2.8 
NNRTI 1 4.4 0 0.0 10 11.2 2 9.1 6 6.8 72 7.1 14 6.9 0 0.0 
PI 0 0.0 0 0.0 1 2.2 1 4.6 2 2.2 16 1.6 1 0.5 1 2.8 
Minor PI mutations only 6 26.1 5 31.3 11 12.4 9 40.9 50 56.2 299 29.6 41 20.2 17 48.6 
No mutations 1 4.3 0 0.0 2 2.2 1 4.5 9 10.1 47 4.6 11 5.4 2 5.7 
Total 23 100.0 16 100.0 89 100.0 22 100.0 89 100.0 1,011 100.0 203 100.0 35 100.0 
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Resistance to the NRTI drug class 
Overall, 843 (56.7%) of the cohort presented with one or more NRTI drug 
resistance mutations.  The majority had one NRTI resistance mutation 
(n=274, 18.4%), 136 (9.1%) had two, 132 (8.9%) three, 157 (10.6%) four, 80 
(5.4%) five, 44 (3.0%) six, 15 (1.0%) seven, four (0.3%) with eight and one 
patient (0.1%) presented with 10 NRTI mutations. 
Table 5.4: Prevalence of specific nucleoside reverse transcriptase inhibitors 
(NRTI) “lifetime mutations” in the treatment-experienced clinical cohort. 
M184V was the most common mutation, followed by T215Y and M41L.  
Prevalence 
of NRTI 
mutations 
Currently 
on ART 
(n=680) 
Not on ART 
but previous 
experience 
(n=213) 
Treatment-
experienced but 
not indicated 
whether current or 
previous ART 
experience 
(n=595) 
Total 
(n=1,488) 
n % n % n % n % 
M41L 189 27.8 46 21.6 64 10.8 299 20.1 
A62V 12 1.8 5 2.3 8 1.3 25 1.7 
K65R 12 1.8 6 2.8 25 4.2 43 2.9 
D67N 185 27.2 41 19.2 58 9.7 284 19.1 
69Insert 
T69D 
T69N 
38 
14 
5.6 
2.1 
3 
0 
1.4 
0 
7 
3 
1.2 
0.5 
38 
17 
2.6 
1.1 
K70R 125 18.4 33 15.5 58 9.7 216 14.5 
L74V 43 6.3 7 3.3 26 4.4 76 5.1 
V75I 10 1.5 4 1.9 7 1.2 21 1.4 
F77L 10 1.5 3 1.4 4 0.7 17 1.1 
Y115F 6 0.9 4 1.9 15 2.5 25 1.7 
F116Y 8 1.2 2 0.9 2 0.3 12 0.8 
Q151M 9 1.3 2 0.9 4 0.7 15 1.0 
M184I 15 2.2 2 0.9 19 3.2 36 2.4 
M184V 305 44.9 78 36.6 167 28.1 550 37.0 
L210W 128 18.8 28 13.1 33 5.5 189 12.7 
T215F 51 7.5 11 5.2 16 2.7 78 5.2 
T215Y 205 30.1 48 22.5 57 9.6 310 20.8 
K219E 37 5.4 14 6.6 23 3.9 74 5.0 
K219Q 59 8.7 12 5.6 22 3.7 93 6.3 
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Combinations of major NRTI mutations including TAMs 
Of the 843 patients with major NRTI mutations, 330 (39.1%) had three or 
more TAMs: 165 (50.0%) had three TAMs, 116 (35.2%) had four, 36 (10.9%) 
had five and 13 (3.9%) had six.  Of the 330, 180 (54.5%) had three or more 
TAMs and the M184V mutation; 170 (51.5%) had a combination of 
M41L+L210W+T215F/Y and 14 (4.2%) had a combination of K65R+M184V 
(seven of these patients had one other NRTI mutation including two with 
A62V, two with L74V and three with Y115F; one patient had two other NRTI 
mutations including L74V+Y115F). 
There was a significant difference (p<0.05) between the EC and the LC with 
72.6% of the EC and 48.0% of the LC presenting with one or more major 
NRTI mutations.  There was a significant decline in the prevalence of the 
following NRTI mutations in the LC compared with the EC: M41L, D67N, 
T69D/N, K70R, L74V, M184V, L210W, T215F/Y, K219Q.  
The NRTI mutations K65R and Y115F were the only mutations to 
significantly increase in prevalence between the EC and LC. 
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Graph 5.2a: Prevalence of thymidine analogue mutations (TAMs) and M184V (major nucleoside reverse 
transcriptase inhibitors (NRTI) mutations) from 1996 to 2006.  Pattern shows suboptimal treatment in 1996-1997 
(stavudine (d4T)/zidovudine (ZDV)). From 1998 onwards, the prevalence of the NRTI mutations decreased as 
highly active antiretroviral therapy (HAART) was successful in suppressing replicating virus. 
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Graph 5.2b: Prevalence of other major nucleoside reverse transcriptase inhibitors (NRTI) mutations (contd.) from 
1996 to 2006.  The frequency of these NRTI mutations was generally lower (<10.0%) compared with the 
prevalence of the thymidine analogue mutations (TAMs) and M184V illustrated above. 
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Resistance to the NNRTI drug class 
Of the cohort, 566 (38.0%) presented with NNRTI mutations.  The majority of 
the 566 had one NNRTI mutation (n=320, 21.5%), 200 (13.4%) had two, 43 
(2.9%) had three and three patients (0.2%) had four NNRTI mutations. 
Table 5.5: Prevalence of specific non-nucleoside reverse transcriptase 
inhibitors (NNRTI) mutations in the treatment-experienced clinical cohort. 
K103N was the most common mutation, followed by Y181C.  
Prevalence 
of NNRTI 
mutations 
Currently 
on ART 
(n=680) 
Not on ART 
but previous 
experience 
(n=213) 
Treatment-
experienced but 
not indicated 
whether current 
or previous ART 
experience 
(n=595) 
Total 
(n=1,488) 
n % n % n % n % 
V90I 0 0.0 0 0.0 0 0.0 0 0.0 
A98G 31 4.6 4 1.9 16 2.7 51 3.4 
L100I 8 1.2 4 1.9 9 1.5 21 1.4 
K101E 36 5.3 6 2.8 23 3.9 65 4.4 
K101H 0 0.0 0 0.0 0 0.0 0 0.0 
K101P 0 0.0 0 0.0 0 0.0 0 0.0 
K103N 163 24.0 44 20.7 109 18.3 316 21.2 
V106A 17 2.5 4 1.9 5 0.8 26 1.7 
V106I 1 0.1 0 0.0 0 0.0 1 0.07 
V106M 0 0.0 0 0.0 4 0.7 4 0.3 
V108I 27 4.0 8 3.8 31 5.2 66 4.4 
E138A 0 0.0 0 0.0 0 0.0 0 0.0 
V179D 10 1.5 5 2.3 10 1.7 25 1.7 
V179F 0 0.0 0 0.0 0 0.0 0 0.0 
V179T 0 0.0 0 0.0 0 0.0 0 0.0 
Y181C 108 15.9 22 10.3 74 12.4 204 13.7 
Y181I 5 0.7 2 0.9 2 0.3 9 0.6 
Y181V 0 0.0 0 0.0 0 0.0 0 0.0 
Y188C 3 0.4 0 0.0 1 0.2 4 0.3 
Y188H 1 0.1 0 0.0 2 0.3 3 0.2 
Y188L 8 1.2 3 1.4 14 2.4 25 1.7 
G190A 86 12.6 17 8.0 43 7.2 146 9.8 
G190S 6 0.9 3 1.4 5 0.8 14 0.9 
P225H 4 0.6 5 2.3 14 2.4 23 1.5 
M230L 0 0.0 0 0.0 6 1.0 6 0.4 
Key:  
NNRTI mutations in bold and highlighted in pink were considered major NNRTI mutations as 
per the IAS-USA mutation list (Johnson et al 2009). 
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The prevalence of one or more NNRTI mutations was comparable amongst 
the EC (38.3%) and the LC (37.9%).   
Two NNRTI mutations showed a significant difference between the EC and 
LC: the prevalence of V108I and P225H significantly increased from the EC 
to the LC. 
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Graph5.3a: Prevalence of major non-nucleoside reverse transcriptase inhibitors (NNRTI) mutations from 1996 to 
2006.  K103N was the most prevalent major NNRTI mutation overall, followed by Y181C and G190A. 
 
 
 
94
Chapter 5: Resistance in a UK HIV-1 treatment-experienced clinical cohort 
Graph 5.3b: Prevalence of other major non-nucleoside reverse transcriptase inhibitors (NNRTI) mutations (contd.) 
from 1996 to 2006.  Compared with Graph 5.3a these major NNRTI mutations were prevalent at much lower rates 
(<7.0%).  
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Resistance to the PI drug class 
The PR mutations were most prevalent: 1,343 (90.3%) of the cohort had 
such mutations.  The most frequent was one PR mutation (n=501, 33.7%), 
410 (27.6%) had two, 157 (10.6%) three, 86 (5.8%) four, 63 (4.2%) five, 46 
(3.1%) six, 31 (2.1%) seven, 29 (1.9%) eight, 16 (1.1%) nine, and four 
patients (0.3%) had ≥10 PR mutations (maximum 12).   
Of the 1,343 patients with PR mutations, only 358 (26.7%) were classed as 
having major PR mutations.  The majority had one major PR mutation 
(n=181, 13.5%), 108 (8.0%) had two, 56 (4.2%) three, six (0.4%) four, five 
(0.4%) five, and two (0.1%) had six major PR mutations. 
Table 5.6: Prevalence of specific protease inhibitor (PI) mutations in the 
treatment-experienced clinical cohort.  L90M was the most common major 
mutation, followed by M46I and V82A.  L63P was the most prevalent minor 
mutation, followed by M36I and L10I.  
Prevalence 
of PI 
mutations 
Currently 
on ART 
(n=680) 
Not on ART 
but previous 
experience 
(n=213) 
Treatment-
experienced but 
not indicated 
whether current or 
previous ART 
experience 
(n=595) 
Total 
(n=1,488) 
n % n % n % n % 
L10C 0 0.0 0 0.0 0 0.0 0 0.0 
L10F 4 0.6 1 0.5 12 2.0 17 1.1 
L10I 153 22.5 36 16.9 73 12.3 262 17.6 
L10R 2 0.3 1 0.5 0 0 3 0.2 
L10V 34 5.0 15 7.0 37 6.2 86 5.8 
V11I 0 0.0 0 0.0 0 0.0 0 0.0 
I13V 0 0.0 0 0.0 2 0.3 2 0.1 
G16E 0 0.0 0 0.0 0 0.0 0 0.0 
K20I 0 0.0 0 0.0 0 0.0 0 0.0 
K20M 12 1.8 4 1.9 13 2.2 29 1.9 
K20R 65 9.6 27 12.7 78 13.1 170 11.4 
K20T 0 0.0 0 0.0 0 0.0 0 0.0 
K20V 0 0.0 0 0.0 0 0.0 0 0.0 
L24I 16 2.4 1 0.5 4 0.7 24 1.4 
D30N 38 5.6 7 3.3 10 1.7 55 3.7 
V32I 6 0.9 2 0.9 5 0.8 13 0.9 
L33F 16 2.4 0 0.0 11 1.8 27 1.8 
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Table 5.6 (contd.): Prevalence of specific protease inhibitor (PI) mutations 
in the treatment-experienced clinical cohort.  L90M was the most common 
major mutation, followed by M46I and V82A.  L63P was the most prevalent 
minor mutation, followed by M36I and L10I. 
 
Prevalence 
of PI 
mutations 
Currently 
on ART 
(n=680) 
Not on ART 
but previous 
experience 
(n=213) 
Treatment-
experienced but 
not indicated 
whether current or 
previous ART 
experience 
(n=595) 
Total 
(n=1,488) 
n % n % n % n % 
L33I 0 0.0 0 0.0 1 0.2 1 0.1 
L33V 0 0.0 0 0.0 0 0.0 0 0.0 
E34Q 0 0.0 0 0.0 0 0.0 0 0.0 
E35G 0 0.0 0 0.0 0 0.0 0 0.0 
M36I 261 38.4 115 54.0 374 62.9 750 50.4 
M36L 1 0.1 0 0.0 4 0.7 5 0.3 
M36V 1 0.1 1 0.5 2 0.3 4 0.3 
K43T 0 0.0 0 0.0 0 0.0 0 0.0 
M46I 70 10.3 13 6.1 25 4.2 108 7.3 
M46L 28 4.1 3 1.4 10 1.7 41 2.8 
I47A 0 0.0 0 0.0 0 0.0 0 0.0 
I47V 2 0.3 1 0.5 4 0.7 7 0.5 
G48V 20 2.9 2 0.9 4 0.7 26 1.7 
I50L 0 0.0 0 0.0 0 0.0 0 0.0 
I50V 8 1.2 3 1.4 1 0.2 12 0.8 
F53L 4 0.6 3 1.4 7 1.2 14 0.9 
F53Y 0 0.0 0 0.0 0 0.0 0 0.0 
I54A 1 0.1 0 0.0 0 0.0 1 0.1 
I54L 5 0.7 1 0.5 5 0.8 11 0.7 
I54M 0 0.0 0 0.0 0 0.0 0 0.0 
I54S 0 0.0 0 0.0 0 0.0 0 0.0 
I54T 0 0.0 0 0.0 2 0.3 2 0.1 
I54V 68 10.0 12 5.6 20 3.4 100 6.8 
Q58E 0 0.0 0 0.0 0 0.0 0 0.0 
D60E 0 0.0 0 0.0 0 0.0 0 0.0 
I62V 0 0.0 0 0.0 0 0.0 0 0.0 
L63P 383 56.3 105 49.3 263 44.2 764 51.3 
I64L 0 0.0 0 0.0 0 0.0 0 0.0 
I64M 0 0.0 0 0.0 0 0.0 0 0.0 
I64V 0 0.0 0 0.0 0 0.0 0 0.0 
H69K 1 0.1 0 0.0 5 0.8 6 0.4 
A71I 3 0.4 0 0.0 1 0.2 4 0.3 
A71L 0 0.0 0 0.0 0 0.0 0 0.0 
A71T 72 10.6 22 10.3 31 5.2 125 8.4 
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Table 5.6 (contd.): Prevalence of specific protease inhibitor (PI) mutations 
in the treatment-experienced clinical cohort.  L90M was the most common 
major mutation, followed by M46I and V82A.  L63P was the most prevalent 
minor mutation, followed by M36I and L10I. 
Prevalence 
of PI 
mutations 
Currently 
on ART 
(n=680) 
Not on ART 
but previous 
experience 
(n=213) 
Treatment-
experienced but 
not indicated 
whether current or 
previous ART 
experience 
(n=595) 
Total 
(n=1,488) 
n % n % n % n % 
A71V 94 13.8 15 7.0 36 6.1 145 9.7 
G73A 0 0.0 0 0.0 0 0.0 0 0.0 
G73C 1 0.1 0 0.0 0 0.0 1 0.1 
G73S 32 4.7 2 0.9 8 1.3 42 2.8 
G73T 0 0.0 0 0.0 1 0.2 1 0.1 
T74P 0 0.0 0 0.0 0 0.0 0 0.0 
L76V 0 0.0 0 0.0 0 0.0 0 0.0 
V77I 142 20.9 11 5.2 4 0.7 157 10.6 
V82A 78 11.5 12 5.6 18 3.0 108 7.3 
V82F 4 0.6 0 0.0 1 0.2 5 0.3 
V82L 0 0.0 0 0.0 0 0.0 0 0.0 
V82S 1 0.1 0 0.0 2 0.3 3 0.2 
V82T 7 1.0 0 0.0 2 0.3 9 0.6 
N83D 0 0.0 0 0.0 0 0.0 0 0.0 
I84V 32 4.7 7 3.3 17 2.9 56 3.8 
I85V 0 0.0 0 0.0 0 0.0 0 0.0 
N88D 23 3.4 6 2.8 9 1.5 38 2.6 
N88S 1 0.1 0 0.0 3 0.5 4 0.3 
L89V 0 0.0 0 0.0 0 0.0 0 0.0 
L90M 116 17.1 23 10.8 32 5.4 171 11.5 
I93L 0 0.0 0 0.0 0 0.0 0 0.0 
I93M 0 0.0 0 0.0 0 0.0 0 0.0 
Key:  
PR mutations in bold and highlighted in pink were considered major PR mutations as per the 
IAS-USA mutation list (Johnson et al 2009). 
The prevalence of one or more PI mutations was comparable amongst the 
EC (89.7%) and the LC (90.6%).  Major PI mutations were significantly more 
prevalent in the EC however (39.6%) compared with the LC (15.6%) 
(p<0.05).  
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There was a significant decline in the prevalence of the following major PI 
mutations in the LC compared with the EC: D30N, M46I/L, G48V, V82A, 
I84V, L90M.  There was also a significant decline in the prevalence of the 
following minor PI mutations in the LC compared with the EC: L10I, L24I, 
L33F, L63P, A71T/V, G73S, V77I, N88D. Only two PI mutations, both minor, 
showed an increase in prevalence from the EC to the LC: M36I and F53L. 
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Graph 5.4a: Prevalence of major protease inhibitor (PI) mutations from 1996 to 2006.  All mutations excluding 
M46I had a prevalence of <10.0%, with a clear decline to approximately 2001 and stability afterwards reflecting 
the use of more potent PIs. 
100
Chapter 5: Resistance in a UK HIV-1 treatment-experienced clinical cohort 
 
Graph 5.4b: Prevalence of major protease inhibitor (PI) mutations (contd.) from 1996 to 2006.  Prevalence of 
these PI mutations peaked in 1997/1998 and declined to <10.0% (as per the PI mutations in the graph above) 
from 2001 onwards. 
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Evidence of resistance in the 298 treatment-experienced patients with 
more than one genotypic report available 
Of the 298 treatment-experienced patients with more than one genotypic 
resistance report available, conducted across different years: 210 had two 
reports, 58 had three reports, 22 had four reports, five had five reports and 
three patients had six reports.  A total of 725 resistance reports were 
available for the 298 treatment-experienced patients. 
At the time of genotyping, 525/725 (72.4%) were currently on ART treatment 
with the majority taking a combination with three to four drugs (462, 63.7%). 
Of those currently on ART, it was indicated that 320 (61.0%) also had 
previous experience with other drugs.  There were 91 patients (12.6%) not 
on ART but who had previous experience and 109 (15.0%) were treatment-
experienced but it was not indicated whether they were on a current ART 
regimen and/or had previous ART experience. 
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Table 5.7: Comparison of the prevalence of major mutations by the type of analysis: year by year or accumulative; 
by drug classes affected.  Year by year analyses show the number of patients with major mutations in that year.  
Cumulative analyses reflect the accumulation of major resistance mutations over the years.     
 
Major 
mutations and 
drug class 
affected 
Type of 
analysis 
 
 
1996 
 
 
1997 
 
 
1998 
 
 
1999 
 
 
2000 
 
 
2001 
 
 
2002 
 
 
2003 
 
 
2004 
 
 
2005 
 
 
2006 
 
 
Total 
All three drugs 
classes 
Year by 
year 
0 0 2 15 22 20 24 20 6 1 2 112 
Cumulative 0 0 2 17 39 59 83 103 109 110 112 112 
Two drugs 
classes 
Year by 
year 
1 4 15 33 37 32 62 43 18 2 0 247 
Cumulative 1 5 20 53 90 122 184 227 245 247 247 247 
NRTI+PI Year by year 0 4 11 12 8 8 17 14 3 2 0 79 
Cumulative 0 4 15 27 35 43 60 74 77 79 79 79 
NNRTI+PI Year by year 0 0 1 0 0 1 2 1 1 0 0 6 
Cumulative 0 0 1 1 1 2 4 5 6 6 6 6 
NRTI+NNRTI Year by year 1 0 3 21 29 23 43 28 14 0 0 162 
Cumulative 1 1 4 25 54 77 120 148 162 162 162 162 
One drug class Year by 
year 
0 1 6 15 21 28 28 46 14 9 2 170 
Cumulative 0 1 7 22 43 71 99 145 159 168 170 170 
NRTI Year by year 0 1 4 10 8 18 20 25 5 1 1 93 
Cumulative 0 1 5 15 23 41 61 86 91 92 93 93 
NNRTI Year by year 0 0 1 2 12 9 7 21 8 8 1 69 
Cumulative 0 0 1 3 15 24 31 52 60 68 69 69 
PI Year by year 0 0 1 3 1 1 1 0 1 0 0 8 
Cumulative 0 0 1 4 5 6 7 7 8 8 8 8 
Total year by year 1 5 23 63 80 80 114 109 38 12 4 529 
Total cumulative 1 6 29 92 172 252 366 475 513 525 529 529 
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Overall, 529 (73.0%) of the 725 resistance entries for 298 treatment-
experienced patients in the cohort with >1 genotypic report available 
presented with major resistance mutations which impacted one or more drug 
class:  
• 170 (23.4%) had major mutations which impacted one drug class 
(12.8% NRTIs; 9.5% NNRTIs; 1.1% PIs) 
• 247 (34.0%) had major mutations which impacted two drugs classes 
(22.3% NRTI+NNRTI; 10.9% NRTI+PI; 0.8% NNRTI+PI)  
• 112 (15.4%) had major mutations to all three drugs classes.   
 
One hundred and sixty-nine (23.3%) presented with minor PI mutations only, 
while 27 (3.7%) of the cohort had no mutations.   
 
These results were comparable with the findings of the patients with one 
resistance report only (overall resistance 65.7%, resistance to one drug 
class 21.5%, to two drugs classes 33.0%, to three drugs classes 11.2%, to 
minor mutations 29.4%, had no mutations 4.9%).   
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Graph 5.5a: For 298 treatment-experienced patients (pt’s) with more than one genotypic result available (n=725 
results), the graph shows the percentage of pt’s per year, identified with major mutations (muts) which conferred 
resistance to the antiretroviral therapies within one drug class, two drugs classes or all three drugs classes. The 
graph also shows the frequency of minor protease inhibitor (PI) mutations over the years. 
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Graph 5.5b: For 298 treatment-experienced patients (pt’s) with more than genotypic result available (n=725), the 
graph shows the accumulation of major mutations (muts), year on year, which conferred resistance to the 
antiretroviral therapies within one drug class, two drugs classes or all three drugs classes; alongside minor 
protease inhibitor (PI) mutations over the years. 
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Discussion 
The resistance mutation profiles from 2,213 reports for 1,786 treatment-
experienced patients were analysed.  It was determined 68.1% of the 
samples submitted for genotypic resistance testing had major mutations; 
22.1% had mutations which impacted one drug class, 33.3% had mutations 
which impacted two drugs classes and 12.6% had mutations which impacted 
all three drugs classes.   
Analyses were conducted independently for those treatment-experienced 
patients with one resistance report only (n=1,488) and for those patients who 
had more than one resistance report available over the study time period 
(n=298, 725 reports). 
Resistance in the 1,488 treatment-experienced patients with one 
genotypic report available 
Of the 1,488 treatment-experienced patients, 56.7% harboured major 
mutations to the NRTI drug class; 38.0% had major mutations to the NNRTI 
drug class and 26.7% had major mutations to the PI drug class (90.3% had 
minor PI mutations).  At the time of treatment, only three drugs classes were 
available to treat these patients and for those in the EC, there were fewer 
treatment options available.  For the 38.0% of patients who had resistance 
mutations to the NNRTIs, this drug class was no longer available to them as 
one mutation conferred resistance to all of the first-generation NNRTIs within 
this class.  For the 56.7% of patients with NRTI resistance and 26.7% with PI 
resistance, the clinician would have considered the resistance report output 
that was provided to them and taken into account any previous drugs that 
had been used and the potential for the mutations that were identified at this 
resistance test to impact on future treatment options.  At the ICVC, the 
Clinical Director was available to discuss patient cases and alongside the 
clinician, review the resistance output and provide expert interpretation of the 
mutational profile and potential treatment options.  
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NRTI resistance mutations 
There was a significant decline in the prevalence of NRTI resistance 
mutations from the EC to the LC.  Graphs 5.2a-b and statistical analyses of 
the specific NRTI mutations prevalent in the EC and the LC, determined a 
significant decline in the prevalence of the TAMs (M41L, D67N, K70R, 
L210W, T215F/Y, K219Q); mutations associated with the early NRTI drugs 
ZDV and d4T, that were available for treatment (Shafer and Schapiro 2008).  
With the introduction of newer and more robust drugs to the NRTI class, 
there was a more marked suppression of viral replication and thus a 
decreased opportunity for resistance mutations to emerge, as is evident in 
the LC. 
Two NRTI mutations: K65R and Y115F did significantly increase in 
prevalence between the EC and LC.  K65R is observed in patients treated 
with ddC (Gu et al 1994), ddI (Zhang et al 1994), ABC (Miller et al 2000) and 
TDF (Margot et al 2002).  Its increase in the LC likely reflects the extent of 
treatment with NRTI drugs in this cohort: 98.8% currently on treatment and 
94.1% with previous ART experience were on NRTI containing regimens. 
The Y115F mutation confers resistance to ABC (Miller et al 2000) and its 
appearance in the LC likely reflects the significant increased use of this drug 
in the LC: 8.6% of the EC had experience with ABC compared with 16.5% of 
the LC (p<0.05). 
NNRTI resistance mutations 
Of the NNRTI major mutations (Graphs 5.3a-b), K103N was the most 
prevalent mutation and remained so over time.  Graph 5.3a clearly reflects 
the introduction of NNRTIs to treatment regimens, particularly EFV in 1998, 
with a peak in 1999 of the major mutations: K103N (30.0% prevalence), 
Y181C (20.0%) and G190A (14.0%).  These three mutations remained 
dominant, although their prevalence declined over time.   
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All other major NNRTI mutations (Graph 5.3b) remained at a prevalence of 
<7.0%: a significant increase in the prevalence of V108I and P225H from the 
EC to the LC was seen, with P225H first appearing in 2001.  V108I is 
associated with NVP and EFV drug use and reduces susceptibility by two-
fivefold (Rhee et al 2003, Shafer and Schapiro 2008).  P225H is associated 
with EFV use and is generally seen in the presence of K103N (Bacheler et al 
2001, Shafer and Schapiro 2008): 22 of the 23 patients with P225H in this 
cohort also had K103N.  First-generation NNRTIs used with this group of 
treatment-experienced patients had a low genetic barrier and once one of 
these major mutations were established, the drug class was no longer 
efficacious (Shafer and Schapiro 2008). 
PI resistance mutations 
Major PI resistance mutations were significantly more prevalent in the EC 
compared with the LC with Graphs 5.4a-b clearly showing the significant 
decline in the major PR mutations D30N, M46I/L, G48V, V82A, I84V and 
L90M over time.  All these mutations followed a similar pattern of decline and 
it likely reflects the introduction of more potent PI drugs, in particular the 
effect of using RTV to boost the other PI drugs.   
The mutation M46I, did not follow this general pattern of decline and as 
shown on Graph 5.4a, it had a saw-tooth pattern: the mutation was first seen 
in 1997 (5.0% prevalence) which increased to 13.0% in 1999, declined to 
4.0% in 2000, increased to 10.0% in 2002, declined to 3.0% in 2003, 
increased to 6.0% in 2005 and decreased to 0.0% in 2006.  M46I was 
considered a major PR mutation for resistance to IDV/r and a minor mutation 
for NFV, LPV/r, ATV/r and FPV/r.  These drugs were available for treatment 
at different time points throughout the span of this study with IDV and RTV 
introduced in 1996, NFV in 1997, LPV/r in 2000, ATV/r and FPV/r in 2003.  
The spike in prevalence of M46I coincides with the introduction of these 
drugs and may reflect this and the development and appearance of this 
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mutation as a major and minor mutation dependent on the specific PI drug 
used. 
 
Resistance in the 298 treatment-experienced patients with more than 
one genotypic report available (n=725) 
 
Of the 725 reports for 298 treatment-experienced patients, 61.5% harboured 
major mutations to the NRTI drug class; 48.1% had major mutations to the 
NNRTI drug class and 28.3% had major mutations to the PI drug class 
(90.9% had minor PI mutations).  The prevalence of major NRTI and NNRTI 
resistance mutations was higher in this sub-group of patients compared with 
the 1,488 with one report only (56.7% NRTI mutations, 38.0% NNRTI 
mutations) whilst the prevalence of PI major and minor mutations was 
comparable (26.7% major PI mutations, 90.3% minor PI mutations).  
 
Table 5.7 highlighted the different interpretation analyses used, which 
showed the prevalence of resistance mutations over time, either year by 
year, or cumulative analyses.  This cumulative approach was used to 
illustrate that once mutations are identified in a patient, they may disappear 
from the plasma and may not be seen in the next resistance test but they are 
archived and retained in memory cells and can be recalled if the appropriate 
drug is given: these are “lifetime mutations”.  Using Graphs 5.5a-b to 
consider this concept further: Graph 5.5a (one resistance report per patient, 
per year) showed major mutations to two drugs classes had declined over 
time with a 10.0% prevalence in 2005 and no resistance in 2006.  However, 
Graph 5.5b (accumulation of resistance mutations) showed a prevalence of 
~35.0% in 2005 of major mutations impacting two drugs classes year on 
year, which was maintained in 2006.  Graph 5.5a showed more fluctuation in 
the frequencies of patients with mutations impacting the drug classes 
whereas using the cumulative approach (Graph 5.5b), a more stable 
interpretation was provided.   
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Further studies need to be conducted to evaluate this cumulative design and 
concept.  For each patient with >1 resistance report, a cumulative mutational 
profile could be determined (see Figure 5.1 for an example). 
 
Figure 5.1: The mutational profile of one of our patients who had five 
resistance entries available on the ICVC Clinical Cohort Resistance 
Database.  The boxes highlighted in red indicate the identification of 
mutations that year and showed that at some time points, mutations seen 
previously had been archived.  For example, the PI mutation M46I/L was 
identified in 2000, was undetected in 2001, detected again in 2002 and 2004 
and undetected in 2005.  The final column shows the accumulated mutations 
that can be found in the patient’s plasma or memory cell archive since the 
patient started his first treatment.   
 
 
Resistant mutations 
Year resistance test 
conducted 
 
“Lifetime 
mutations” 2000 2001 2002 2004 2005 
 
PI mutations 
M46I/L       
I47V       
I54L       
I84V       
L90M       
NRTI 
mutations 
M41L       
T69N       
L74V       
M184V       
L210W       
T215Y       
NNRTI 
mutations 
K101E       
K103N       
Y181C       
G190A       
 
Future research will be undertaken to interrogate the ICVC Clinical Cohort 
Resistance Database to evaluate using mutational profiles e.g. the treatment 
pathway information for this patient, alongside this mutational profile (Figure 
5.1) which illustrated the “lifetime mutations” this patient had; this could 
provide a powerful tool to aid the clinical management of patients with HIV-1. 
 
In conclusion, this study showed at a population level, the prevalence and 
trends of resistance mutations in a UK treatment-experienced clinical cohort.  
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The clinicians would use the resistance reports to determine the best 
treatment options for their patient and ensure the best possible care for 
them.  These analyses also provided evidence of the key mutations 
circulating in the treatment-experienced population in a community, and 
therefore the potential mutations that may be transmitted to newly infected 
persons. 
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As detailed in the previous chapter, high-levels of resistant mutations were 
circulating within the treatment-experienced community.  Failure of the 
‘traditional’ first-generation ART to completely suppress the patients’ 
circulating viruses (due to resistance), led to the development of mutations to 
the available drugs.  Newer and more robust drugs were required for the 
treatment of patients with numerous mutations.  Two second-generation 
drugs, developed against viruses with resistant mutations, have been 
approved for use with patients with HIV-1: a new NNRTI TMC 125, Etravirine 
(ETV) (European Medicines Agency (EMEA) 2007); and a new PI TMC 114, 
Darunavir (DRV), for use in treatment-experienced (EMEA 2008) and 
treatment-naive patients (EMEA 2009). 
Overall research aims 
Using the published resistance mutations profiles for ETV and DRV, I 
developed a new model for assessing the “theoretical susceptibility” of our 
treatment-experienced clinical cohort to these new drugs.  I investigated: 
• the frequency and type of NNRTI resistance mutations present in
NNRTI treatment-experienced patients with HIV-1 infection, whether
they were currently taking NNRTIs or had previous experience
• the NNRTI mutations present and the “theoretical susceptibility” of the
NNRTI treatment-experienced clinical cohort for the potential use of
ETV
• the frequency and type of PI resistance mutations present in PI
treatment-experienced patients with HIV-1 infection, whether they
were currently taking PIs or had previous experience
• the PI mutations present and the “theoretical susceptibility” of the PI
treatment-experienced clinical cohort for the potential use of DRV.
The second-generation NNRTI: Etravirine (ETV) 
Since 1996, the first-generation NNRTIs NVP, EFV and DLV have formed an 
essential component of HAART (Jayaweera et al 2008).  However, their low 
genetic barrier to resistance (one mutation produced 100.0% resistance to 
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all first-generation NNRTIs) resulted in widespread drug failure with 
resistance.  Archiving of these mutations precluded, forever, further use of 
this drug class, as discussed in the previous chapter, 38.0% of the 
treatment-experienced cohort had major first-generation NNRTI mutations 
and could not utilize this drug class again. 
The second-generation NNRTI ETV, is a diarylpyrimidine NNRTI and was 
designed to be active against HIV-1 with resistance mutations from the use 
of the first-generation NNRTIs (Das et al 2004).  Etravirine can bind the RT 
in multiple conformations, blocking the enzyme’s activity, and has a high 
genetic barrier compared to the first-generation NNRTIs, i.e. >3 NNRTI 
mutations are required for resistance to occur to ETV.   
The phase III clinical trials DUET 1 and 2, were conducted to determine the 
efficacy of ETV in treatment-experienced patients.  These trials were 
randomised, double-blind, placebo-controlled multinational trials with 612 
patients in the DUET 1 trial (Madruga et al 2007) and 591 patients in the 
DUET 2 trial (Lazzarin et al 2007).  The primary endpoint of both trials was 
the proportion of patients fully suppressed with a VL <50 c/mL.   
Etravirine related mutations were also determined, with 13 mutations 
identified as associated with a decreased virologic response:  
V90I*, A98G*, L100I, K101E*/P, V106I*, V179D*/F*, Y181C/I/V*, G190A/S.  
Key: * Novel mutations to ETV, not seen with the first-generation NNRTIs.  
High-level resistance was associated with the accumulation of ≥3 of these 
mutations (Vingerhoets et al 2007, Katlama et al 2007a).  
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Graph 6.1: Shows the effect of an increased number of etravirine (ETV) 
mutations on the virological suppression of a patient’s virus: the greater the 
number of baseline ETV mutations, the fewer the patients with undetectable 
viral load (VL) (Katlama et al 2007a). 
 
 
 
Further analyses of the DUET 1 and 2 data identified four further novel ETV 
mutations: K101H, E138A, V179T and M230L (Vingerhoets et al 2008). 
 
These 17 mutations were weighted to indicate the relative impact the 
individual ETV mutations would have on the patient’s total virological 
response: Y181I and Y181V had the greatest impact (score 3), followed by 
L100I, K101P, Y181C and M230L (score 2.5), the remaining mutations had a 
lesser impact (score 1.5 to 1), (Vingerhoets et al 2008; Vingerhoets et al 
2010). 
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Figure 6.1: Genotypic ‘weighted score’ of individual etravirine (ETV) 
mutations on virological response.  In practice, a patient with an ETV 
weighted score of ‘0 to 2’, would have the highest response to the drug; if a 
patient had an ETV score of ‘2.5 to 3.5’ they would have an intermediate 
response to the drug and if a patient had a score of ‘≥4’, they would have a 
reduced response (Vingerhoets et al 2008; Vingerhoets et al 2010). 
Key: ᵝV179F was never present as single ETR RAM (always with Y181C) 
ETV research aim 
The aim of this study was to define the frequency and type of NNRTI 
resistance mutations present in our NNRTI treatment-experienced clinical 
cohort and determine the “theoretical susceptibility” of this cohort to the 
future use of ETV. 
Method 
Patient selection 
Using the treatment-experienced clinical cohort, all patients whose clinicians 
indicated on the ICVC resistance request form that their patient had 
treatment experience with the NNRTIs NVP, DLV and EFV (whether current 
usage or previous treatment experience), were identified and included in the 
analyses (1996-2006).   
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Determining resistance 
The mutational profile for each NNRTI treatment-experienced patient was 
established, including the prevalence of first-generation NNRTI mutations 
(EFV, NVP), and the specific ETV related mutations, as identified by the 
DUET 1 and 2 clinical trials, and confirmed by the IAS-USA drug resistance 
mutations list (Johnson et al 2009): 
The “theoretical susceptibility” of the cohort to the use of ETV was 
determined as: for patients with ≤2 ETV related mutations, they should be 
susceptible to ETV.  For those identified with ≥3 ETV related mutations, their 
mutational profiles were further evaluated using the genotypic weighted 
score (see Figure 6.1, Vingerhoets et al 2008; Vingerhoets et al 2010) to 
determine the likely clinical response (high response, intermediate response, 
reduced response) against the specific ETV mutations that were identified. 
Results 
Nine hundred and sixty-seven NNRTI treatment-experienced patients were 
identified in the cohort: 
• 550 (56.9%) were currently failing (CF) on a NNRTI-containing
regimen (NVP 51.6%, EFV 45.7%, DLV 1.5%, NVP+EFV 1.3%)
• 417 (43.1%) had previous treatment experience (PE) with a NNRTI-
containing regimen (NVP 48.2%, EFV 29.5%, DLV 1.4%, NVP+EFV
17.3%, NVP+DLV 1.9%, EFV+DLV 0.2%, all three NNRTIs 1.4%), but
were not currently on NNRTI treatment.
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Table 6.1: Demographics of patients currently failing (CF) or with previous experience (PE) of non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) containing regimens. 
 
 
 
 
 
 
Currently failing (CF) pts (n=550) Previous experience (PE) pts (n=417) 
All CF 
CF with NNRTI 
muts 
(n=412) 
CF with no NNRTI muts 
(n=138) All PE 
PE with NNRTI 
muts 
(n=188) 
PE with no NNRTI 
muts 
(n=229) 
n % n % n % n % n % n % 
Sex      Male 
Female 
372 
142 
72.4 
27.6 
283 
102 
73.5 
26.5 
89 
40 
69.0 
31.0 
276 
128 
68.3 
31.7 
132 
53 
71.4 
28.6 
144 
75 
65.8 
34.2 
Age     Min 
Max 
Mean 
18 
77 
44.3 
18 
75 
44.6 
20 
77 
43.5 
20 
75 
43.6 
21 
69 
44.2 
20 
75 
43.1 
Risk group 
Hetero 
MSM 
IDU 
Blood/tissue 
transfer 
Mother-to-child 
Sharps injury 
MSM/IDU 
 
136 
89 
10 
12 
 
3 
1 
0 
 
53.5 
35.0 
3.9 
4.7 
 
1.2 
0.4 
0.0 
 
99 
71 
8 
12 
 
1 
1 
0 
 
51.5 
37.1 
4.1 
6.2 
 
0.5 
0.5 
0.0 
 
37 
18 
2 
0 
 
2 
0 
0 
 
62.5 
30.9 
3.3 
0.0 
 
3.3 
0.0 
0.0 
 
99 
61 
8 
3 
 
2 
3 
2 
 
55.0 
33.9 
4.4 
1.7 
 
1.1 
1.7 
1.1 
 
46 
33 
5 
2 
 
2 
0 
1 
 
51.1 
36.7 
5.6 
2.2 
 
2.2 
0.0 
1.1 
 
53 
28 
3 
1 
 
0 
3 
1 
 
58.9 
31.1 
3.3 
1.1 
 
0.0 
3.3 
1.1 
Origin 
Europe 
Africa 
North America 
Asia 
South America 
Carribean 
Australasia 
Middle East 
 
260 
200 
11 
10 
4 
3 
2 
0 
 
53.0 
40.7 
2.2 
2.0 
0.8 
0.6 
0.4 
0.0 
 
199 
143 
10 
8 
4 
3 
1 
0 
 
54.1 
38.9 
2.7 
2.2 
1.1 
0.8 
0.3 
0.0 
 
61 
57 
1 
2 
0 
0 
1 
0 
 
50.0 
46.7 
0.8 
1.6 
0.0 
0.0 
0.8 
0.0 
 
197 
143 
5 
7 
3 
0 
4 
1 
 
54.6 
39.6 
1.4 
1.9 
0.8 
0.0 
1.1 
0.3 
 
87 
66 
2 
5 
0 
0 
4 
0 
 
53.0 
40.2 
1.2 
3.0 
0.0 
0.0 
2.4 
0.0 
 
110 
77 
3 
2 
3 
0 
0 
1 
 
56.3 
39.1 
1.5 
1.0 
1.5 
0.0 
0.0 
0.5 
Key: 
CF currently failing on non-nucleoside reverse transcriptase inhibitors (NNRTI) -containing regimen, PE previous experience of a NNRTI-
containing regimen. 
Risk group: Hetero heterosexual, MSM men who have sex with men, IDU injecting drug users.  
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Of the 967 NNRTI treatment-experienced patients, 600 (62.1%) presented with at least one NNRTI related mutation, 367/600 
(61.2%) had specific ETV related mutations (CF patients, 74.9% (412/550) NNRTI related mutations, 252/412 (61.2%) ETV 
related mutations; PE patients, 45.1% (188/417) NNRTI related mutations, 115/188 (61.2%) ETV related mutations).     
 
Table 6.2: The number of non-nucleoside reverse transcriptase inhibitors (NNRTI) mutations that were identified in the cohort 
and the breakdown of these by the number of etravirine (ETV) specific mutations that were seen in all patients; those who were 
currently failing (CF) on a NNRTI regimen (n=550) and those with previous experience (PE) of NNRTI usage (n=417). 
  
Number of NNRTI 
mutations 
Number of ETV specific mutations 
0 1 2 3* 4* Total 
All CF PE All CF PE All CF PE All CF PE All CF PE All CF PE 
0 367 138 229 0 0 0 0 0 0 0 0 0 0 0 0 367 138 229 
1 183 119 64 102 57 45 0 0 0 0 0 0 0 0 0 285 176 109 
2 42 34 8 120 89 31 49 33 16 0 0 0 0 0 0 211 156 55 
3 8 7 1 19 15 4 34 27 7 13 9 4 0 0 0 74 58 16 
4 0 0 0 4 3 1 5 4 1 10 7 3 3 2 1 22 16 6 
5 0 0 0 1 1 0 2 1 1 2 1 1 3 3 0 8 6 2 
Total 600 298 302 246 165 81 90 65 25 25 17 8 6 5 1 967 550 417 
 
Key:  
CF currently failing on non-nucleoside reverse transcriptase inhibitors (NNRTI)-containing regimen, PE previous experience of a NNRTI-containing 
regimen.  * Patients highlighted in the blue box had ≥3 ETV related mutations 
 
• Overall, 91.6% of all patients (91.3% CF and 92.2% PE) in this NNRTI treatment-experienced clinical cohort failing first-
generation NNRTIs that were evaluated in the “theoretical susceptibility” model would be susceptible to the new NNRTI: 
ETV. 
• Thirty-one patients (highlighted in the blue box) had ≥3 ETV related mutations: 8.4% (31/367) of all patients, 8.7% 
(22/252) CF patients, 7.8% (9/115) PE patients, and may not benefit from taking ETV (see Table 6.4 for further analyses). 
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Table 6.3: The prevalence of specific etravirine (ETV) related mutations 
seen in all non-nucleoside reverse transcriptase inhibitors (NNRTI) 
experienced patients; currently failing (CF) and with previous experience 
(PE). 
 
ETV related 
mutations 
All pts CF pts PE pts 
n % n % n % 
V90I 0 0.0 0 0.0 0 0.0 
A98G 43 4.5 32 5.8 11 2.6 
L100I 28 2.9 20 3.6 8 1.9 
K101E 61 6.3 45 8.2 16 3.8 
K101H 0 0.0 0 0.0 0 0.0 
K101P 0 0.0 0 0.0 0 0.0 
V106I 1 0.1 1 0.2 0 0.0 
E138A 0 0.0 0 0.0 0 0.0 
V179D 26 2.7 17 3.1 9 2.2 
V179F 0 0.0 0 0.0 0 0.0 
V179T 0 0.0 0 0.0 0 0.0 
Y181C* 194 20.1 131 23.8 63 15.1 
Y181I 4 0.4 4 0.7 0 0.0 
Y181V 0 0.0 0 0.0 0 0.0 
G190A** 145 15.0 98 17.8 47 11.3 
G190S 19 2.0 16 2.9 3 0.7 
M230L 4 0.4 3 0.6 1 0.2 
 
Key:  
CF currently failing on non-nucleoside reverse transcriptase inhibitors (NNRTI)-containing 
regimen, PE previous experience of a NNRTI-containing regimen. 
 
*Y181C, a potent mutation associated with ETV resistance, had a 
prevalence of 20.1% in all patients; 23.8% of CF patients and 15.1% of PE 
patients.  
 
**G190A, a mutation associated with minimal ETV resistance, was the next 
most prevalent mutation, seen in 15.0% of all patients; 17.8% of the CF 
patients and 11.3% of the PE patients.  
 
All other ETV related mutations were seen at a prevalence of <10.0% or not 
at all. 
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Table 6.4: The weighted score of 31 patients (22 were currently failing (CF) on a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) containing regimen, nine had previous experience (PE) with a NNRTI-containing regimen) identified with ≥3 etravirine (ETV) 
related mutations, and their likely clinical response to ETV (Vingerhoets et al 2008; Vingerhoets et al 2010).  Thirty out of the 31 
patients (96.8%) would have a reduced response to ETV. 
Combinations of NNRTI mutations: ETV specific 
mutations highlighted in blue 
CF 
pts 
(n=22) 
PE pts 
(n=9) 
Weighted score of ETV 
mutation combinations* 
Response to 
ETV$ 
5 NNRTI muts: 
L100I+Y181C+G190A+A98G+V108I 
K103N+Y181C+G190A+A98G+K101E 
K103N+Y181C+G190A+K101E+K101Q 
K103N+Y181C+G190A+K101E+V108I 
2 
1 
1 
- 
- 
- 
- 
1 
7 
5.5 
4.5 
4.5 
Reduced 
Reduced 
Reduced 
Reduced 
4 NNRTI muts: 
K103N+Y181C+G190A+A98G 
K103N+Y181C+G190A+K101E 
Y181C+G190A+K101E+V108I 
Y181C+G190A+A98G+K101E 
Y181C+G190A+K101E+V108I 
Y181C+G190A+A98G+V108I 
Y181C+G190S+A98G+K101E 
1 
2 
1 
- 
2 
1 
2 
- 
- 
1 
1 
1 
1 
- 
4.5 
4.5 
4.5 
5.5 
4.5 
4.5 
6 
Reduced 
Reduced 
Reduced 
Reduced 
Reduced 
Reduced 
Reduced 
3 NNRTI muts: 
Y181C+G190A+A98G 
Y181C+G190A+K101E 
G190A+A98G+K101E 
4 
4 
1 
- 
4 
- 
4.5 
4.5 
3 
Reduced 
Reduced 
Intermediate 
Key: 
* Weighted scores: L100I 2.5, Y181C 2.5, G190S 1.5, G190A 1, A98G 1, K101E 1
$ Response to ETV: ETV score ≥4 reduced response, ETV score 2.5 to 3.5 intermediate response, ETV score 0 to 2 highest response
(Vingerhoets et al 2008, 2010).
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The second-generation PI: Darunavir (DRV) 
For resistance to the PIs to occur, an accumulation of major mutations and 
several minor mutations are required to decrease efficacy, with some 
specific mutations resulting in cross-resistance to the whole PI class.  Today, 
all PIs prescribed in UK clinics are boosted with RTV to enhance PI drug 
levels and provide a higher genetic barrier. This strategy has helped to 
reduce failure to the PI class of drugs as witnessed in the previous chapter 
with the significant decline in major PI resistance mutations from the EC to 
the LC (39.6% EC vs 15.6% LC, p<0.001).  
Substantial resistance to the ‘first-generation’ unboosted PIs resulted in 
significant PI resistance in patients in the community.  ‘Second-generation’ 
PIs (all boosted with RTV) had increased efficacy with less resistance, but 
toxicity became an issue.  The development of newer PIs designed against 
resistant viruses were required.   
The new second-generation PI: DRV was developed against a drug resistant 
PI target and had a strong binding affinity for the HIV-1 PR (De Meyer et al 
2005).  The major ‘POWER’ clinical trials (De Meyer et al 2005; De Meyer et 
al 2006; Katlama et al 2007b; Haubrich et al 2007) demonstrated the 
benefits of using boosted-DRV in treatment-experienced patients (and later 
with treatment-naïve patients (Ortiz et al 2008)) and highlighted new 
mutational profiles associated with a diminished response to DRV, including: 
V11I; V32I; L33F; I47V; I50V; I54L/M; G73S; L76V; I84V and L89V. 
If ≥3 DRV specific mutations were present at baseline, this significantly 
reduced the virological response (De Meyer et al 2008). 
DRV research aims 
The aim of the first DRV study undertaken was to define the frequency and 
type of PI resistance mutations present in our PI treatment-experienced 
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clinical cohort and determine the “theoretical susceptibility” of this cohort to 
the future use of DRV (using genotype analyses). 
A second study was undertaken to evaluate the predictive value of using 
virtual phenotype analyses relative to genotype analyses alone, to determine 
susceptibility to DRV.  Did either the genotype or virtual phenotype analyses 
provide a more effective tool than the other, or were they comparable?  
Method 
Patient selection 
Using the treatment-experienced clinical cohort, all patients whose clinicians 
indicated on the ICVC resistance request form that their patient had 
treatment experience with the PIs SQV, IDV, RTV, NFV, APV, LPV, LPV/r, 
TPV, ATV, FPV (whether currently failing (CF) on their PI-containing 
regimen; with previous experience (PE) of a PI-containing regimen but not 
currently taking PIs or currently not on any treatment but with previous PI 
experience), were identified and included in the analyses (1996-2006). 
Determining resistance 
The mutational profile for each PI treatment-experienced patient was 
established, including the prevalence of first-generation PIs and second-
generation PIs (all boosted with RTV) mutations, and the specific DRV 
related mutations, as identified by the POWER clinical trials: 
V11I, V32I, L33F, I47V, I50V, I54L, I54M, G73S, L76V, I84V, L89V 
Key: 
mutations in bold were initially defined as high impact (HI) mutations in the POWER studies, 
developed in ≥10.0% of virological failures 
and as per the IAS-USA drug resistance mutations list (Johnson et al 2009): 
NB. Assignment of high impact/major mutations by the POWER and IAS-USA lists differed 
somewhat (mutations in bold); the POWER studies identified G73S as a relevant mutation 
but this was not confirmed by the IAS-USA list who had T74P on the list which was not 
indicated by the POWER studies. 
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The “theoretical susceptibility” of our cohort to the use of DRV was 
determined as: for patients with ≤2 DRV related mutations, they should be 
susceptible to DRV.  For those identified with ≥3 DRV related mutations, 
their mutational profiles were further evaluated using virtual phenotype 
analyses to determine the likely clinical response (maximal response, 
reduced response, minimal response) against the specific DRV mutations 
that were identified. 
Results of the DRV genotype study 
Eight hundred and eighty-five PI treatment-experienced patients were 
identified in the cohort: 
• 532 (60.2%) were CF on a PI-containing regimen (72.0% one PI;
27.0% two PIs; 1.0% ≥ three PIs)
• 188 (21.0%) with PE but not currently on a PI-containing regimen
(57.0% one PI; 27.0% two PIs; 6.0%  ≥ three PIs)
• 165 (19.0%) currently not on any treatment but with PE of PIs (53.0%
one PI; 31.0% two PIs; 16.0% ≥ three PIs)
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Table 6.5: Demographics of patients currently failing (CF) or with previous experience (PE) of protease inhibitors (PIs) containing 
regimens. 
 
 
 
Currently failing (CF) pts (n=532) Previous experience (PE) pts (n=353) 
All CF CF with no DRV muts (n=428) 
CF with DRV 
muts 
(n=104) 
All PE 
PE with no DRV 
muts 
(n=331) 
PE with DRV 
muts 
(n=22) 
n % n % n % n % n % n % 
Sex      Male 
Female 
386 
120 
76.3 
23.7 
308 
102 
75.1 
24.9 
78 
18 
81.3 
18.8 
262 
81 
76.4 
23.6 
241 
81 
74.8 
25.2 
21 
0 
100.0 
0.0 
Age     Min 
Max 
Mean 
20 
71 
44.5 
20 
69 
44.2 
30 
71 
45.7 
23 
74 
43.9 
23 
74 
43.7 
37 
59 
45.7 
Risk group 
Hetero 
MSM 
IDU 
Blood/tissue 
transfer 
Mother-to-child 
Sharps injury 
MSM/IDU 
 
191 
87 
4 
7 
 
2 
0 
0 
 
65.4 
29.8 
1.4 
2.4 
 
0.7 
0.0 
0.0 
 
160 
62 
4 
7 
 
2 
0 
0 
 
51.5 
37.1 
4.1 
6.2 
 
0.5 
0.5 
0.0 
 
31 
25 
0 
0 
 
0 
0 
0 
 
55.4 
44.6 
0.0 
0.0 
 
0.0 
0.0 
0.0 
 
104 
156 
5 
8 
 
1 
3 
1 
 
58.4 
31.5 
2.8 
4.5 
 
0.6 
1.7 
0.6 
 
103 
52 
5 
8 
 
1 
3 
1 
 
59.5 
30.1 
2.9 
4.6 
 
0.6 
1.7 
0.6 
 
1 
4 
0 
0 
 
0 
0 
0 
 
20.0 
80.0 
0.0 
0.0 
 
0.0 
0.0 
0.0 
Origin 
Europe 
Africa 
North America 
Asia 
South America 
Carribean 
Australasia 
South Africa 
 
234 
176 
12 
11 
8 
1 
3 
1 
 
52.5 
39.5 
2.7 
2.5 
1.8 
0.2 
0.7 
0.2 
 
186 
149 
5 
10 
6 
1 
1 
0 
 
52.0 
41.6 
1.4 
2.8 
1.7 
0.3 
0.3 
0.0 
 
61 
57 
1 
2 
0 
0 
1 
0 
 
50.0 
46.7 
0.8 
1.6 
0.0 
0.0 
0.8 
0.0 
 
189 
95 
5 
2 
0 
0 
3 
0 
 
64.1 
32.2 
1.7 
0.7 
0.0 
0.0 
1.0 
0.0 
 
177 
94 
4 
2 
0 
0 
3 
0 
 
63.0 
33.5 
1.4 
0.7 
0.0 
0.0 
1.1 
0.0 
 
12 
1 
1 
0 
0 
0 
0 
0 
 
85.7 
7.1 
7.1 
0.0 
0.0 
0.0 
0.0 
0.0 
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Of the 885 PI treatment-experienced patients, 759 (86.0%) presented with at least one PI related mutation, 126/759 (16.6%) had 
specific DRV related mutations (CF patients, 80.3% (427/532) PI related mutations, 104/427 (24.6%) DRV related mutations; PE 
patients, 94.1% (332/353) PI related mutations, 22/332 (6.3%) DRV related mutations).     
 
Table 6.6: The number of protease inhibitors (PI) mutations that were identified in the cohort and the breakdown of these by the 
number of darunavir (DRV) specific mutations that were seen in all patients; those who were currently failing (CF) on a PI 
regimen (n=532) and those with previous experience (PE) of PI usage (n=353). 
  
Number of PI mutations 
Number of DRV specific mutations 
0 1 2 3* ≥4* Total 
All CF PE All CF PE All CF PE All CF PE All CF PE All CF PE 
0 80 32 48 0 0 0 0 0 0 0 0 0 0 0 0 80 32 48 
1 239 118 121 2 2 0 0 0 0 0 0 0 0 0 0 241 120 120 
2 214 126 88 1 0 1 0 0 0 0 0 0 0 0 0 215 126 89 
3 101 60 41 6 5 1 0 0 0 0 0 0 0 0 0 107 65 42 
4 55 37 18 13 9 4 1 1 0 0 0 0 0 0 0 69 47 22 
5 27 20 7 19 16 3 1 1 0 2 1 1 0 0 0 49 38 11 
≥6 43 34 9 57 51 6 13 11 2 7 5 2 4 4 0 124 104 21 
Total 759 427 332 98 83 15 15 13 2 9 6 3 4 4 0 885 532 353 
 
Key:  
CF currently failing on protease inhibitors (PI)-containing regimen, PE previous experience of a PI-containing regimen.   
* Patients highlighted in the blue box had ≥3 DRV related mutations 
 
• Overall, 89.7% of all patients (91.3% CF and 92.2% PE) in this PI treatment-experienced clinical cohort failing PIs that 
were evaluated in the “theoretical susceptibility” model would be susceptible to the new PI: DRV. 
• Thirteen patients (highlighted in the blue box) had ≥3 DRV related mutations: 1.5% (13/885) of all patients, 1.9% (10/532) 
CF patients, 0.8% (3/353) PE patients, and may not benefit from taking ETV. 
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Table 6.7: Prevalence of specific darunavir (DRV) related mutations and the 
combinations of mutations in those patients with more than one related 
mutation. 
DRV related mutations n=126 n % 
V32I 5 4.0 
L33F 16 12.7 
I47V 2 1.6 
I50V 4 3.2 
I54L 4 3.2 
G73S 21 16.7 
I84V 46 36.5 
V32I + L33F 1 0.8 
V32I + I47V 2 1.6 
L33F + I50V 1 0.8 
L33F + I54L 1 0.8 
L33F + G73S 2 1.6 
L33F + I84V 3 2.4 
I54L + I84V 2 1.6 
G73S + I84V 3 2.4 
V32I + L33F + I47V 1 0.8 
V32I + L33F + I84V 2 1.6 
V32I + I47V + I50V 1 0.8 
V32I + I47V + I54M 1 0.8 
V32I + I47V + I84V 1 0.8 
L33F + I47V + I84V 1 0.8 
L33F + G73S + I84V 1 0.8 
I54L + G73S + I84V 1 0.8 
V32I + I47V + I54L + I84V 2 1.6 
V32I + L33F + I47V + I54L + I84V 2 1.6 
• Of the 126 patients with DRV related mutations, 98 (77.8%) had only
one DRV mutation, 15 (11.9%) had two, nine (7.1%) had three, two
(1.6%) had four and two (1.6%) had five DRV related mutations.
Patient selection for the virtual phenotype and genotype study 
Using the same PI treatment-experienced clinical cohort as in the genotype 
study, a case-control design was utilised whereby patients who were 
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identified in the first study as having DRV-related mutations (the cases) were 
paired with sequential controls (i.e. those patients with no DRV-related 
mutations) and matched by sex, age and number of PI (non-DRV related) 
mutations. 
The genotype FASTA sequences generated using the TRUGENE® system 
were sent to VircoLab Inc. to be analysed by their virtual phenotype tool.   
Results of the DRV virtual phenotype and genotype study 
A total of 194 virtual phenotype analyses were conducted: 97 patients were 
in both the case (DRV related mutations) and control (no DRV related 
mutations) groups. 
Table 6.8: Background prevalence of protease mutations in the case and 
control groups.  The case group on average had more protease inhibitor (PI) 
mutations (6.45 PI mutations) than the control group (2.07 PI mutations), 
(p<0.001). 
No. PI muts No. RT muts No. PI polys No. RT polys 
Case Control Case Control Case Control Case Control 
Mean 6.45 2.07 5.54 2.27 7.27 6.29 9.64 9.66 
Minimum 1 0 0 0 1 1 2 2 
Maximum 12 7 11 11 15 13 19 20 
Review of the case group (n=97) 
Using the genotype analyses; in the case group, 88.7% of the patients had 
two or less DRV related mutations and would therefore be susceptible to this 
new drug; with 11.3% presenting with ≥3 DRV related mutations.  The 
specific DRV mutations prevalent included: V32I (14.4%), L33F (24.7%), 
I47V (11.3%), I50V (5.2%), I54L (10.3%), I54M (1.0%), G73S (20.6%) and 
I84V (53.6%).  The V11I, T74P, L76V and L89V DRV related mutations were 
not seen in the case group. 
Using the virtual phenotype analyses, 86.6% of the case groups’ sequences 
were interpreted as having ‘maximal response’ to DRV, confirming good 
agreement between the two systems used. 
128
Chapter 6: The “theoretical susceptibility” of the cohort to new ARVs 
Table 6.9: Virtual phenotype analyses of the case group - the ‘maximal 
response’ finding of 86.6% was comparable with the genotype finding of 
88.7% susceptibility (not significant (NS)). 
Frequency % Fold change 
Minimum Maximum Mean Standard 
Deviation 
Maximal 
response 
84 86.6 0.4 9.8 2.31 1.93 
Reduced 
response 
12 12.4 10.6 70.9 30.38 16.31 
Minimal 
response 
1 1.0 163.8 163.8 163.8 - 
Key: 
Virtual phenotype clinical cut-off vales: 
Low clinical cut-off (Maximal virologic response (CCO1)) = 10.0 
High clinical cut-off (Minimal virologic response (CCO2)) = 106.9 
Table 6.10: Review of the 12 case group patients with a ‘reduced response’ 
as per the virtual phenotype analyses; in relation to the darunavir (DRV) 
related mutations and combinations, and genotype interpretation. 
DRV mutation combinations as 
determined by genotype Genotype 
interpretation 
Virtual 
phenotype 
interpretation No. of muts Combination n 
1 I50V 3 Susceptible Reduced response 
2 V32I+I47V I54L+I84V 
1
1
Susceptible 
Susceptible 
Reduced 
response 
3 
V32I+L33F+I84V 
V32I+I47V+I50V 
V32I+I47V+I84V 
L33F+I47V+I84V 
2
1
1 
1 
Possible 
resistance 
Reduced 
response 
4 V32I+I47V+I54L+I84V 1 Resistance Reduced response 
5 V32I+L33F+I47V+I54L+I84V 1 Resistance Reduced response 
Mutations for the one patient reported as having a minimal response by the 
virtual phenotype tool were the same as the mutations seen with the reduced 
response patient who also had five DRV related mutations: 
V32I+L33F+I47V+I54L+I84V.  The fold change for the virtual phenotype 
minimal response patient was 163.8 whilst the fold change for the virtual 
phenotype reduced response patient was 70.9.  Table 6.12 compares the 
two patients’ demographics, treatment history and mutational profiles. 
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Table 6.11: Comparison of the demographics, treatment history and 
mutation profiles of the minimal response patient and the reduced response 
patient who both presented with five darunavir (DRV) related mutations: 
V32I+L33F+I47V+I54L+I84V. 
 
 Virtual phenotype 
minimal response 
patient 
Virtual phenotype 
reduced response 
patient 
Sample date 19/03/2004 29/08/2003 
Reason for test Viral rebound on salvage 
therapy 
Viral load raised 
Origin of infection European European 
Ethnicity White non-hispanic White non-hispanic 
Risk group MSM MSM 
Current VL (c/mL) 215,000 21,100 
CD4 (cells//µL) 104 284 
Current treatment SQV, LPV/r LPV/r, APV, TDF, 3TC 
Previous treatment IDV, NFV, EFV, ddI, ABC, 
d4T, TDF, 3TC, ZDV, APV  
(3 previous PIs) 
d4T, ddI, EFV, SQV, 
ABC          
(1 previous PI) 
Subtype B B 
Protease (PR) 
mutations 
K20R, V32I, L33F, M36I, 
M46I, I47V, F53L, I54L, 
L63P, A71V, I84V, L90M 
(n=12) 
L10F, V32I, L33F, 
M46I, I47V, I54L, 
L63P, A71T, I84V 
(n=9) 
Reverse 
transcriptase (RT) 
mutations 
V75I, F77L, Y115F, 
F116Y, V118I, Q151M, 
M184V, G190A (n=8) 
A62V, D67N, L74V, 
V75T, L100I/M, K103N, 
M184V, K219Q (n=8) 
PR polymorphisms G16A, E34V, E35D, S37D, 
K55R, Q58E, D60E, I62V, 
G68E, L89I, I93L (n=11) 
I13V, G16A, L19P, 
E35D, I64V, P79S, 
T91A, F99L 
(n=8) 
RT polymorphisms S68G, D121Y/C, S162C, 
I178L, Q207E, R211K 
(n=6) 
I50N, F61S, S68N, 
I178M, Q207K, R211S 
(n=6) 
Virtual phenotype 
fold change 
163.8 70.9 
Key: 
MSM men who have sex with men 
DRV related mutations highlighted in bold 
 
Of other (not DRV related) PR mutations, the patients had two in common: 
M46I and L63P.  Different PR mutations prevalent included: K20R, M36I, 
F53L, A71V and L90M for the virtual phenotype minimal response patient 
and L10F and A71T for the virtual phenotype reduced response patient. 
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Review of the control group (n=97) 
Using the genotype analyses; no DRV related mutations were identified in 
the control group. Using the virtual phenotype analyses, all control group 
patients would have maximal response to DRV. 
Table 6.12: Virtual phenotype analyses of the control group: the maximal 
response finding of 100.0% supported the genotype analyses findings of no 
darunavir (DRV) related mutations. 
Frequency % Fold change 
Minimum Maximum Mean Standard 
Deviation 
Maximal 
response 
97 100.0 0.3 7.4 0.67 0.71 
Discussion 
In this study, I evaluated a “theoretical susceptibility” model using published 
resistance profiles of new ARVs including the second-generation NNRTI: 
ETV; and the second-generation PI: DRV. 
Of the NNRTI treatment-experienced clinical cohort, 91.6% were “theoretical 
susceptible” to ETV as they had ≤2 ETV related mutations.  Of the 31 
patients with ≥3 ETV related mutations, on further analysis using the 
weighted genotype score proposed by Vingerhoets et al (2008; Vingerhoets 
et al 2010); 30/31 (96.8%) would have a reduced response to ETV, with one 
patient having an intermediate response to ETV use. 
Vingerhoets et al (2010) determined that the Y181I and Y181V mutations 
would have the highest weight factor, therefore impact on ETV and in our 
cohort, <1.0% presented with the Y181I mutation and no patients had the 
Y181V mutation.  Apart from a prevalence of 20.1% of the Y181C mutation 
and 15.0% of the G190A mutation, our cohort did not harbour DRV related 
mutations.  
Of the PI treatment-experienced clinical cohort, 89.7% were “theoretical 
susceptible” to DRV as they had ≤2 DRV related mutations.  Of the 13 
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patients with ≥3 DRV related mutations, on further analysis using virtual 
phenotype outputs, 12 patients would have a reduced response to DRV, with 
one patient having a minimal response. 
 
Two patients had five DRV related mutations V32I+L33F+I47V+I54L+I84V, 
with the virtual phenotype tool interpreting this as minimal response for one 
patient and reduced response for the other.  There were no clear indications 
as to why these two patients, with the same DRV related mutations, had 
been characterised as such, but possible explanations for this interpretation 
(using the data presented in Table 6.12) may include: 
• the minimal response patient was more treatment-experienced (10 
ARVs) compared to the reduced response patient (five ARVs): the 
patient had treatment experience with APV; the V32I and I47V 
mutations are associated with APV resistance 
• the minimal response patient presented with a larger number of PR 
mutations and the following were different to the reduced response 
patient: K20R, M36I, F53L, A71V and L90M.  Although none of these 
mutations have been reported in the research literature as having an 
impact on DRV, De Meyer et al (2008) did report that when ≥3 DRV 
related mutations were present, alongside a high number of other PR 
mutations, then a significantly reduced virological response was 
observed  
• the reduced response patient had L10F and A71T PR mutations, 
again, the research literature does not report that these mutations 
have an impact on DRV 
• the minimal response patient had 11 PR polymorphisms whilst the 
reduced response patient had eight.  
 
To conclude, availability of new second-generation drugs like ETV and DRV 
provide new treatment options for patients failing older ARVs and as shown 
by our “theoretical susceptibility” model, a large majority of our treatment-
experienced clinical cohort would benefit from these new drugs. 
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Historically, the HIV-1 research conducted and the literature published has 
focussed on subtype B populations.  This has occurred, due to the fact that 
treatment for HIV-1 patients was originally only available in the Western, 
developed countries, therefore sequences were only available from these 
countries and when analysed, subtype B viruses were predominant.  With the 
increase in treatment worldwide and with the ‘migration of viruses’ from 
endemic regions to Western countries and having access to treatment, there 
has been an increase in the identification of non-B subtypes. 
Earlier research work conducted at the ICVC identified the Roche 
AMPLICOR HIV-1 MONITOR Test version 1.0 (v1.0) assay was not 
detecting, or was suboptimally detecting, the VL of HIV-1 viruses with a non-
B subtype (Arnold et al 1995).  The primers used in the Roche AMPLICOR 
HIV-1 MONITOR Test v1.0 assay were based on subtype B and on 
identification of these discordant VL results, new primers were added which 
were susceptible to non-B subtypes (Roche AMPLICOR HIV-1 MONITOR 
Test v1.5).  The ICVC collaborated with Roche in the SENTRY Study to 
ensure that the performance of the Roche AMPLICOR HIV-1 MONITOR Test 
v1.5 and future assays, maintained their reliability over time as evolution of 
HIV-1 non-B viruses were identified further  
(http://www.roche.com/media/store/releases/med_dia_2002-07-03.htm). 
Subtype B only accounts for 11.0% of the global epidemic (Hemelaar et al 
2011), therefore a focus on the other subtypes is warranted.  The genotype 
resistance test kits and the rules-based algorithms used to interpret 
mutational profiles are based on a reference subtype B virus (De Luca and 
Perno 2003; Youree and D’Aquila 2002).  Until recently, the majority of the 
published resistance data has been based on subtype B sequences.  The 
relevance of PR and RT sequence differences among non-B viruses, as 
compared to subtype B viruses, and the relevance this may have for 
therapeutic success is not known (Clavel et al 2004).   
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Research aims 
Using available FASTA ‘pol’ (PR and RT) sequences generated by the 
TRUGENE® GeneLibrarian™ archive for the treatment-naïve and treatment-
experienced patients, I investigated: 
• The utility and concordance of results amongst five freely available
online analytical tools to determine subtype.
On completion of this characterisation and assignment of a subtype I then 
investigated: 
• the prevalence of subtype B, pure non-B subtypes and recombinant
forms circulating in the treatment-naïve and treatment-experienced
populations
• whether PR and RT mutation and polymorphic profiles emerged and
evolved differently in patients infected with subtype B or non-B/CRF
subtypes.
Method 
Characterising subtype profiles in the ICVC Clinical Cohort Resistance 
Database: The Quad Study 
A total of 1,642 complete FASTA ‘pol’ sequences (i.e. full PR and RT 
sequences; partial PR only or RT only sequences were excluded) were 
manually entered into five online analytical tools to determine subtype 
including: 
• the Stanford subtyping tool: //hivdb.Stanford.edu/
• the NCBI subtyping tool: //www.ncbi.nlm.nih.gov/
• the Los Alamos RIP 2.0 subtyping tool: //hiv-web.lanl.gov/content/hiv-
db/RIPPER/RIP.html/
• the STAR subtyping tool: //www.vgb.ucl.ac.uk/starn.shtml/
• the REGA subtyping tool: //dbpartners.stanford.edu/RegaSubtyping/
The Stanford, NCBI and Los Alamos RIP 2.0 subtyping tools used a 
similarity search tool whereby a ‘window’ slid along the query FASTA 
sequence, and each ‘window’ was compared by BLAST (a protein database 
search programme) to the reference sequences for different virus subtypes 
134
Chapter 7: The evolution of subtype profiles in the clinical cohort 
 
(Rozanov et al 2004; Gifford et al 2006).  The STAR subtyping tool used a 
distance-based protocol and an underlying statistical model to determine 
subtype (Myers et al 2005).  The REGA subtyping tool used phylogenetic 
analyses to determine subtype (de Oliveira 2005).  Please see Appendix 2 
for examples of the subtype outputs from each of the subtyping tools 
employed. 
 
In order to assign an overall subtype for each patient sequence where there 
were discordant outputs from the five tools, the following rules were applied: 
• if REGA assigned a subtype, used REGA (due to its use of 
phylogenetic analyses and therefore employing a tool closer to the 
‘gold standard’ interpretation of full-length genome sequences 
(Robertson et al 1999)) 
• if REGA was ‘unassigned’, the NCBI subtyping graphical output 
allowed thorough examination of the sequence to determine 
subtype/recombination (please see Appendix 2) 
• if the NCBI graphical output was indeterminable, the Los Alamos RIP 
2.0 subtyping tool output was reviewed for confirmation, followed by 
the Stanford and STAR outputs.   
 
The Stanford, NCBI and Los Alamos subtyping tools assigned a subtype to 
all 1,642 sequences submitted.  REGA (n=252, 15.3%) and STAR (n=145, 
8.8%) were unable to assign subtype for a significant number of sequences 
(p<0.05).  Reasons for REGA non-assignment included ‘no cluster with pure 
subtype, no detection of recombination’ (n=65, 25.8%); ‘cluster with pure 
subtype, detection of recombination but failure to classify as CRF’ (n=85, 
33.7%); ‘cluster with CRF, detection of recombination in pure subtype but 
failure to classify as CRF’ (n=33, 13.1%); ‘cannot explain’ (n=84, 33.3%). 
 
The five online tools produced concordant subtype results for 1,186 (72.2%) 
of the sequences submitted.  The remaining 456 sequence analyses (27.8%) 
resulted in 57 combinations of concordant/discordant/unassigned results 
across the five tools.  Using the rules described above, an overall subtype 
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was however, assigned for each sequence.  Complete discordance across 
all five tools (including unassignment) was only found in 51 (5.1%) of the 
sequences submitted.   
The use of one subtyping tool alone, compared with any of the other tools, 
would have resulted in the misclassification of >27.0% or more of patients’ 
subtype.  Discordant outputs across the tools probably reflects the content of 
the comparative databases used in each tool, and the difficulty in keeping 
these tools up-to-date for determination of new and recombinant viruses.   
Patient selection 
All patients identified on the ICVC Clinical Cohort Resistance Database who 
had a consensus subtype available, were eligible for inclusion in the study. 
For any patients who had more than one resistance entry available on the 
ICVC Clinical Cohort Resistance Database and therefore had more than one 
FASTA sequence available; the earliest sample date/FASTA 
sequence/subtype result, was included. 
Determining resistance 
The IAS-USA Update of the Drug Resistance Mutations in HIV-1: December 
2009 list (Johnson et al 2009) was used to determine major resistance 
mutations prevalent in this study. 
NRTI mutations included: M41L, A62V, K65R, D67N, 69Insert, K70R, L74V, 
V75I, F77L, Y115F, F116Y, Q151M, M184I/V, L210W, T215F/Y, K219E/Q. 
NNRTI mutations included: V90I, A98G, L100I, K101E/H/P, K103N, 
V106A/M, V108I, E138A, V179D/F/T, Y181C/I/V, Y188C/L/H, G190A/S, 
P225H, M230L. 
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PI mutations included: L10C/F/I/R/V, V11I, I13V, G16E, K20I/M/R/T/V, L24I, 
D30N, V32I, L33F/I/V, E34Q, E35G, M36I/L/V, K43T, M46I/L, I47A/V, G48V, 
I50L/V, F53L/Y, I54A/L/M/S/T/V, Q58E, D60E, I62V, L63P, I64L/M/V, H69K, 
A71I/L/T/V, G73A/C/S/T, T74P, L76V, V77I, V82A/F/L/S/T, N83D, I84V, 
I85V, N88D/S, L89V, L90M, I93L/M. 
Key: 
For those NNRTI and PR amino acid positions highlighted in bold, they were considered 
major (primary) mutations which occur first and the non-bold were minor (secondary 
mutations) that are supportive to the molecular changes which are associated with the 
primary mutations. 
Statistical analyses were conducted using SPSS (version 22).  Chi2 (χ2) 
analyses were used to test for any significant differences in the distribution of 
subtypes between the EC and the LC; and to test for any significant 
differences in the distribution of mutations between the non-B/CRF subtypes 
cohort and the subtype B cohort.  Significance was assigned at the 0.05 level 
(p<0.05). 
Results 
A total of 1,642 patients’ consensus subtype data were included in this study.  
Of 518 treatment-naïve patient sequences submitted for subtype analyses, 
283 (54.6%) had a subtype B virus, 200 (38.6%) were pure non-B subtypes 
and 35 (6.8%) CRFs.   
Of 1,124 treatment-experienced patient sequences analysed, 584 (52.0%) 
were subtype B, 424 (37.7%) pure non-B subtypes and 116 (10.3%) CRFs.  
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Table 7.1: Prevalence of specific pure subtypes and circulating recombinant 
forms (CRFs) within the treatment-naïve and treatment-experienced clinical 
cohort populations. Overall, 52.8% of patients were subtype B, 38.0% of 
patients had a pure non-B subtype and 9.2% of patients had a CRF. 
 
Consensus 
subtype 
Treatment-naive Treatment-experienced Total 
n % n % n % 
A1 19 3.7 87 7.7 106 6.5 
A1; B 1 0.2 1 0.1 2 0.1 
A1; CRF01_AE 1 0.2 0 0.0 1 0.1 
A1; D 0 0.0 2 0.2 2 0.1 
A1; G 0 0.0 2 0.2 2 0.1 
A1; J 0 0.0 1 0.1 1 0.1 
A2 0 0.0 3 0.3 3 0.2 
A2; D 0 0.0 1 0.1 1 0.1 
B 283 54.6 584 52.0 867 52.8 
B; A1 0 0.0 1 0.1 1 0.1 
C 160 30.9 240 21.4 400 24.4 
C; B 0 0.0 3 0.3 3 0.2 
CRF01_AE 5 1.0 12 1.1 17 1.0 
CRF01_AE; A1 0 0.0 2 0.2 2 0.1 
CRF02_AG 14 2.7 59 5.2 73 4.4 
CRF02_AG; B 0 0.0 1 0.1 1 0.1 
CRF02_AG; G 0 0.0 1 0.1 1 0.1 
CRF06_cpx 1 0.2 5 0.4 6 0.4 
CRF10_CD 6 1.2 5 0.4 11 0.7 
CRF13_cpx 0 0.0 2 0.2 2 0.1 
D 13 2.5 57 5.1 70 4.3 
D; A1 2 0.4 2 0.2 4 0.2 
D; B 1 0.2 3 0.3 4 0.2 
D; C 0 0.0 2 0.2 2 0.1 
D; G 0 0.0 5 0.4 5 0.3 
F1 0 0.0 10 0.9 10 0.6 
F2 0 0.0 1 0.1 1 0.1 
G 8 1.5 21 1.9 29 1.8 
G; A1 1 0.2 0 0.0 1 0.1 
G; B 1 0.2 1 0.1 2 0.1 
H 0 0.0 1 0.1 1 0.1 
H; A1 0 0.0 2 0.2 2 0.1 
J 0 0.0 4 0.4 4 0.2 
J; B 0 0.0 1 0.1 1 0.1 
J; C 1 0.2 0 0.0 1 0.1 
J; F 1 0.2 0 0.0 1 0.1 
J; K 0 0.0 2 0.2 2 0.1 
TOTAL 518 100.0 1,124 100.0 1,642 100.0 
Key: consensus subtypes with a ‘;’ between the letters indicates PR subtype followed by RT 
subtype e.g. A1; B = A1 subtype characterised in PR and B subtype in RT.  
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Gender and subtype 
Of the treatment-naïve patients (n=505/518 with corresponding gender data), 
of those with a subtype B virus, 263/278 (94.6%) were male, whilst 143/227 
(63.0%) of those characterised with a non-B/CRF subtype were female. 
Of the treatment-experienced cohort (n=876/1,124 with corresponding 
gender data), 414/476 (87.0%) were male with a subtype B virus whist 
218/400 (54.5%) were female and characterised with a non-B/CRF subtype. 
There was a significant difference observed in both the treatment-naïve and 
treatment-experienced patient groups with subtype B associated with males 
and subtype non-B/CRF significantly associated with females (p<0.05). 
Risk exposure group and subtype 
Heterosexual risk exposure was associated with non-B/CRF subtype viruses: 
treatment-naïve n=161/189 (85.2%) classified as heterosexual and non-B; 
treatment-experienced n=187/218 (90.3%) classified as heterosexual and 
non-B.  In this non-B heterosexual population, subtype C was the most 
predominant: treatment-naïve n=118/161 (73.3%); treatment-experienced 
n=96/187 (51.3%).  MSM was associated with a subtype B diagnosis: 
treatment-naïve n=148/162 (91.4%) classified as MSM and subtype B; 
treatment-experienced n=137/144 (95.1%) classified as MSM and subtype B. 
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Hospital area and subtype 
Of the treatment-naïve subtype non-B/CRF patients analysed, 104/235 (44.3%) were seen in hospitals in the Greater London area; 
78/235 (33.2%) in the South East and low frequencies elsewhere. Of the treatment-experienced subtype non-B/CRF patients, the 
majority 428/540 (79.3%) were seen in hospitals in the Greater London area. 
Table 7.2: Overall, the majority of patients in the North West, Wales and East Midlands geographical regions were characterised 
with subtype B viruses; a greater number of patients in the South West and Eastern regions were characterised with non-B 
subtypes/circulating recombinant forms (CRFs); whilst the prevalence of subtype B/non-B/CRFs were in total, comparable across 
the South East and Greater London regions. 
Geographical region 
Treatment-naïve Treatment-experienced Total 
Subtype B Subtype non-B/CRF Subtype B Subtype non-B/CRF Subtype B Subtype non-B/CRF 
n % n % n % n % n % n % 
Scotland 0 0.0 0 0.0 1 100.0 0 0.0 1 100.0 0 0.0 
North West 5 71.4 2 28.6 7 87.5 1 12.5 12 80.0 3 20.0 
Wales 6 85.7 1 14.3 49 92.5 4 7.5 55 91.7 5 8.3 
East Midlands 2 50.0 2 50.0 9 64.3 5 35.7 11 61.1 7 38.9 
Eastern 22 37.9 36 62.1 40 44.4 50 55.6 62 41.9 86 58.1 
Greater London 187 64.3 104 35.7 398 48.2 428 51.8 585 52.4 532 47.6 
South East 50 39.1 78 60.9 67 67.0 33 33.0 117 51.3 111 48.7 
South West 11 47.8 12 52.2 13 40.6 19 59.4 24 43.6 31 56.4 
Total 283 54.6 235 45.4 584 52.0 540 48.0 867 52.8 775 47.2 
Non-B subtypes and CRFs characterised in the early cohort (EC: 1996-2000) versus the late cohort (LC: 2001-2006) 
There was a significant increase in non-B subtypes and CRFs characterised over time with 32/132 (24.2%) of the EC and 
743/1,510 (49.2%) in the LC, p<0.05 (illustrated in Graphs 7.1 and 7.2 below). 
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Graph 7.1: Non-B subtypes and circulating recombinant forms (CRFs) 
characterised in the early cohort (1996-2000): subtype C was the 
predominant non-B subtype (50.0%). 
Graph 7.2: Non-B subtypes and circulating recombinant forms (CRFs) 
characterised in the late cohort (2001-2006): there was a significant 
expansion in non-B subtypes and CRFs compared with the early cohort. 
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Prevalence of PR and RT resistance mutations/polymorphisms in 
subtype non-B and subtype B patient sequences 
Combining the distinct non-B/CRF subtypes into an overall non-B treatment-
naïve group and treatment-experienced group (due to low frequencies of 
distinct non-B/CRF subtypes in the cohort), statistical analyses were 
performed to determine the differences in prevalence of resistance mutations 
and polymorphisms identified in subtype non-B/CRF and subtype B patient 
sequences. 
Table 7.3: Significant protease (PR) mutations associated with non-B 
subtypes compared to subtype B in the treatment-naïve and treatment-
experienced patients (p<0.05). 
PR 
mutations 
Treatment-naïve Treatment-experienced 
Subtype 
B 
Subtype non-
B/CRF 
Subtype 
B 
Subtype non-
B/CRF 
n % n % n % n % 
I13V 55 19.4 79 33.6 137 23.5 247 45.7 
G16E 13 4.6 24 10.2 15 2.6 67 12.4 
K20R 9 3.2 50 21.3 33 5.7 105 19.4 
M36I 54 19.1 209 88.9 139 23.8 494 91.5 
D60E 20 7.1 55 23.4 43 7.4 74 13.7 
H69K 5 1.8 208 88.5 10 1.7 421 78.0 
I93L 144 50.9 185 78.7 236 40.4 265 49.1 
There were no significant differences in the prevalence of RT mutations in 
the treatment-naïve and treatment-experienced subtype non-B/CRF and 
subtype B groups.   
Table 7.4: Significant protease (PR) mutations associated with subtype B 
compared to subtype non-B/CRF in the treatment-naïve and treatment-
experienced patients (p<0.05). (* Major PR mutations) 
PR 
mutations 
Treatment-naïve Treatment-experienced 
Subtype 
B 
Subtype non-
B/CRF 
Subtype 
B 
Subtype non-
B/CRF 
n % n % n % n % 
L10I 41 14.5 17 7.2 114 19.5 47 8.7 
L10V 29 10.2 12 5.1 0 0.0 0 0.0 
D30N* 0 0.0 0 0.0 24 4.1 6 1.1 
M46I* 0 0.0 0 0.0 54 9.2 27 5.0 
L63P 190 67.1 74 31.5 374 64.0 166 30.7 
A71T 27 9.5 5 2.1 60 10.3 11 2.0 
A71V 0 0.0 0 0.0 81 13.9 14 2.6 
I84V* 0 0.0 0 0.0 39 6.7 11 2.0 
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Table 7.4 (contd.): Significant protease (PR) mutations associated with 
subtype B compared to subtype non-B/CRF in the treatment-naïve and 
treatment-experienced patients (p<0.05). (* Major PR mutations) 
PR 
mutations 
Treatment-naïve Treatment-experienced 
Subtype 
B 
Subtype non-
B/CRF 
Subtype B Subtype non-
B/CRF 
n % n % n % n % 
N88D* 0 0.0 0 0.0 18 3.1 6 1.1 
L90M* 0 0.0 0 0.0 70 12.0 35 6.5 
There were no significant differences in the prevalence of RT mutations 
amongst the treatment-naïve subtype B and non-B/CRF groups: Table 7.5 
highlights the significant RT mutations observed in the treatment-
experienced group.  
Table 7.5: Significant reverse transcriptase (RT) mutations associated with 
subtype B compared to subtype non-B/CRF in the treatment-experienced 
patients (p<0.05). 
RT mutations 
Treatment-experienced 
Subtype B Subtype non-B/CRF 
n % n % 
M41L 117 20.0 48 8.9 
A62V 18 3.1 5 0.9 
T69D 16 2.7 6 1.1 
L210W 79 13.5 27 5.0 
T215Y 115 19.7 55 10.2 
Within the treatment-naïve cohort, 14 significant PR polymorphisms 
associated with the non-B subtypes compared to subtype B were identified 
including: T12S, I15V, L19I/T/V, S37K/N, R41K/N, K45R, Q61E, K70R, 
T74S, L89M.  Twenty-two RT polymorphisms were statistically different in 
the non-B treatment-naïve cohort compared to subtype B including: T39D/E, 
E40D, S48T, K49R, E53D, V60I, D121H/Y, D123G/N/S, I135V, E138A, 
K173A/T, Q174K, D177E, T200A, Q207E, R211S, V245Q. 
Within the treatment-experienced cohort, 15 significant PR polymorphisms 
associated with the non-B subtypes compared to subtype B were identified 
including: T12S, K14R, I15V, L19I/T/V, S37K/N, R41K, K45R, R57K, Q61E, 
K70R, T74S, L89M.  Twenty-seven RT polymorphisms were statistically 
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different in the non-B treatment-experienced cohort compared to subtype B 
including: T39D/E, E40D, S48T, K49R, V60I, D121H/Y, D123G/N/S, E138A, 
T139A, K173A/T, Q174K, D177E, I178M, T200A/E, I202V, E204K, Q207E, 
R211K/S, V245K/Q. 
Discussion 
Of 1,642 FASTA patient sequences submitted to five online analytical tools 
for subtype determination, there was 72.2% concordance across all five 
tools.  A subtype could be determined for the 27.8% of sequences submitted 
whereby there were discordant/unassigned outputs across the five tools, but 
this required a knowledge and understanding of the tools and their outputs to 
ensure appropriate subtype characterisation.  Such online tools were 
evaluated as it was deemed that in the future, clinicians could use such tools, 
on provision of their patient’s FASTA sequence, to determine subtype and 
assist in the clinical management of their patient.   
Overall, 52.8% of the patients were classed as having a subtype B virus; 
38.0% had pure non-B subtypes, of which, the majority were subtype C 
(24.4%); with 9.2% CRFs.  There was a significant increase in the 
prevalence of non-B subtypes and CRFs from the EC (24.2%) to the LC 
(49.2%). In the EC, 4 pure non-B subtypes were characterised (A1, C, D, F1) 
alongside CRF02_AG whilst in the LC, 9 pure non-B subtypes were 
characterised (A1, A2, C, D, F1, F2, G, H, J) alongside 27 CRFs, illustrating 
the increasing genetic diversity and expansion of viruses and evolution over 
time.  
Subtype B characterisation was significantly associated with males whose 
risk group was MSM, conversely, subtype non-B subtypes were associated 
with the heterosexual risk group.  
Non-B subtypes and CRFs were evident in all geographical regions included 
in this study apart from Scotland, where only one subtype B patient was 
characterised.  The non-B/CRF subtypes were more prevalent in the larger 
144
Chapter 7: The evolution of subtype profiles in the clinical cohort 
 
populated regions, in particular Greater London, where 532/775 (68.7%) of 
the non-B/CRF subtypes were characterised. 
 
Analyses indicated some significant differences in the prevalence of PR 
mutations amongst the non-B and the B subtypes in the treatment-naïve and 
treatment-experienced populations including I13V, G16E, K20R, M36I, 
D60E, H69K and I93L.  These are all minor PR mutations as per the IAS-
USA mutation list (Johnson et al 2009).  The mutation I13V is associated 
with subtypes A, G and CRF02_AG and this was evident here where 87.7% 
of subtype A had the mutation, 96.6% of subtype G and 82.2% of the 
CRF02_AG subtypes.  The mutations M36I and I93L are both associated 
with subtype C (Grossman et al 2001) with 44.0% of all subtype C viruses 
harbouring the M36I mutation and 88.7% with the I93L mutation. 
 
Of the significant PR mutations seen in the treatment-experienced patients, 
there were three major PR mutations as per the IAS-USA list (Johnson et al 
2009) with the N88D mutation facilitating the appearance of D30N and L90M 
after NFV treatment failure (Mitsuya et al 2006). 
 
A number of significant PR and RT polymorphisms were associated with the 
non-B subtypes compared with the subtype B viruses in the treatment-naïve 
cohort and alongside the minor PR mutations, warrant further investigation to 
determine whether these mutations/polymorphisms lead to different 
mutational pathways in the non-B subtypes.  At the ICVC, work has started 
to determine the ‘genetic fingerprints’ of the treatment-naïve patients by 
individual subtype to define whether different mutational pathways are 
evident (please see Figure 7.1 below), and work in this field will continue 
based on the initial findings from this study. 
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Figure 7.1: Attempts to define the ‘genetic fingerprint’ of the non-B subtype treatment-naïve patients with >20.0% prevalence of 
protease (PR) mutations/polymorphisms compared with the subtype B treatment-naïve patients.   
 
L10 T12 I13 K14 I15 G16 L19 K20 E35 M36 S37 R41 K45 R57 D60 Q61 I62 L63 I64 C67 H69 K70 V77 L89 I93
A I V V R D I D or N K K K M A
(n=19) 30.8% 87.7% 23.1% 53.8% 84.6% 100.0% 23.1% or 76.9% 84.6% 76.9% 76.9% 100.0% (n=19)
B V D N K V P I L B
(n=283) 21.7% 43.1% 47.1% 22.5% 31.6% 58.5% 25.7% 44.9% (n=283)
C S V I R D I N K E P K M L C
(n=160) 69.3% 80.2% 60.4% 20.8% 24.8% 90.0% 74.3% 82.2% 25.7% 22.8% 95.1% 70.3% 97.5% (n=160)
CRF01_AE V V E D I N K R K K M CRF01_AE
(n=5) 28.6% 100.0% 57.1% 100.0% 100.0% 100.0% 100.0% 28.6% 28.6% 100.0% 100.0% (n=5)
CRF02_AG K V R D I N K P K R M CRF02_AG
(n=14) 20.0% 82.2% 76.9% 26.7% 100.0% 86.7% 93.3% 26.7% 93.3% 40.0% 100.0% (n=14)
D V I N K V V D
(n=13) 56.3% 46.2% 75.0% 93.8% 25.0% 62.5% (n=13)
G A V R V D or Q I N K E K M G
(n=8) 28.6% 96.6% 100.0% 42.9% 28.6% 100.0% 85.7% 100.0% 42.9% 100.0% 85.7% (n=8)
L10 T12 I13 K14 I15 G16 L19 K20 E35 M36 S37 R41 K45 R57 D60 Q61 I62 L63 I64 C67 H69 K70 V77 L89 I93
Treatment-naïve cohort - PR Mutations and Polymorphisms >20% frequency by subtype
 
 
Key:  
boxes highlighted in red indicate significant PR polymorphisms in the treatment-naïve non-B subtype patients relative to the subtype B patients. 
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The ICVC was established to provide VL and genotypic resistance testing for 
clinical centres across the UK to ensure the best possible care for their 
patients with HIV-1.  The ICVC was a small, functional unit, which prided 
itself on its high quality of sample management: patient samples were 
transported and separated on the same day of arrival at the laboratory and 
stored appropriately to maintain the quality of the sample to ensure 
successful VL/resistance testing outcomes.  At the time, this was not 
common practice in laboratories, although the National Health Service (NHS) 
has now caught-up with these standards and have set-up their own 
laboratories to test all HIV-1 VL/resistance samples, so the ICVC no longer 
provides this service. 
The over-riding aim of each of the studies conducted and presented in this 
thesis, was to provide data and evidence of current issues impacting on the 
clinical care of patients living with HIV-1 infection in the UK, and consider 
how best to manage and improve their care.  Using a bespoke clinical cohort 
resistance database, the clinical and resistance mutations data were 
interrogated to determine how the clinical care of HIV-1 patients, whether 
treatment-naïve or treatment-experienced; of subtype B or non-B origin; 
could be managed and improved. 
Limitations encountered 
The clinicians who requested genotypic tests were conducted on their 
patients’ samples were asked to complete a corresponding ICVC resistance 
request form.  We were reliant on the clinicians/clinical centres completing 
these forms appropriately, although it is evident this did not always occur. 
From the data analyses, there were some clear discrepancies e.g. in the 
treatment-experienced clinical cohort analyses, it was stated the majority of 
the cohort were male (n=968), although the risk exposure group data 
indicated 250 (52.1%) were heterosexual and 170 (35.4%) were MSM.  One 
would expect the majority of male cases to be related to the MSM risk 
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exposure group, but if the clinician did not specify this on the resistance 
request form, then it was not assumed, and the field was left blank on the 
database.   
Another example which suggested the clinical data provided did not always 
tally completely with the resistance data, related to the persistence of the 
M184I/V NRTI mutation which by and large, disappears within 12 days of 
treatment cessation (Zaccarelli et al 2003).  In the treatment-experienced 
clinical cohort analyses, based on the clinical data provided, 37.5% of 
patients classed as ‘not on ART but previous experience’ and 31.3% of 
patients classed as ‘treatment-experienced but not indicated whether current 
or previous ART experience’ had evidence of this M184I/V mutation 
suggesting their treatment classification was suspect, but, if it was not clearly 
indicated on the resistance request form, then nothing was assumed. 
Other limitations included the oversimplification of some of the analyses, in 
particular with the treatment-experienced data where patient analyses 
included numerous drugs/drug classes; the frequency of taking these drugs; 
whether the patient was currently on or off treatment and any previous 
treatment history.  With more than 50 mutations associated with the NRTIs, 
40 mutations associated with the NNRTIs and more than 60 mutations 
associated with PI resistance (Shafer and Schapiro 2008), the complexity of 
interpreting these mutations and the effect of single and multiple mutations 
on treatment analyses were likely oversimplified also.  
Resistance in a UK HIV-1 treatment-naïve clinical cohort 
This study identified 380 treatment-naïve patients who had genotypic 
resistance tests conducted between 2001 and 2004, and determined an 
overall resistance prevalence rate of 16.5%.  From 2001 to 2002, resistance 
prevalence rates increased (10.8% to 16.9%), declined in 2003 (7.2%) and 
then rose again, up until the end of June 2004 (14.9%).  The overall 
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prevalence rate for patients grouped as PHI was 14.5%, for those grouped 
as CN it was 11.1%, and for those who were pregnant and treatment-naïve it 
was 8.0%. 
 
Table 8.1 presents the findings of other research groups who conducted 
analyses into the prevalence of resistance mutations in treatment-naïve 
populations.  All research groups who presented an overall resistance 
prevalence rate reported a finding of >10.0%, although the ICVC’s overall 
rate of 16.5% was the highest.  Our pattern of resistance prevalence rates 
over the years: increase between 2001 and 2002; decrease between 2002 
and 2003; increase between 2003 and 2004; were generally supported by 
the other research groups’ findings although there was some variability in the 
actual percentage rates. 
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Table 8.1: Comparison of the ICVC clinical cohort treatment-naïve resistance prevalence rates with other research. 
 
Reference Time- 
scale 
Treatment-
naïve 
population 
Resistance 
mutation 
interpretation 
tool/algorithm 
used 
Main Findings 
Overall 
resistance 
(%) 
Resistance by year Resistance by drug class Resistance by 
grouping 
2001 
(%) 
2002 
(%) 
2003 
(%) 
2004 
(%) 
 NRTI 
(%) 
NNRTI 
(%) 
PI 
(%) 
PHI 
(%) 
CN 
(%) 
Preg 
(%) 
ICVC Clinical Cohort 
Resistance Database 
2001-
2004 
(end of 
June 
2004) 
n=380 
20.0% PHI 
UK 
 
TRUGENE® 
GuideLines 
16.5 10.8 16.9 7.2 14.9 Overall 1.8 9.2 1.6 14.5 11.1 8.0 
2001 2.7 8.1 0.0  
2002 2.2 14.6 2.2 
2003 0.6 7.2 0.0 
2004 3.4 8.0 4.6 
UK HIV Drug Resistance 
Database  
(HPA 2006) 
2002-
2004 
n=2,469 
UK 
IAS-USA  
Guidelines 
(version 2005) 
 
+ additional 
mutations agreed 
by virologists who 
were members of 
UK Collaborative 
Group on HIV 
Drug Resistance 
 
11.4 - 16.0 12.0 9.0 2004 4.5 4.5 2.1 - - - 
Figures above since 
updated on the UK HIV 
Drug Resistance 
Database 
(http://www.hivrdb.org.uk/) 
2002-
2004 
n=4,148 
UK 
11.6 - 13.6 11.4 11.0 2002 9.4 5.0 4.2 - - - 
2003 7.1 5.1 2.7 
2004 6.5 4.3 2.6 
UK Group on Transmitted 
HIV Drug Resistance  
(Cane et al 2005) 
1996-
2003 
(Feb 
1996 to 
May 
2003) 
n=2,357 
7.0% PHI 
UK 
Stanford 
HIVdb 
algorithm  
(version 
2004.04) 
 
14.2 2000-2001 
16.2 
2002-2003 
19.2 
Overall 9.9 4.5 4.6 22.0 14.0 - 
2002-
2003 
12.4 8.1 6.6  
CATCH  
(Wensing et al 2005) 
1996-
2002 
n=2,208 
35.2% PHI 
 
European 
cohort 
including 19 
countries 
 
IAS-USA 
Guidelines 
(version 2002) 
 
+ substitutions at 
codon 215 
10.4 - - - - Overall 7.6 2.9 2.5 13.5 8.7 - 
1996-
1998 
13.4 
 
2.3 
 
2.3 
 
 
1999-
2000 
9.8 3.1 3.1 
2001-
2002 
6.3 9.2 9.2 
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The most striking difference between the ICVC’s prevalence rates and those 
reported by the other research groups, involved the resistance by drug class 
findings.  Overall, the ICVC identified a prevalence rate of resistance 
mutations impacting on the NRTI drug class as 1.5%, the NNRTI class as 
9.2% and the PI class as 1.6%.  However, the other groups with comparable 
findings reported much higher NRTI resistance rates: 9.9% (Cane et al 
2005), 7.6% (Wensing et al 2005); lower NNRTI rates: 4.5% (Cane et al 
2005), 2.9% (Wensing et al 2005) and higher PI rates: 4.6% (Cane et al 
2005), 2.5% (Wensing et al 2005).  On review and re-grouping of the yearly 
findings, our NNRTI resistance rates were comparable: 2001-2002, 12.7% 
(ICVC) 9.2% (Wensing et al 2005); 2002-2003, 9.8% (ICVC) 8.1% (Cane et 
al 2005); however our NRTI and PI resistance rates remained low compared 
with the other findings. 
This variability in the findings likely reflects the design and methodology of 
the different research studies.  For example, the TRUGENE® GuideLines 
Rules were used in this study to interpret the resistance mutations that were 
identified in the ICVC cohort as this reflected the resistance report returned 
to the clinicians.  The other studies presented here employed a range of 
interpretation tools including the IAS-USA mutation list, the Stanford 
database, and supplemented these lists with mutations that they deemed as 
important. 
The impact of these studies on the guidelines and recommendations 
for resistance testing in treatment-naïve patients with HIV-1 
Collectively, all of these studies which determined an increase in the 
prevalence of resistance mutations in the treatment-naïve population, 
particularly with rates above 10.0%, provided evidence that genotypic 
resistance testing for all treatment-naïve patients with HIV-1 infection, should 
be conducted before the commencement of HAART.  This would ensure the 
patients were starting on the optimal first-line treatment regimen to suppress 
their virus, and afford them the best clinical care.  By 2003, the ICVC had 
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highlighted the significant level of resistance in treatment-naïve patients and 
was promoting the genotypic testing of all treatment-naïve patients (Loveday 
at al 2003, MacRae et al 2003).  National, European, and International 
guidelines, were subsequently amended to reflect this recommendation 
(Vandamme et al for the European HIV Drug Resistance Panel 2004, 
Gazzard on behalf of the BHIVA Writing Committee 2005, Hammer et al 
2006). 
An update on the prevalence of resistance in the UK HIV-1 treatment-
naïve population 
The UK HIV Drug Resistance Database has continued surveillance into the 
prevalence of drug resistance mutations in the treatment-naïve population in 
the UK.  Since 2005, the prevalence of resistance to any drug class has 
remained below 10.0% (~8.0%) and for 2013, it was reported to be 6.6% 
(http://www.hivrdb.org.uk/).  There appears to be an association in baseline 
resistance testing strategies as advocated at the ICVC and which were 
finally integrated into treatment guidelines with lower levels of resistance 
now reported in treatment-naive patients.  The prevalence of drug resistance 
mutations in each of the drugs classes in 2013 was 3.4% for the NRTIs, 
3.0% for the NNRTIs and 1.6% for the PIs.  With the development of more 
potent and tolerable drugs and combinations to treat patients with HIV-1 and 
ensure virus suppression; this has led to a decrease in transmitted drug 
resistance mutations (Kouyos and Günthard 2015). 
Contribution of this study to contemporary/scientific knowledge 
The ICVC collaborated with and shared this treatment-naïve clinical cohort 
data with the CATCH Study (Combined Analysis of Resistance Transmission 
Over Time of Chronically and Acute Infected HIV Patients, Wensing et al 
2005).  The CATCH study pooled treatment-naïve data from 19 European 
countries (n=2,208) and analysed the data set with uniformed definitions: 
10.4% of treatment-naïve patients had evidence of ≥1 drug resistance 
mutations.  By sharing our data and collaborating with 18 other European 
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clinical cohort research groups, a larger “supercohort” was developed (Lau 
et al 2007); with the CATCH study producing a definitive report of the 
prevalence of resistance in a European-wide study.  
In conclusion, using the ICVC Clinical Cohort Resistance Database, a 
significant increase in the prevalence of resistance mutations in a UK 
treatment-naïve clinical cohort was identified.  On presentation of this work 
at International and European conferences, alongside other research groups’ 
work, guidelines were updated to recommend resistance testing was 
conducted for all treatment-naïve patients, including those who were PHI 
and CN.   
The overall impact of conducting this study has led to an improvement in the 
clinical care of treatment-naïve patients: by mandating the use of genotypic 
resistance tests for treatment-naïve patients before the commencement of 
ART, it can be ensured that they start on the optimum treatment regimen to 
suppress their virus. 
Resistance in a UK HIV-1 treatment-experienced clinical cohort  
Of 1,786 treatment-experienced patients who had genotypic resistance tests 
conducted between 1996 and 2006, an overall resistance prevalence rate of 
68.1% was determined.  Other clinical cohort research studies determined 
prevalence rates of between 70.0-80.0% (Gallego et al 2001, Tamalet et al 
2003, Gonzales et al 2003, Pillay et al 2005, De Mendoza et al 2007).  This 
study identified a decrease in resistance to the two drug class combination of 
NRTIs+PIs from the EC to the LC; and an increase in NNRTI mutations and 
resistance to NRTI+NNRTI combinations in the LC, compared to the EC 
(these findings were supported by Pillay et al 2005, Mendoza et al 2007). 
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Application of the treatment-experienced clinical cohort findings to the 
use of ART in the developing World 
Identification of mutations and mutational patterns from the treatment-
experienced clinical cohort resistance study can be applied to the developing 
countries, where the majority of the 35.3 million people infected with HIV-1 
live, with 70.8% residing in sub-Saharan Africa (Joint United Nations 
Programme on HIV/AIDS (UNAIDS) 2013).  Due to the failure of vaccine 
studies to control and protect against HIV-1 transmission (The rgp120 HIV 
Vaccine Study Group 2005; Buchbinder et al 2008; Rerks-Ngarm et al 2009), 
‘treatment as prevention’ has been introduced to try and contain the main 
global HIV-1 pandemic (Barnighausen et al 2014), until a vaccine is 
developed.  Access to ART has expanded in recent years in these countries 
after the World Health Organization (WHO) launched and updated numerous 
goals and guidelines to expand global ART coverage: 8 million people 
(54.0%) of those with a CD4 count of ≤350 cells/µL (the level at which the 
WHO recommended initiation of treatment) were on ART by the end of 2011, 
with 9.7 million people on ART by the end of 2012 (WHO 2013a). 
 
In order to reach treatment targets and expand access to ART, simple and 
affordable regimens which could be prescribed to large numbers of people 
were required and the WHO initially recommended treatment with a fixed-
dose combination of two NRTIs and a NNRTI (d4T+3TC+NVP) for first-line 
treatment.  Recommendations have since been updated with 
TDF+3TC+EFV (or TDF+FTC) preferred, with ZDV+3TC+EFV (or NVP) 
suggested as an alternative first-line regimen (WHO 2013b).  For those 
clinically failing their first-line treatment regimen, the WHO recommended 
second-line ART should include a boosted PI (LPV/r or ATV/r) and two 
NRTIs (ZDV+3TC or TDF+3TC (FTC)), dependent on what was used 
previously.  The WHO have adopted the use of these fixed-dose 
combinations as they are efficacious, tolerable, robust, convenient (no 
food/drink restrictions), affordable, and compatible with other drugs e.g. co-
infection with TB/hepatitis (Vitoria et al 2014).    
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Monitoring in these settings is often by clinical deterioration alone, resistance 
tests are rarely available for clinical care in the developing countries: before 
initiation of ART, a CD4 test is recommended.  To determine treatment 
success, clinical observations are used; with further CD4 tests 
recommended every six months if possible; a VL test at six months after 
initiating ART if possible, and every 12 months thereafter if possible (WHO 
2013b). The WHO have recognised the value of VL testing to determine 
treatment failure but it is not routinely used in all cases due to cost; the WHO 
aim to increase the capacity of developing countries to incorporate its use 
into clinical care which will likely lead to an increased demand for second 
and third-line treatment regimens (Vitoria et al 2014). 
Applying the findings from the treatment-experienced clinical cohort 
resistance study, Table 8.2 highlights the prevalence of the resistance 
mutations identified in this cohort, related to the drugs recommended by the 
WHO for use in first-line treatment in the developing countries. 
Table 8.2: Prevalence of resistance mutations identified in the ICVC 
treatment-experienced clinical cohort in relation to the first-line treatment 
regimens recommended by the World Health Organisation (WHO) for use in 
developing countries. Key: * Thymidine analogue mutations (TAMs) 
Resistance mutations and the drug 
class impacted as per the WHO’s first-
line treatment recommendations 
Currently 
on ART 
(n=680) 
All 
treatment-
experienced 
patients 
(n=1,488) 
n % n % 
N
R
TI
 m
ut
at
io
ns
 a
nd
 
dr
ug
 im
pa
ct
ed
 
M41L* d4T, ZDV 189 27.8 299 20.1 
K65R d4T, 3TC, TDF 12 1.8 43 2.9 
D67N* d4T, ZDV 185 27.2 284 19.1 
K70R* d4T, ZDV 125 18.4 216 14.5 
M184I 3TC 15 2.2 36 2.4 
M184V 3TC 305 44.9 550 37.0 
L210W* d4T, ZDV 128 18.8 189 12.7 
T215F* d4T, ZDV 51 7.5 78 5.2 
T215Y* d4T, ZDV 205 30.1 310 20.8 
K219E* d4T, ZDV 37 5.4 74 5.0 
K219Q* d4T, ZDV 59 8.7 93 6.3 
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Table 8.2 (contd.): Prevalence of resistance mutations identified in the ICVC 
treatment-experienced clinical cohort in relation to the first-line treatment 
regimens recommended by the World Health Organisation (WHO) for use in 
developing countries. 
Resistance mutations and the drug 
class impacted as per the WHO’s first-
line treatment recommendations 
Currently 
on ART 
(n=680) 
All 
treatment-
experienced 
patients 
(n=1,488) 
n % n % 
N
N
R
TI
 m
ut
at
io
ns
 a
nd
 
dr
ug
 im
pa
ct
ed
 
L100I NVP, EFV 8 1.2 21 1.4 
K103N NVP, EFV 163 24.0 316 21.2 
V106A NVP, EFV 17 2.5 26 1.7 
V106M NVP, EFV 0 0.0 4 0.3 
V108I NVP, EFV 27 4.0 66 4.4 
Y181C NVP, EFV 108 15.9 204 13.7 
Y181I NVP, EFV 5 0.7 9 0.6 
Y188C NVP, EFV 3 0.4 4 0.3 
Y188H NVP, EFV 1 0.1 3 0.2 
Y188L NVP, EFV 8 1.2 25 1.7 
G190A NVP, EFV 86 12.6 146 9.8 
G190S NVP, EFV 6 0.9 14 0.9 
Of the NRTI treatment-experienced clinical cohort, 39.1% had three or more 
TAMs which impacted d4T and ZDV usage with 72.6% of the EC presenting 
with one or more major NRTI mutations.  The prevalence of the M184V 
mutation which impacts 3TC usage was 37.0% in this cohort and these data 
likely reflects the resistance patterns that are circulating within the 
developing countries who are using the older first-generation NRTI drugs as 
first-line treatment.  Ominously, a study newly published which conducted 
resistance testing in patients on long-term antiretroviral treatment in routine 
HIV clinics in Togo (n=164 patients on first-line ART), reported 99.4% of 
those patients as having drug resistance mutations (Konou et al 2015). 
Prevalence of the M184V mutation was reported as 99.4%, with TAMs 
reported in 71.0% of patients. 
As was indicated, K103N, Y181C and G190A were the dominant major 
NNRTI mutations in this treatment-experienced clinical cohort and as 
established in the treatment-naïve clinical cohort analyses, these NNRTI 
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mutations were transmitted and persisted in the treatment-naive cohort.  Due 
to the NNRTIs low genetic barrier, the development of one of these 
mutations precludes the usage of any of the first-generation NNRTIs (WHO 
initially recommended NVP then EFV for first-line treatment).  Again, 
troublingly, the research findings from Togo confirmed our findings and 
reported the most frequent NNRTI mutations seen were indeed the K103N, 
Y181C and G190A mutations, although specific prevalence rates were not 
reported (Konou et al 2015). 
Contribution of this study to contemporary/scientific knowledge 
Initially, this study was conducted to determine at a population level, the 
prevalence and trends of resistance mutations in a UK treatment-
experienced clinical cohort to ensure the clinicians were provided with 
evidence to determine the best treatment options for their patients and 
ensure the best possible clinical care for them. 
An important facet of the study was also to provide evidence of the key 
mutations circulating in the treatment-experienced population and therefore 
the source of the potential mutations that may be transmitted to newly 
infected persons. 
Finally, applying the treatment-experienced clinical cohort findings to the 
developing world where access to treatment has expanded greatly but 
resistance testing is not conducted, one can foresee the resistance 
mutations and patterns that are likely to arise.   
In conclusion, using the ICVC Clinical Cohort Resistance Database, the 
prevalence of resistance mutations in a UK treatment-experienced clinical 
cohort were established and showed the success of new ART treatments by 
their impact on the EC and LC and the reduction in mutations/resistance. 
Resistance testing is one important tool that can be used to define the next 
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best treatment options and ensure the best possible care for patients with 
HIV-1. 
The “theoretical susceptibility” of the clinical cohort to new ARVs 
A model was developed to determine the “theoretical susceptibility” of the 
treatment-experienced clinical cohort’s potential to use two new second-
generation drugs.  Using published mutation profiles, the prevalence of these 
resistance mutations within the clinical cohort were reviewed and the 
patients’ “theoretical susceptibility” to these new drugs was determined. 
Using the mutational profile for the second-generation NNRTI, ETV, it was 
established that 91.3% of the NNRTI treatment-experienced patients in the 
clinical cohort who were currently failing treatment with their first-generation 
NNRTIs would be “theoretically susceptible” to treatment with ETV.  Only 
8.7% presented with ≥3 ETV mutations and would not be susceptible to its 
use.  This theoretical approach for the determination of the utility of new 
drugs in different communities/populations is a useful way of predicting new 
drug usage and in this case, the ETV findings were supported by the data of 
other researchers including Llibre et al (2008) who determined 8.1% of their 
clinical cohort had ≥3 ETV mutations; Picchio et al (2008) determined a rate 
of 7.5% and Scott et al (2008) 10.5%.  Of interest, the resistance study from 
Togo (Konou et al 2015) noted 21.5% of their patients were resistant to ETV 
and it would be interesting to review the specific ETV related mutations 
prevalent and apply our “theoretical susceptibility” model to their findings.  
The model was also applied to the new PI DRV to determine how many of 
the PI treatment-experienced patients within the cohort would be 
“theoretically susceptible” to its future use.  Again, using the published 
resistance mutation profiles, it was established that 89.7% of the PI 
treatment-experienced patients would be “theoretically susceptible” to 
treatment with DRV.  The model’s findings were supported by the virtual 
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phenotype analyses which were conducted on our behalf by Virco, and 
comparable levels of susceptibility to the new PI DRV were determined.  
Also, other research groups’ findings generally supported this work including 
Rusconi et al (2007) who reported 94.8% of their cohort had ≤2 DRV related 
mutations and therefore would be susceptible to its use;  Mitsuya (2007) 
reported 95.9% of their cohort would be susceptible with Lathouwers (2015) 
reporting a rate of 92.5%. 
Contribution of this study to contemporary/scientific knowledge 
This “theoretical susceptibility” model has since been imitated by another 
research group (Hofstra et al 2014) to determine the prevalence of 
resistance mutations to the second-generation NNRTI rilpivirine in treatment-
naïve patients from Europe.  As per our model, they used a list of NNRTI 
mutations and determined the prevalence of these mutations in their cohort, 
and then predicted susceptibility to rilpivirine using the Stanford algorithm to 
score levels of resistance and proposed the number of patients who would 
be susceptible to the use of rilpivirine. 
This research by Hofstra et al (2014) displayed the utility of our model and 
that the “theoretical susceptibility” model can easily be used in the future 
when new PI/NRTI/NNRTI drugs are launched, to determine the likely 
success of these new drugs within treatment-experienced and treatment-
naïve cohorts.  Ultimately, the model provides a simple tool which can be 
used to translate the resistance mutations prevalent in the clinical cohort and 
inform the potential use and susceptibility of the cohort to these new drugs.    
The evolution of subtype profiles in the clinical cohort 
The subtype profiles of 1,642 patients in the clinical cohort were determined 
by manually submitting their FASTA sequences to five, online subtyping 
tools.  Overall, these tools provided a concordant subtype result for 72.2% of 
the sequences submitted.  For the other 27.8% of subtype results, an overall 
159
Chapter 8: Final Discussion 
subtype result could be assigned by the researcher based on the outputs of 
the tools and applying specific rules to assign subtype.  The study 
highlighted the complexity of subtype characterisation using such tools and 
that the operator needs some knowledge of how the tools work and the 
requirement that these online tools are kept up-to-date, as HIV-1 viruses 
continue to evolve and recombine over time.   
A significant increase in the prevalence of pure and recombinant non-B 
subtypes in the LC (49.2%) compared with the EC (24.2%) was determined 
and this genetic expansion over time was confirmed by the findings of the 
UK Collaborative Group on HIV Drug Resistance, 2014.   
Some PR mutations and polymorphisms specific to the non-B subtypes 
compared to subtype B were identified, which may have an impact on the 
resistance pathways of non-B subtypes.  As illustrated (Figure 7.1), a 
‘genetic fingerprint’ for each of the individual non-B subtypes has started to 
be developed at the ICVC.  Due to the small frequencies of individual non-B 
subtypes seen, studies frequently combine these subtypes altogether into 
one non-B subtype group but future work and collaboration is required to 
pool the data of other clinical cohort research groups and develop a larger 
“supercohort” (Lau et al 2007), to consider the individual non-B subtypes.  
This would produce a powerful tool which could be utilised to determine the 
relevance of subtype characterisation on patients’ clinical care and whether 
subtype diversity and recombination may pose potential problems for patient 
care in relation to HIV-1 pathogenesis, clinical response, natural drug 
mutations and molecular assay efficacy.  
Contribution of this study to contemporary/scientific knowledge 
Through collaboration with the CATCH research group, the FASTA 
sequences submitted to them were shared (with permission from the ICVC 
Collaborative Research Group), with the researchers who developed the 
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REGA subtyping tool and the sequences were used to validate this subtype 
tool (de Oliveira et al 2005).  As determined in our study, the REGA 
subtyping tool provided a powerful tool to determine subtype and through 
this collaboration, we contributed to its development.  Since these analyses 
were conducted, the REGA subtyping tool’s algorithm and reference dataset 
has been updated  (version 3.0) and on evaluation against other online 
subtyping tools, showed a sensitivity and specificity of more than 96.0% in 
the pol region (Pineda-Peña et al 2013). 
Final conclusions 
The engagement of the clinical centres who used the ICVC to establish the 
ICVC Collaborative Research Group and support the pooling of the clinical 
and resistance data to form the ICVC Clinical Cohort Resistance Database; 
allowed the development of a powerful tool to conduct analyses to ultimately, 
try and improve the clinical care of patients with HIV-1.  That is, with the 
recommendation of genotype resistance testing in treatment-naïve patients 
with HIV-1; the surveillance of treatment-experienced patients to ensure they 
were on the optimal treatment regimen and the development of new, more 
potent therapies/drug classes; the surveillance of subtype non-B and CRF 
forms and their mutational pathways: the treatment and clinical care of 
patients with HIV-1 in the UK has improved significantly.   
As indicated, these issues are now of importance in the developing world 
and with the introduction of ‘treatment as prevention’ to try and control the 
global pandemic; the patients living with HIV-1 need to be supported to 
ensure treatment continuity and high adherence levels to the ART; and 
importantly, early diagnosis of new HIV-1 cases to suppress further 
transmission.  With increased travel and movement between countries; 
vigilance is required, as the biggest threat to effective ART treatment 
remains the virus’ ability to replicate and recombine and mutate and evolve 
within an individual host and within the larger community. 
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Appendix 1: Protocol F10: ROCHE COBAS AMPLICOR HIV-1 MONITOR v1.5 
ASSAY (STANDARD) 
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Reagents 
 
Absolute alcohol *    
Distilled water 
Isopropanol 
Roche Amplicor HIV-1 Monitor v1.5 kit ** 
Milton 
 
*   Flammable (Store at room temperature in a fireproof container). 
** Toxic, harmful, corrosive (Store at 2-8ºC, DO NOT FREEZE). 
 
Equipment 
 
100µl -1000µl pipette     5µl-50µl pipette 
20µl-200µl pipette     Plugged tips 
2ml unskirted Sarstedt tubes    Vortex mixer 
600ml beaker      Fine tipped pastettes 
A-rings       D-cups 
10ml graduated pipettes      Pipetboy 
Cobas Amplicor equipment and accessories   Class 2  safety cabinet 
100ml Clear glass screw neck bottle.   37°C Water bath 
Centrifuge 
 
Procedure 
NOTE: all VORTEX steps should last a minimum of 15 seconds unless otherwise stated.  
 
a) Sample Preparation 
 
1. Thaw plasma samples in a tray of water at room temperature 
2. Complete Q31, Cobas Amplicor Audit Sheet. 
3. Remove the following items from the Cobas Amplicor kit: 
• lysis reagent,  
• QS,  
• NHP,  
• negative control,  
• Low +ve control. 
• High +ve control. 
 
4. Place lysis reagent in 37°C water bath.  (do not leave it in the water bath for longer than 10-15 
minutes) 
 
5. Date, number and place orientation marks on 2ml unskirted Sarstedt tubes: 
Use 24 tubes if there are 21 samples (+ 3 controls).  
Use 12 tubes if there are 9 samples (+ 3 controls). 
 
b) Preparation of Standard Working Lysis Reagent  
 
1. Check lysis reagent is fully dissolved, VORTEX until no crystals are visible. VORTEX QS 
tubes (at least 10 seconds)  Then VORTEX QS tubes upside down for 10 seconds.  Add 100µl 
QS to each lysis reagent bottle and VORTEX. 
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2. Add 600µl of lysis reagent to each sample and control tube tube. 
 
3. VORTEX plasma tube, transfer 200µl of plasma to the appropriately labeled tube containing 
lysis. Repeat for each sample. 
 
4. For kit controls VORTEX negative human plasma (NHP) and transfer 200µl to each control 
lysis tube (tube # 22,23 and 24 if 21 samples, tube # 10,11and 12 if 9 samples) and VORTEX. 
 
5. VORTEX kit control tube and transfer 50µl to the correct control lysis tube. Repeat for each 
control.  
 
6. VORTEX all lysis tubes for 20 seconds. 
 
7. Incubate lysis tubes for 10 minutes at room temperature in the Class II Microbiological Safety 
Cabinet. 
 
8. During incubation return plasma samples to freezer and prepare fresh 70% ethanol (21ml 
absolute ethanol + 9ml distilled water). 
 
9. Add 800µl of isopropanol to each tube and VORTEX for 20 seconds. 
 
10. Spin at maximum speed (12500-16000g) for 15 minutes room temperature. (place orientation 
marks on the outside).  If the COBAS is available, prepare the A-rings during this spin. 
 
11. Using a fine tip pastette carefully remove the supernatant and discard into the waste beaker.  
Take care not to disturb the pellet. 
 
12. Add 1ml of 70% ethanol to each tube and VORTEX.  
 
13. Spin at maximum speed (12500-16000g) for 5 minutes (place orientation marks facing out). 
 
14. Using fine tip pastette completely remove supernatant and check lid. 
 
15. Add 400µl of diluent (HIV-1 Dil) to each tube and VORTEX. 
 
16. Transfer 50µl of extract to each A-ring tube. Load extracts 1-12 into A-ring A and extracts 
13-24 into A-ring B. 
 
17. If COBAS is unavailable, store extracts in the freezer between –60°C and -80°C. 
 
18. Transfer A-rings to post PCR laboratory and follow COBAS instructions. Amplification 
MUST be started within 45 minutes after adding extract to A-ring.  (Refer to Protocol F9, 
Operation of COBAS) 
 
c) A-Ring Preparation   (to be started during 15 min centrifugation step if COBAS is available) 
 
1. Label A-rings A and B and make a note of the serial numbers on the working list. 
 
2. VORTEX manganese (Mn++) solution (pink). Mix MMX by inverting 10-12 times. 
 
3. Add 100µl of Mn++ solution to each tube of master mix (MMX). 
 
4. Mix by inversion (10-12 times). 
 
5. Add 50µl of MMX to each tube in two A-rings (24 tubes). 
 
6. Place A-rings in bags in fridge (can be kept for a maximum of 3 hrs). 
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Documentation 
 
Q31 Cobas Amplicor Audit sheet 
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Appendix 2: Frequencies of specific protease (PR) and reverse transcriptase (RT) 
mutations found in the clinical cohort, using the TRUGENE® resistance guidelines 
(Genelibrarian version current at time of testing). 
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Appendix 2_Table 9.1a: Frequencies of specific protease (PR) mutations 
found in the cohort, using the TRUGENE® resistance guidelines 
(Genelibrarian version current at time of testing) showed a broad range of 
mutations. 
Protease (PR) mutations n % 
L10I 483 15.6 
L10R 5 0.2 
L10V 194 6.3 
K20M 59 1.9 
K20R 348 11.3 
L23I 3 0.1 
L24I 35 1.1 
D30N 78 2.5 
V32I 28 0.9 
L33F 60 1.9 
M36I 1,545 50.0 
M36L 16 0.5 
M36TIPL 1 0.03 
M36V 11 0.4 
M46I 197 6.4 
M46L 64 2.1 
I47V 20 0.6 
G48V 42 1.4 
I50V 16 0.5 
F53L 32 1.0 
I54A 2 0.1 
I54L 20 0.6 
I54M 2 0.1 
I54T 3 0.1 
I54V 171 5.5 
L63A 4 0.5 
L63HPYS 3 0.1 
L63P 1,519 49.1 
L63PLSF 8 0.3 
L63S 34 1.1 
L63T 26 0.8 
L63TIPL 8 0.3 
L63TRSP 1 0.03 
A71T 231 7.5 
A71V 271 8.8 
G73S 63 2.0 
G73T 5 0.2 
V77I 265 8.6 
V82A 167 5.4 
V82F 16 0.5 
V82S 5 0.2 
V82T 23 0.7 
I84V 99 3.2 
N88D 56 1.8 
N88S 5 0.2 
L90M 298 9.6 
Key: mutations in bold are classed as major resistance mutations as per the IAS-USA Update of the 
Drug Resistance Mutations in HIV-1: December 2009 list (Johnson et al 2009), and reduce ART 
susceptibility. 
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Appendix 2_Table 9.1b: Frequencies of specific reverse transcriptase (RT) 
mutations found in the cohort, using the TRUGENE® resistance guidelines 
(Genelibrarian version current at time of testing) showed a broad range of 
mutations.
Reverse transcriptase (RT) mutations n % 
M41L 496 16.1 
E44D 59 1.9 
A62V 46 1.5 
K65R 73 2.4 
D67N 499 16.1 
T69D 73 2.4 
T69N 34 1.1 
T69S 4 0.1 
K70E 1 0.03 
K70G 1 0.03 
K70R 372 12.1 
L74I 5 0.2 
L74V 139 4.5 
V75I 30 1.0 
V75M 6 0.2 
V75T 22 0.7 
F77L 31 1.0 
W88G 2 0.1 
A98G 84 2.7 
A98S 42 1.4 
L100I** 52 1.7 
K101E** 108 3.5 
K101P** 2 0.1 
K101Q** 40 1.3 
K103N** 560 18.1 
K103R** 10 0.3 
K103S** 10 0.3 
V106A** 44 1.4 
V106I** 3 0.1 
V106M** 7 0.2 
V108I 116 3.8 
Y115F 40 1.3 
F116Y 23 0.7 
V118I 160 5.2 
Q151M 28 0.9 
V179D 54 1.7 
V179E 18 0.6 
Y181C** 345 11.2 
Y181I** 10 0.3 
M184I 61 2.0 
M184V 871 28.2 
Y188C** 7 0.2 
Y188H** 7 0.2 
Y188L** 37 1.2 
G190A** 254 8.2 
G190E** 3 0.1 
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Appendix 2_Table 9.1b (contd.): Frequencies of specific reverse 
transcriptase (RT) mutations found in the cohort, using the TRUGENE® 
resistance guidelines (Genelibrarian version current at time of testing) 
showed a broad range of mutations.
Reverse transcriptase (RT) mutations n % 
G190S** 28 0.9 
H208Y 44 1.4 
L210W 311 10.1 
T215C 10 0.3 
T215D 13 0.4 
T215F 139 4.5 
T215NTYS 23 0.7 
T215S 26 0.8 
T215Y 504 16.3 
K219E 125 4.0 
K219Q 168 5.4 
P225H** 39 1.3 
F227L** 25 0.8 
M230L** 9 0.3 
P236L** 1 0.03 
Key: mutations in bold are classed as major resistance mutations as per the IAS-USA Update 
of the Drug Resistance Mutations in HIV-1: December 2009 list (Johnson et al 2009), and 
reduce ART susceptibility.        
** are specific NNRTI RT mutations. 
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Appendix 3: Demographics, protease (PR) and/or reverse transcriptase (RT) 
mutations and drug class impacted (non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors 
(PIs)) in the treatment-naïve patients 
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Appendix 3_Table 10.1a: Demographics, protease (PR) and/or reverse transcriptase (RT) mutations and drug 
class impacted (non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase 
inhibitors (NRTIs), protease inhibitors (PIs)) in treatment-naïve patients in 2001: three out of the four patients had 
evidence of resistance (R) to the NNRTI drug class. 
Pt Sex+ Age Reas^ Origin Risk# VL 
(c/mL) 
CD4 
(cells/µL) 
Hospital 
Area$ 
Subtype Mutations Drug Class 
Impacted 
1 M 45 CN Africa Hetero - - EA C PR: K20R, 
M36I, 
L63P/S 
RT: A98S 
A98S 
possible R to 
NNRTIs 
2 M 33 CN Europe MSM 178,000 - GL B PR: M36I, 
L63P  
RT: V179E 
V179E 
possible R to 
NNRTIs 
3 M 68 PHI Europe MSM 830,000 580 SE B PR: L63P  
RT: K103N 
K103N 
R to NNRTIs 
4 M 35 CN Europe MSM >75,000 50 SE B PR: A71T, 
V77I  
RT: T69N 
T69N  
R to ddC, 
possible R to 
ddI (NRTIs) 
Key: 
+Sex: M male, F female
^Reason for test: CN chronic-naïve, PHI primary HIV-1 infection
#Risk group: MSM men who have sex with men, Hetero heterosexual
$Hospital area: EA Eastern, GL Greater London, SE South East
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Appendix 3_Table 10.1b: Demographics, protease (PR) and/or reverse transcriptase (RT) mutations and drug 
class impacted (non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase 
inhibitors (NRTIs), protease inhibitors (PIs)) in treatment-naïve patients in 2002: the majority of the patients identified 
with drug resistance mutations were from the Greater London area (14/15 patients); presented with mutations to 
the NNRTI drug class (12/15 patients) and one patient had resistance mutations which impacted all three drugs 
classes. 
Pt Sex+ Age Reas^ Origin Risk# VL 
(c/mL) 
CD4 
(cells/µL) 
Hosp 
Area$ 
Subtype Mutations Drug Class 
Impacted 
1 M 28 PHI Europe MSM 131,000 446 GL B PR: L10I  
RT: K103N 
K103N 
R to NNRTIs 
2 M 28 PHI Europe MSM 459,000 422 GL B PR: L10I  
RT: K103N 
K103N 
R to NNRTIs 
3 M 42 CN Europe MSM 24,700 - GL B PR: L10I   
RT:K103N/T 
K103N 
R to NNRTIs 
4 M 32 PHI Europe MSM 100,000 538 NW B PR: L10I  
RT: V179D 
V179D 
possible R to 
NNRTIs 
5 M 41 CN Europe MSM 413,000 315 GL B PR: K20M, 
M36I, L63P  
RT: V179D 
V179D 
possible R to 
NNRTIs 
6 M 36 CN Europe MSM 211,000 139 GL B PR: D30N, 
L63P, 
A71V, N88D  
RT: D67N, 
K101E, 
K219Q 
D30N R to NFV.  
N88D+A71V 
possible R to NFV 
(PIs). 
D67N+/or K219Q 
possible R to 
ZDV+ABC (NRTIs). 
K101E, possible R 
to NNRTIs 
7 M 49 PHI Europe MSM 156,000 550 GL B PR: M36I, 
L63P  
RT: A98S 
A98S 
possible R to 
NNRTIs 
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Appendix 3_Table 10.1b (contd.): Demographics, protease (PR) and/or reverse transcriptase (RT) mutations and 
drug class impacted (non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase 
inhibitors (NRTIs), protease inhibitors (PIs)) in treatment-naïve patients in 2002: the majority of the patients identified 
with drug resistance mutations were from the Greater London area (14/15 patients); presented with mutations to 
the NNRTI drug class (12/15 patients) and one patient had resistance mutations which impacted all three drugs 
classes. 
Pt Sex+ Age Reas^ Origin Risk# VL 
(c/mL) 
CD4 
(cells/µL) 
Hosp 
Area$ 
Subtype Mutations Drug Class 
Impacted 
8 M 44 CN Europe MSM >100,000 75 GL C PR: M36I, 
L63#  
RT: V179D 
V179D 
possible R to 
NNRTIs 
9 M 39 CN Africa Hetero 282,000 34 GL C PR: M36I  
RT: Y181C 
Y181C 
R to NVP+DLV, 
possible R to EFV 
(NNRTIs) 
10 M 43 CN Europe MSM 203,000 135 GL B PR: L63P, 
A71T  
RT: M41L 
M41L  
possible R to ZDV 
(NRTI) 
11 M 36 PHI Europe MSM 86,800 880 GL B PR: L63P, 
A71V  
RT: V179D 
V179D 
possible R to 
NNRTIs 
12 M 47 CN - - 62,600 63 GL B PR: L63P  
RT: K103N 
K103N 
R to NNRTIs 
13 M 28 PHI Europe MSM 29,800 517 GL B PR: L63P  
RT: K103N, 
Y181C 
K103N+Y181C 
R to NNRTIs 
14 M 31 PHI Europe MSM 368,000 444 GL B PR: A71T, 
L90M 
R to SQV+NFV, 
poss R to IDV+RTV 
(PIs) 
15 M 38 CN Europe MSM >750,000 18 GL B RT: K103N K103N 
R to NNRTIs 
Key: 
+Sex: M male, F female     ^Reason for test: CN chronic-naïve, PHI primary HIV-1 infection
#Risk group: MSM men who have sex with men, Hetero heterosexual     $Hospital area: GL Greater London, NW North West
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Appendix 3_Table 10.1c: Demographics, protease (PR) and/or reverse transcriptase (RT) mutations and drug 
class impacted (non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase 
inhibitors (NRTIs), protease inhibitors (PIs)) in treatment-naïve patients in 2003: the majority of the patients exhibited 
resistance mutations to the NNRTI drug class (11/12); one patient had resistance mutations which impacted two 
drugs classes (NRTI and NNRTI). 
Pt Sex+ Age Reas^ Origin Risk# VL 
(c/mL) 
CD4 
(cells/µL) 
Hospital 
Area$ 
Subtype Mutations Drug Class 
Impacted 
1 M 35 CN - MSM 13,300 - GL B PR: L10I  
RT: 
K103N 
K103N, R to 
NNRTIs 
2 M 34 CN Europe MSM 279,000 206 GL B PR: L10I  
RT: 
K103N, 
V118I* 
K103N, R to 
NNRTIs 
3 M 36 CN S. 
Africa 
MSM >10,000 69 NW B PR: L10I, 
M36I  
RT: 
V179D 
V179D, poss R to 
NNRTIs 
4 M 41 CN Europe - 60,500 - GL B PR: L10I, 
L63P  
RT: 
V179D 
V179D, poss R to 
NNRTIs 
5 F - Preg Africa Hetero 892,000 - GL A PR: K20R, 
M36I  RT: 
K103N 
K103N, R to 
NNRTIs 
6 F 30 Preg Africa Hetero 80,700 - GL C PR: K20R, 
M36I, 
A71T  
RT: K65R, 
Y115F, 
Y181C 
K65R, R to 
ddI+ddC, poss R 
to TDF (NRTIs). 
K65R+Y115F poss 
R to ABC (NRTI). 
Y181C R to 
NVP+DLV, poss R 
to EFV (NNRTIs). 
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Appendix 3_Table 10.1c (contd.): Demographics, protease (PR) and/or reverse transcriptase (RT) mutations and 
drug class impacted (non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase 
inhibitors (NRTIs), protease inhibitors (PIs)) in treatment-naïve patients in 2003: the majority of the patients exhibited 
resistance mutations to the NNRTI drug class (11/12); one patient had resistance mutations which impacted two 
drugs classes (NRTI and NNRTI). 
Pt Sex+ Age Reas^ Origin Risk# VL 
(c/mL) 
CD4 
(cells/µL) 
Hospital 
Area$ 
Subtype Mutations Drug Class 
Impacted 
7 M 36 CN Asian Hetero 200,000 - EA C PR: M36I  
RT:K101Q 
K101Q, poss R to 
NNRTIs 
8 F 42 CN Africa Hetero - - SE C PR: M36I, 
L63P  RT: 
K103N 
K103N, R to 
NNRTIs 
9 M 42 CN Europe - 277,000 258 GL B PR: M36I, 
L63P  RT: 
V179D 
V179D, poss R to 
NNRTIs 
10 M 32 CN Europe MSM 359,000 329 GL B PR: L63P  
RT: 
K103N 
K103N, R to 
NNRTIs 
11 M 37 CN - - 230,000 180 GL B PR: L63P  
RT: 
K103N 
K103N, R to 
NNRTIs 
12 M 43 PHI Europe MSM 113,000 203 EA B RT: 
K101Q 
K101Q, poss R to 
NNRTIs 
Key: 
+Sex: M male, F female
^Reason for test: CN chronic-naïve, PHI primary HIV-1 infection
#Risk group: MSM men who have sex with men, Hetero heterosexual
$Hospital area: EA Eastern, GL Greater London, NW North West, SE South East
*Presence of specific mutation reflects horizontal transmission although mutation alone does not affect any of the drug classes
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Appendix 3_Table 10.1d: Demographics, protease (PR) and/or reverse transcriptase (RT) mutations and drug class impacted (non-
nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs)) 
in treatment-naïve patients in 2004: compared with the previous years where resistance mutations to the NNRTIs were identified in 
the majority of the cases; 2004 saw an expansion in the number of cases with resistance mutations to the other drugs classes (4/13 
had NRTI resistance mutations, 4/13 had PI mutations and 5/13 had NNRTI mutations). 
Pt Sex+ Age Reas^ Origin Risk# VL 
(c/mL) 
CD4 
(cells/µL) 
Hospital 
Area$ 
Subtype Mutations Drug Class 
Impacted 
1 M 35 PHI Europe - 329,000 - GL B PR: L10I, 
L63P  
RT: V118I*, 
K219Q 
K219Q, poss R to 
ZDV (NRTI) 
2 M 39 CN Europe MSM 27,945 321 WA B PR: L10V, 
K20M, 
L63TRSP   
RT: M184T/I 
M184I, R to 3TC, 
poss R to ddC 
(NRTIs) 
3 M 31 CN - - 5,910 - GL B PR: L10V, 
M36I  
RT: K101E 
K101E, poss R to 
NNRTIs 
4 F 45 CN - - 7,570 - GL A; B PR: K20R, 
M36I, L63P 
RT: K70R, 
M184V, 
T215NTYS, 
K219E 
K70R, M184V, 
T215Y, K219E  R 
to ZDV, ddI, ddC, 
3TC, d4T, ABC 
(NRTIs) 
5 F 40 CN Africa Hetero 291,000 100 GL C PR: M36I  
RT: K103N 
K103N, R to 
NNRTIs 
6 M 39 CN - - 161,000 97 GL C PR: M36I, 
L63P/A  
RT: K103N 
K103N, R to 
NNRTIs 
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Appendix 3_Table 10.1d (contd.): Demographics, protease (PR) and/or reverse transcriptase (RT) mutations and drug class 
impacted (non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease 
inhibitors (PIs)) in treatment-naïve patients in 2004: compared with the previous years where resistance mutations to the NNRTIs 
were identified in the majority of the cases; 2004 saw an expansion in the number of cases with resistance mutations to the other 
drugs classes (4/13 had NRTI resistance mutations, 4/13 had PI mutations and 5/13 had NNRTI mutations). 
Pt Sex+ Age Reas^ Origin Risk# VL 
(c/mL) 
CD4 
(cells/µL) 
Hospital 
Area$ 
Subtype Mutations Drug Class 
Impacted 
7 M 35 CN Europe MSM 650,000 450 GL B PR: M36I, 
L63P  
RT: F227L 
F227L, poss R to 
NNRTIs 
8 M 51 PHI - - 107,000 - GL B PR: M36I, 
L63P/S  
RT: M41L, 
T215N/D* 
M41L, poss R to 
ZDV.   
T215D reflects 
prior NRTI usage. 
9 M 58 CN Europe MSM 7,940 423 EA B PR: M46I/L, 
L63P 
M46I/L, poss R to 
IDV, RTV, APV, 
ATAZ (PIs) 
10 M 35 CN - - 83,600 - GL B PR: L63P, 
A71V 
A71V, poss R to 
ATAZ (PI)  
11 M 29 CN - - 274,000 - GL B PR: L63P, 
A71V 
A71V, poss R to 
ATAZ (PI)  
12 M 41 CN - - 63,800 98 GL B PR: L63P  
RT: K101Q 
K101Q, poss R to 
NNRTIs 
13 M 41 CN Europe - >750,000 155 GL B PR: A71T, 
L90M 
L90M, R to 
SQV+NFV, poss R 
to IDV+RTV (PIs) 
Key: 
+Sex: M male, F female     ^Reason for test: CN chronic-naïve, PHI primary HIV-1 infection
#Risk group: MSM men who have sex with men, Hetero heterosexual     $Hospital area: EA Eastern, GL Greater London, WA Wales
*Presence of specific mutation reflects horizontal transmission although mutation alone does not affect any of the drug classes
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Appendix 4: Characterising subtype profiles 
FASTA ‘pol’ (PR and RT) sequences generated by the TRUGENE® system were 
manually entered into five online analytical tools to determine subtype including: 
• the Stanford subtyping tool: //hivdb.Stanford.edu/
• the NCBI subtyping tool: //www.ncbi.nlm.nih.gov/
• the Los Alamos RIP 2.0 subtyping tool: //hiv-web.lanl.gov/content/hiv-
db/RIPPER/RIP.html/
• the STAR subtyping tool: //www.vgb.ucl.ac.uk/starn.shtml/
• the REGA subtyping tool: //dbpartners.stanford.edu/RegaSubtyping/
An example of a FASTA sequence 
>M94-0099|65165|200401261109||VGI nucleotide|PR(10-297),RT(112-741)I+D0
NNNNNNNNNACTCTTTGGCAGCGACCCCTTGTCTCAATAAAAGTAGGGGGcCAgATAAAGGAGG
CTCTCTTAGACACAGGAGCAGATGATACAGTATTAGARGArATAAATTTRCCAGGAAAATGGAAAC
CAAAAATGATAGGRGGAATTGGAGGTTTTATCAAAGTAAGACAGTATGATCAAATACTCATAGAAA
TTTGTGGAAAAAAGGCTATAGGTACAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGA
AAyATGTTGACTCAGCTTGGATGCACACTAAACTTYNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNTGTGAAGAAATGGAGAAGGAAGGAAAAATTACAAAAATWGGG
CCTgAAAatCCATATAACACTCCAGTGTTTGCCATAAAAAAGAAGGACAGTACTAARTGGAGAAAA
TTAGTAGATTTCAGGGARCTTAATAARAGAACTCAAGACTTYTGGGAAGTTCAATTAGGAATACCC
CACCCAGCAGGGTTAAAAAAGAAAAAATCAGTGACAGTACTAGAYGTGGGAGATGCATATTTTTC
AGTTCCTTTAGATAAAGACTTCAGGAARTATACTGCATTcACcATACCTAGTATAAACAATGAAACA
CcAGGGATTAGATATCAATAYAATGTRCTTCCACAGGGATGGAAAGGATCACCAGCAATATTCCA
GAGTAGCATGACAAAAATCTTAGAGCCCTTTAGGGCACAAAATCCAGGAATAGTCATCTATCAAT
ATATGGATGACTTGTATGTAGGATCTGACTTAGAAATAGGGCAACATAGAGCAAAAATAGAAGAG
TTAAGAGAACATCTATTGAAGTGGGGATTTACCACACCAGATAAGAAACATCAGAAAGAACCCCC
ATTTCTTTGGATGGGGTATGAACTCCATCCTGACAAATGGACAGTACAGCCTATAGAGCTGCCA
180
Appendix 4: Characterising subtype profiles 
The Stanford subtyping tool output 
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The NCBI subtyping tool output 
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The Los Alamos RIP 2.0 subtyping tool output 
183
Appendix 4: Characterising subtype profiles 
The STAR subtyping tool output 
C 
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The REGA subtyping tool output 
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2011 
C Loveday, E MacRae.  The prevalence of E138K mutation and other 
polymorphisms prior to ETV usage in a drug-experienced cohort failing on M184I/V-
inducing NRTI regimens.  In XV International HIV Drug Resistance Workshop: 2011 
June 7-11; Los Cabos, Mexico.  Abstract number 49  
Background: The E138K mutation confers 3-4-fold resistance to etravirine (ETV) 
and other second-generation NNRTIs in tissue culture and in clinical trials. 
Examination of recombinant viruses and RT enzymes containing E138K with 
M184I/V showed reversal of low processivity and low fitness normally associated 
with the latter. Here, we have examined the prevalence and frequency of 
polymorphisms at codon 138 of RT in the ICVC Cohort failing on 3TC, FTC, ABC 
and/or ddI prior to introduction of ETV, to estimate the background changes and 
drug impact at codon 138 relative to a drug-naïve population. 
Methods: The ICVC database contains over 5,000 RT/PR sequences with 
demographics from drug-naïve (DN) and drug-experienced (DE) UK patients. We 
selected consecutive patients, prior to the ETV era, failing on selected NRTIs 
(±M184I/V) and examined the frequency and nature of polymorphic changes at 
codon 138. Statistical analysis was by SPSS (version 17). 
Results: Sequences from 3,071 patients (DE: 2,356, DN: 715) were included with 
~40% currently having M184I/V. Polymorphisms (A, D, G, K, Q, X) were seen at 
codon 138 in 130/2,356 (5.5%) of DE and 43/715 (6.0%) of DN (not significant [NS]). 
A higher frequency of E138K was found in DE (13/2,356; 0.55%) than DN (1/715; 
0.1%; NS). All 13 of these DE patients were currently failing with M184I/V. 
Polymorphism E138A had significantly higher prevalence in the DN (39/715; 5.5%) 
than the DE (82/2,356; 3.5%; p<0.01). Polymorphisms at E138D/G/Q/X all had 
<0.5% prevalence with no differences between DE and DN patients. 
Conclusions: In the pre-ETV era, codon 138 was highly polymorphic but exhibits a 
low frequency of change from WT (<5.0%) in patients failing with M184I/V or on 
therapies driving these mutations. The E138A frequency significantly declined in DE 
patients and E138K had a tantalizing, but non-significant, increase in the DE 
patients. It would appear that prior to ETV, there was no major pathway to enhance 
replication of M184I/V-bearing viruses via codon 138. However, this study defines a 
baseline for further exploration of recent databases in the ETV era, and directs future 
in vitro recombinant studies.   
E MacRae, C Loveday.  A retrospective cross-sectional comparison of fluid-phase 
inflammatory markers including: immunoglobulin (Ig) G, M and A, associated 
circulating immune complexes (CIC) and total complement activation markers in 
AIDS, HIV-1 antibody positive and negative patient cohorts.  In 6th IAS Conference 
on HIV Pathogenesis, Treatment and Prevention, 2011 July 17-20, Rome, Italy. 
Abstract number CDA059. 
C Loveday, E MacRae.  An audit of HIV/AIDS clinic care in a small rural UK clinic 
showed Caucasian (C) versus black African (BA) late presenters had equally good 
responses to therapy.  In 6th IAS Conference on HIV Pathogenesis, Treatment and 
Prevention, 2011 July 17-20, Rome, Italy.  Abstract number CDB348. 
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Background: Small rural HIV/AIDS services (<300 patients) can be under-
resourced in terms of staff, expertise and networks, and their patient populations 
skewed by patient self-selection, overseas asylum seekers and late presenters. To 
address strategies for optimizing patient care at our centre we carried out a 
retrospective clinical notes audit to determine population demographics, disease 
stage and current responses to therapy. 
Method: Our care model used European and BHIVA guidelines, 3 monthly patient 
visits and weekly review of patient issues by 1 doctor, HIV nurse, HCA, pharmacist, 
social worker and a community worker, all with part-time contracts. We had an 
external network to clinics and nurse networks regionally. Daily telephone access 
for advice and additional care was available through the HIV nurse. 
The audit collected anonymous, consecutive, retrospective, demographic, 
virological and therapeutic data from patients over a 2 month period. These data 
were analyzed by SSPS version 17. 
Results: The patients (n=33) included C(39%, male:10, female:3) and BA (55%, 
male:6,female:12) with a mean age 42.6 years (range:17-60) and 79% >38 yrs. 
Comparison of C v BA showed mean ages 44.1 v 41 yrs, symptomatic/AIDS 46 v 
83%, highest VL 5.11 v 5.2 log copies/ml, lowest CD4 228 v 183/mm3, on therapy 
85 v 89%, current VL>40:100 v 100%, current CD4 687 v 476/mm3 ,time 
undetectable 44.5 v 36.1 months, on 1st therapy 45 v 75%, respectively. There was 
low level co-infection with HBV and no HCV, and patients allowing GP shared care 
was significantly higher in C (62%) versus BA (37%, p<0.01). 
Conclusion: There was 100% undetectable VL, a mean CD4 rise of 371/mm3 over 
a mean 44 months in C and BA late presenters in our rural UK clinic setting. Our 
care model adhered closely to guidelines, had weekly virtual ward rounds and took 
advantage of regional networks. 
C Loveday, E MacRae, D Human, RM Lloyd Jr.  Evaluation of a strategy to deliver 
low-technology laboratory (LTL) support to provide cost-effective, real-time and 
contemporary clinical care to patients in resource-limited settings (R-LS) – phase 1: 
molecular tests.  In 6th IAS Conference on HIV Pathogenesis, Treatment and 
Prevention, 2011 July 17-20, Rome, Italy.  Abstract number MOPE421. 
C Loveday, R Lloyd, R Diaz, E MacRae, Z Grossman, R Mathis, D Burns and M 
Holodney.  Evaluation of a dry plasma matrix transport device for genotyping of HIV-
1, HBV and HCV, and quantification of HIV-1 VL to provide an economic approach 
for real-tie clinical care in resource-limited settings.  In BHIVA 17th Annual 
Conference: 2011 April 6-8, Bournemouth, UK.  Oral abstract number O10. 
2010 
C Loveday, RM Lloyd Jr, E MacRae, Z Grossman, R Mathis, D Burns, J Cooper and 
M Holodniy. A simple solid matrix transport device SampleTanker for economic 
collection, storage and transport of patient plasma between clinical sites for 
HIV-1 molecular and antibody testing.  In Second Joint Conference of the British 
HIV Association and the British Association for Sexual Health and HIV; 2010 April 
20-23; Manchester, UK.  Abstract number P55
188
Appendix 5: Publications arising from this thesis 
 
C Loveday, E MacRae and RM Lloyd Jr.  Evaluation of an economic solid matrix 
dry plasma transportation device (SampleTanker: Vive STIM) for qualitative 
and quantitative HIV-1 serology using patient plasma posted between different 
clinical sites.  In XVIII International AIDS Conference; 2010 July 18-23; Vienna, 
Austria.  Abstract  
 
 
2009 
 
Loveday C, MacRae E, Holodniy M, Mathis R, Burns D, Cooper J, Lloyd Jr RM, 
Grossman Z. Evaluation of SampleTanker® for Collection, Storage and 
Transport of Dried Plasma from a Resource-Limited Setting (R-LS) to a 
Resource-Rich Setting (R-RS) for HIV-1 Genotypic Analysis. In XVIII 
International HIV Drug Resistance Workshop; 2009 June 9-13; Fort Myers, Florida.  
Abstract  
 
 
Dimitrios Paraskevis, Oliver Pybus, Gkikas Magiorkinis, Angelos Hatzakis, 
Annemarie MJ Wensing, David A van de Vijver, Jan Albert, Guiseppe Angarano, 
Birgitta Äsjö, Claudia Balotta, Enzo Boeri, Ricardo Camacho, Marie-Laure Chaix, 
Suzie Coughlan, Dominique Costagliola, Andrea DeLuca, Carlos de Mendoza, Inge 
Derdelinckx, Zehava Grossman, Osama Hamouda, I M Hoepelman, Andrzej 
Horban, Klaus Korn, Claudia Kuecherer, Thomas Leitner, Clive Loveday, Eilidh 
MacRae, I Maljkovic, Laurence Meyer, Claus Nielsen, Eline LM Op de Coul, Vidar 
Ormaasen, Luc Perrin, Elisabeth Puchhammer-Stöckl, Lidia Ruiz, Mika Salminen, 
Jean-Claude Schmit, Rob Schuurman, Vincent Soriano, J Stanczak, Maja 
Stanojevic, Daniel Struck, Kristel Van Laethem, M Violin, Sabine Yerly, Maurizio 
Zazzi, Charles A Boucher and Anne-Mieke Vandamme.  Tracing the HIV-1 
subtype B mobility in Europe: a phylogeographic approach.  Retrovirology 
2009; 6: 49 
 
 
 
2008 
 
MacRae E, Loveday C and on behalf of the ICVC Clinical Collaborative Research 
Group.  Significant Increase in Prevalence of HIV-1 Recombinant Forms in a 
UK Non-B Subtype Clinical Cohort over 10 Years.  In 15th Conference on 
Retroviruses and Opportunistic Infections (CROI); 2008 February 3-6; Boston, USA.  
Abstract number 511 
 
Background: To determine the prevalence and characterisation of HIV-1 non-B 
(NB) subtypes and recombinant forms in a UK clinical cohort between 1996 and 
2005.    
Methods: As part of clinical care, patient sequences derived from resistance testing 
at baseline were submitted for subtype characterisation using online tools.  
Sequential clinical patient sequences characterised with a NB subtype were 
included in the analyses. The prevalence of NB subtypes and recombinant forms in 
the early cohort (EC: 1996-2000); and the late cohort (LC: 2001-2005) was 
determined. Statistical analyses were performed using SPSS (v14). 
Results:  Total patients characterised with a NB subtype remained unaltered (EC 
n=632; LC n=661). However, there was a significant increase in recombinant forms 
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from the EC: 44/632 (6.96%) presented with a recombinant form versus the LC: 
141/661 (21.33%); p<0.001. The EC revealed five distinct recombinant forms: 
CRF01_AE (38.64%), unclassifiable recombinant forms (34.09%), A/F (15.90%), 
A/C (9.09%), A/D (2.27%); whilst the LC showed 30 distinct recombinant forms: 
including CRF02_AG (43.97%), CRF01_AE (9.93%), CRF10_CD (7.09%), 
CRF06_cpx (4.26%), D/A1, D/G (both 3.55%) CRF13_cpx, D/C, G/B, H/A1, J/K (all 
1.42%). Of eight geographical regions tested in the EC, 88.64% of recombinant 
forms were circulating in Greater London, with patients in three other geographical 
regions presenting with a recombinant form (all CRF01_AE). Of eight geographical 
regions tested in the LC, all regions had evidence of recombinant forms with the 
greatest prevalence in Greater London (83.69%) with 25 distinct recombinant forms 
identified in this region. Demographic data in the EC and LC were not significantly 
different. 
Conclusions: These data reveal a significant increase in numbers and geographical 
distribution of recombinant forms in a UK clinical cohort over the last ten years. Once 
NB subtypes are established in a community it appears that in a short time 
recombination may occur to give new biologically successful viruses.  These findings 
have implications for the clinical / virological management of patients using PCR in 
the future.  
2007 
MacRae E, Loveday C and on behalf of the ICVC Clinical Collaborative Research 
Group.  Susceptibility of a first generation NNRTI treatment experienced UK 
clinical cohort to TMC-125.  In 11th European AIDS Conference (EACS); 2007 
October 24-27; Madrid, Spain.  Abstract number P3.1/05 
2006 
Loveday C, MacRae E, on behalf of the ICVC Clinical Collaborative Research 
Group.  Susceptibility of a protease inhibitor (PI) treatment-experienced UK 
clinical cohort to TMC-114.   Eighth Congress on Drug Therapy in HIV Infection, 
November 12-16, 2006, Glasgow, UK. Abstract PL2-2. 
Purpose of the study: The new PI TMC-114 has approval for use in the USA and 
is likely in the EU later this year. TMC-114 is expected to be effective for many 
patients with extensive PI-treatment experience. The aim of this study was to 
determine the susceptibility of a UK PI treatment-experienced clinical cohort to TMC-
114. 
Methods: PI-experienced patients who had genotypic resistance tests performed at 
failure of their current regimen as part of their clinical care were included (1996-
2006). Mutations were derived from the Power 1, 2 and 3 trials including PR: V11I, 
V32I, L33F, I47V, I50V, I54L, I54M, G73S, L76V, I84V, L89V (bold=high impact 
mutations (HI) developed in ≥10% virologic failures). Statistical analyses were 
performed using SPSS (v14). 
Summary of results: 885 patients were included: 532(60.2%) currently failing with 
PI containing regimens; 188(21.2%) on non-PI treatment but with PI experience; 
165(18.6%) off treatment, but with PI experience. 
104(19.5%) patients currently on PI treatment presented with TMC-114 related 
mutations including: V32I=15, L33F=23, I47V=13, I50V=6, I54L=10, I54M=1, 
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G73S=23, I84V=49. 83 patients had one related mutation (of which, 22 were HI), 11 
had two (13 HI), 6 had three (12 HI), 2 had four (32+47+54L+84) and 2 had five 
(32+33+47+54L+84). 
8 patients on non-PI treatment had L33F=1, I54L=1, G73S=1, I84V=5 (no patient 
had >1 mutation); 14 patients off treatment had: V32I=3, L33F=7, I54L=1, G73S=4, 
I84V=9 (7 with one mutation (3 HI), 4 with two (3 HI), 3 with three (5 HI)).   
Conclusion: In this PI treatment-experienced clinical cohort, the majority had very 
low frequency of TMC-114 related mutations. Only 10 patients had ≥10 PR 
mutations with 2 patients including 4 HI mutations. Based on these data TMC-114 
should be of benefit to PI treatment-experienced patients in a UK clinical cohort. 
Loveday C, MacRae E and on behalf of the ICVC Clinical Collaborative Research 
group [Abstract].  Limitations in using online tools to determine HIV-1 subtype 
in clinical practice: a comparison of 5 tools.  In XV International HIV Drug 
Resistance Workshop: 2006 June 13-17; Sitges, Spain.  Abstract number 116 
Background: HIV-1 subtype characterisation is becoming an important aspect of 
clinical management of infection.  Currently, patients’ HIV-1 subtype is defined by 
submitting pol sequences to one online clinical database.  The aim of this study is 
to compare accuracy of subtype results derived from 5 popular online analytical tools 
using 1002 consecutive clinical samples. 
Methods: Subtype analyses were performed using PR and RT gene sequences 
from clinical samples.  The 5 clinical databases used were:  
Stanford://hivdb.Stanford.edu/,  
NCBI://www.ncbi.nlm.nih.gov/,  
REGA://dbpartners.stanford.edu/RegaSubtyping/,  
STAR: //www.vgb.ucl.ac.uk/starn.shtml/,  
LosAlamos RIP 2.0: //hiv-web.lanl.gov/content/hiv-db/RIPPER/RIP.html/.   
Comparative and statistical analyses were performed using SPSS.     
Results: 1002 sequences were submitted for subtyping.  Stanford, NCBI, 
LosAlamos assigned a subtype to all sequences.  REGA (237, 23.7%) and STAR 
(135,13.5%) were unable to assign subtype for a significant number of sequences 
(p<0.001). 
Concordant results across all 5 tools=585 (58.4%), including subtypes 
A=22(3.8%), B=388(66.3%), C=164(28%), D=6(1%), F=2(0.3%), G=3(0.5%).  The 
remaining 417 (41.6%) analyses resulted in 40 combinations of concordant / 
discordant / unassigned results across the 5 tools.   
Concordance across 4 tools with 1 tool providing a discordant or unassigned result 
=158(15.8%), including:  
Stanford+NCBI+REGA+STAR=68 (LosAlamos discordance associated with 
subtype B=46, CRF02_AG=22).  Stanford+NCBI+STAR+LosAlamos=62 (REGA 
unassigned=61, REGA discordance associated with CRF01_AE).  
NCBI+REGA+STAR+LosAlamos=14 (Stanford discordance associated with A=5, 
C=9). Stanford+NCBI+REGA+LosAlamos=8 (STAR unassigned=8).  
Stanford+REGA+STAR+LosAlamos=6 (NCBI discordance associated with A=5, 
G=1). 
Concordance across 3 tools with the other 2 tools concordant or providing 
discordant / unassigned results=134(13.4%).  Discordance / unassigned results 
across all 5 tools=51(5.1%), including:   
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Stanford+NCBI+LosAlamos discordant, REGA+STAR unassigned=39  
Stanford+NCBI+REGA+LosAlamos discordant, STAR unassigned=11 
Stanford+NCBI+STAR+LosAlamos discordant, REGA unassigned=1 
Overall concordance across the individual tools: Stanford+STAR=80.7%, 
Stanford+NCBI=79.2%, Stanford+LosAlamos=77%, STAR+LosAlamos=76.6%, 
STAR+NCBI=74.7%, NCBI+LosAlamos=70%, REGA+STAR=69.9%, 
REGA+NCBI=69.5%, REGA+Stanford=67.8%, REGA+LosAlamos=63.5%. 
Conclusion:  There was 58.4% concordance across all 5 tools.  Use of one tool 
alone, compared with any of the other tools will result in misclassification of 20% or 
more of patients’ subtype.  Unassignment of sequences by REGA and STAR 
probably reflects the stringency of the tools.  Discordance across the tools reflects 
the difficulty in keeping these tools up-to-date to determine new and recombinant 
viruses.  The evolution of new, complex recombinant viruses at a community level 
will result in subtyping becoming increasingly difficult to interpret.   
van de Vijver DAMC, Wensing AMJ, Angarano G, Asjo B, Balotta C, Boeri E, 
Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinck I, Grossman Z, 
Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, 
Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, 
Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz 
L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, 
Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, 
and Boucher CAB for the SPREAD Programme.  The Calculated Genetic Barrier 
for Antiretroviral Drug Resistance Substitutions is Largely Similar for Different 
HIV-1 Subtypes.  Journal of Acquired Immune Deficiency Syndrome 2006; 41 (3): 
352-360
Loveday C, MacRae E and on behalf of the ICVC Clinical Collaborative Research 
group [Abstract].  Comparison of online clinical database HIV-1 subtyping tools.  
In 13th Conference on Retroviruses and Opportunistic Infections: 2006 February 5-
8; Denver, Colorado, USA.  Poster number 660  [ *Awarded Young Investigator 
Award] 
Background:  Sequences used to define HIV-1 resistance are often applied to 
online databases to define subtype to improve patient care. This study aims to 
compare 3 common analytical tools using sequential clinical samples.     
Methods: Subtype analyses were performed using PR and RT gene sequences 
from samples with epidemiological evidence of genetic diversity (2002 - end Aug 
2005). Three clinical comparative tools were used: Stanford://hivdb.Stanford.edu/, 
NCBI://www.ncbi.nlm.nih.gov/, REGA://dbpartners.stanford.edu/RegaSubtyping/. 
Comparative and statistical analyses were performed using SPSS.     
Results: 1646 sequences were submitted for subtyping. Subtype B=827(50.2%); 
non-B (NB)=800(48.6%); indeterminate=19(1.2%). All three analytical tools 
provided concordant results for 1206(73.3%) of sequences submitted, B=742, 
NB=464, including A=41, C=337, D=9, F=7, G=19, H=2, CRF02_AG=49.   
REGA was unable to assign a significant number of samples n=311,18.9% relative 
to Stanford and NCBI (p<0.001). Of the 311, Stanford and NCBI provided 
concordant subtype analyses for 146(46.9%) and discordant for 165(53.1%). 
Reasons for non-assignment by REGA: no cluster with pure subtype, no detection 
of recombination (n=65:20.9%); cluster with pure subtype, detection of 
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recombination but failure to classify as CRF (n=115:37%); cluster with CRF, 
detection of recombination in pure subtype but failure to classify as CRF 
(n=39:12.5%); cannot explain (n=92:29.6%). 
Of the remaining 129 results, REGA and Stanford were concordant in 12 cases, 
REGA and NCBI in 30, Stanford and NCBI in 25 and there were 62 discordant 
results across the 3 tools. Discordant results were associated with subtype 
A/CRF01_AE (n=48:77.4%), C (n=6:9.7%), F (n=3:4.8%), CRF10_CD (n=2:3.2%), 
CRF06_cpx, CRF13_cpx, J (all n=1:1.6%).  
Conclusions: In 73% of cases there was good agreement between the analytical 
approaches. Unassignment of 18.9% of sequences in REGA probably reflects the 
stringency of the process: query sequences submitted to REGA are interrogated by 
phylogenetic analysis, bootstrap support, bootscanning analysis and phylogenetic 
signal detection. The NCBI tool was more subjective as the user had to interpret the 
graphical output produced. Stanford was easy to use but compares query 
sequences to approx. 94 reference sequences only, and therefore may not detect 
new and recombinant subtypes. Careful consideration is required when using these 
tools in isolation for clinical care 
2005 
MacRae E, Loveday C and on behalf of the ICVC Clinical Collaborative Research 
Group [Abstract].  High prevalence of HIV-1 non-B subtype recombinants and 
diverse polymorphic profiles in a UK clinical cohort - implications for future 
resistance analysis.  In XIV International HIV Drug Resistance Workshop: 2005 
June 7-11; Quebec City, Quebec, Canada.  Abstract number 134 
Background:  Increase in prevalence of non-B subtypes (NB) is associated with 
clinical issues of detection, sequencing and mutational characterisation.  With our 
development of new approaches to sequence difficult samples, our laboratory has 
attracted a unique population of UK NB samples.  In view of the clinical importance 
of diverse viruses we have analysed distribution of NB subtypes in naïve and treated 
patients including the proportion and diversity of recombinants; mutations and 
polymorphisms associated with NB viruses relative to B. 
Methods:  Patients who had genotypic resistance tests performed as part of their 
clinical care between 2003 and February 2005 were included.  Mutations were 
derived from TRUGENE-Genelibrarian (Bayer Diagnostics).  Consensus subtype 
analyses were performed using RT and PR gene sequences with comparative 
databases (Stanford, NCBI, Los Alamos).  Statistical analyses were performed using 
SPSS. 
Results:  The last 945 consecutive clinical patient sequences submitted for analysis 
were included: NB-424(45%), B-521(55%).  Naïve: NB-152(36%), B-252(48%); 
treated: NB-272(64%), B-269(52%).   
NB subtypes included: A(7%), C(50%), CRF01_AE(3%), CRF02_AG(9%), D(9%), 
F(1%), G(4%), H(1%).   
17% were recombinants, with 30 combinations exhibiting different subtypes for PR 
and RT, including: A/CRF01_AE, A/J, J/B, J/C, J/F, J/K, K/C, K/CRF01_AE, K/F.   
Significant PR mutations present in NB versus B using the IAS-USA definition found: 
K20R (naïveNB-20%, B-2.4%; treatedNB-21%, B-7.8%) M36I (naïveNB-99%, B-
19.1%; treatedNB-85%, B-20.8%) more frequently in NB viruses (p<0.05 (Chi2)).  
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L63P was more prevalent in B viruses (naïveNB-23%, B-58.7%; treatedNB-28%, B-
61.3%) (p<0.05).   
15 PR polymorphisms were significantly more prevalent in NB versus B naïve 
sequences: T12S, I13V, I15V, G16E, L19I/T/T;I, S37N, R41K, K45R, D60E, Q61E, 
H69K, K70R, T74S, L89M, I93L (p<0.001).  Applying the Tipranavir resistance 
score, six of these polymorphisms have clinical implications for viral resistance. 
No RT mutations were significantly more prevalent in NB versus B but 16 RT 
polymorphisms were: T39D/E/K, E40D, K43E, S48T, K49R, V60I, D123G/N/S, 
I135V, E138A, S162A, K173A/T, Q174K, D177E, T200A, Q207A/E, V245Q 
(p<0.001). 
Conclusions:  In a UK NB population, there was a high prevalence of new diverse 
recombinant viruses.  Although few resistance mutations were significantly different 
between NB and B, there was disproportionate representation of polymorphisms 
including some currently described as resistance mutations for newer PIs.  These 
data imply the need for specific NB mutational charts for analysis of resistance. 
van de Vijver DAMC, Wensing AMJ, Angarano G, Asjo B, Balotta C, Boeri E, 
Camacho R, Chaix ML, Costagliola D, Op de Coul ELM, de Luca A, Maljkovic I, de 
Mendoza C, Derdelinck I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman IM, 
Hemmer R, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Meyer 
L, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer-Stockl E, Ruiz L, 
Salminen M, Schmit JCC, Schneider F, Schurrmann R, Soriano V, Stanczak G, 
Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, 
and Boucher CAB on behalf of the SPREAD Programme [Abstract]. Differences in 
the frequency of minor substitutions between HIV-1 subtypes and their 
potential impact on the genetic barrier for resistance to protease inhibitors.  In 
XIV International HIV Drug Resistance Workshop: 2005 June 7-11; Quebec City, 
Quebec, Canada.  Abstract number 132 
van de Vijver DAMC, Wensing AMJ, Asjo B, Bruckova M, Brunn Jorgensen L, 
Horban A, Linka M, Lazanas M, Loveday C, MacRae E, Nielsen C, Paraskevis D, 
Poljak M, Puchhammer-Stockl E, Ruiz L, Schmit JCC, Stanczak G, Stanojevic M, 
Vandamme AM, Vercauteren J, and Boucher CAB on behalf of the SPREAD 
Programme [Abstract]. Selective transmission of drug resistance 
mutations.  In XIV International HIV Drug Resistance Workshop: 2005 June 7-11; 
Quebec City, Quebec, Canada.  Abstract number 113  
Loveday C, Grant P, Goodall R, Pillay D, MacRae E, Asboe D, Williams I, Stoehr 
W, Babiker A, on behalf of the Forte Virology Group and Trial Steering 
Committee.  Adding a PI for 6 months to a Standard NNRTI-based Regimen 
Reduces the Risk of Virological Failure without Inducing Resistance to the 
PI: The Forte Virology Analysis [Abstract].  In 12th Conference on Retroviruses 
and Opportunistic Infections: 2005 February 22-25; Boston, Massachusetts, 
USA.  Poster number 575. 
Wensing AMJ, van de Vijver DAMC, Angarano G, Asjo B, Balotta C, Boeri E, 
Camacho R, Chaix ML, Costagliola D, de Luca A, Derdelinck I, Grossman Z, 
Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer 
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C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen 
C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, 
Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak 
G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, 
Zazzi M, and Boucher CAB for the SPREAD Programme.   Prevalence of Drug-
Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for 
Clinical Management.  Journal of Infectious Diseases 2005; 192 (6): 958-966 
2004 
Loveday C, MacRae E, Johnson M and on behalf of the ICVC Clinical Collaborative 
Research Group.  The Changing Prevalence of HIV-1 Protease (PR) and 
Reverse Transcriptase (RT) Polymorphisms in Primary HIV Infection (PHI), 
Chronic-Naïve, and following Exposure to Antiretroviral Therapy (ART) 
[Abstract].  In XIII International HIV Drug Resistance Workshop: 2004 June 8-12; 
Canary Islands, Tenerife, Spain.  Abstract number 82 
Background: The significance of commonly occurring polymorphisms in PR and RT 
in early infection and before and after ART is poorly understood. In previous smaller 
studies using 251 selected polymorphisms with a prevalence of greater than 1% 
derived from the ICVC database we have seen homogeneity at infection with 
increasing polymorphic diversity in chronic-naïve infection, and evidence of 
selection under pressure of ART. Using the database with over 3000 patients we 
explore these questions in detail. 
Methods: The frequency of 251 polymorphisms in PR and RT were analysed 
relative to patient disease stage and therapy, using the ICVC database. Sequence 
data were derived from VGI TRUGENE HIV-1 (Bayer Diagnostics).  Chi-square 
statistical analyses were performed using SPSS (version 12 for Windows). 
Results: Using 646 patient sequences (PHI (n=70), chronic-naïve (n=253) and post-
ART (n=323)), significant homogeneity was exhibited in PHI relative to chronic-naïve 
(PR: p=0.007, RT: p=0.001).  Polymorphisms commonly present at PHI were PR: 
codons 37 (87.14%), 41 (45.71%), 93 (54.29%) and RT: codons 122 (58.57%), 211 
(68.57%), 214 (84.29%) and 245 (58.57%). 
In chronic-naive patients, the polymorphic repertoire expanded significantly (PR: 
p=0.007, RT: p=0.001) with the prevalence of polymorphisms at PR: codon 69 
(p=0.008) and RT: codons 39 (p=0.019), 173 (p=0.028), 174 (p=0.023), 177 
(p=0.017) and 200 (p=0.006) significantly increased compared to PHI. 
Following ART, polymorphisms at PR: codons 13, 16, 55, 64, 70, 72, 74, 93 (all 
p<0.05) and RT: codons 43, 90, 123, 135, 138, 203, 218, 221, 228, 238 (all p<0.05) 
had a significant increase in prevalence relative to chronic-naïve patients.  
Prevalence of PR: codons 19 (p=0.024), 45 (p=0.005) and RT: codons 48 (p=0.011), 
83 (p=0.004), 169 (p=0.011) significantly decreased relative to chronic-naïve 
patients. 
Conclusions: Certain polymorphisms confer biological advantages to HIV during 
early evolution in the host and following ART.  Genetic homogeneity at infection is 
followed by significant genetic expansion in the polymorphic repertoire of chronic-
naïve patients.  Drug pressure showed the polymorphic repertoire altered and 
implies that although these polymorphisms may not confer resistance alone, they 
provide a background to facilitate resistance in the presence of recognized 
mutations. 
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van de Vijver DAMC, Wensing AMJ, Angarano G, Asjo B, Balotta C, Boeri E, 
Camacho R, Chaix ML, Costagliola D, Op de Coul E, de Luca A, Maljkovic I, de 
Mendoza C, Derdelinck I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman IM, 
Hemmer R, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, 
Meyer L, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, Puchhammer-Stockl E, 
Ruiz L, Salminen M, Schmit JCC, Schneider F, Schurrmann R, Soriano V, 
Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, 
Yerly S, Zazzi M, and Boucher CAB on behalf of the SPREAD Programme 
[Abstract]. The Calculated Genetic Barrier For Drug Resistance Mutations In 
Six Different Non-B Subtypes And Two CRF’s In A Large European Dataset 
Is Largely Similar to Subtype B.  In XIII International HIV Drug Resistance 
Workshop: 2004 June 8-12; Canary Islands, Tenerife, Spain. Abstract number 87. 
Loveday C, MacRae E, Johnson M and on behalf of the ICVC Collaborative 
Research Group.  The rising prevalence of subtype non-B in a UK drug-naïve 
cohort [Abstract].  In 2nd European HIV Drug Resistance Workshop: 2004 March 
11-13; Rome, Italy.  Abstract number 1.17
Background: The ICVC undertakes the virological care of over 7000 patients in 37 
clinical centres across the UK.  We, and others have reported a temporal rise in the 
prevalence of subtype non-B and recombinants in the UK and Europe.  This 
retrospective clinical audit aims to investigate drug-naïve resistance profiles in these 
populations to date.   
Methods: All ART-naïve patients who had genotypic resistance tests performed as 
part of their clinical care between 2001 and 2003 were included (VGI TRUGENE 
HIV-1 Bayer Diagnostics).  Mutations were derived from the rules based algorithm 
(Genelibrarian report).  Consensus subtype analyses were performed using pol 
gene sequences with comparative databases.  
(NCBI: http://www.ncbi.nlm.nih.gov/retroviruses/subtype/subtype.html; Stanford: 
http://hivdb.stanford.edu/ Los Alamos: http://www.hiv.lanl.gov/content/index). 
Results: 284 ART-naïve patients presented in the three-year period 2001 to 2003 
(n=38; 89; 157).  Majority were male (33; 70; 110) with mean age (41.3; 37.4; 35.2). 
The majority presented as chronic naïve (24; 57; 117) as PHI (11; 27; 28) as 
pregnant and naïve (3; 5; 12).   
In 2001, 10/38 (26.3%) were subtype non-B; 30/89 (33.7%) were in 2002 and 
72/157 (45.9%) in 2003. Subtype C was predominant (5 (13.2%); 23 (25.8%); 48 
(30.6%)) with increasing diversity and recombinant forms identified too.  
Prevalence of subtype non-B has significantly increased (chi2 = 6.674, p = 0.036).   
Over the years, 33 (9 non-B); 80 (29 non-B); 135 (67 non-B) patients presented with 
listed mutations associated with ART.  Of those, 5 (0 non-Bs); 15 (2 non-Bs); 19 (9 
non-Bs) were found to have at least one major mutation and/or evidence of 
horizontal transmission.  The mutations present did not significantly differ from those 
found in the subtype B cohort.  Of note, the prevalence of all PR mutations in non-
B patients has significantly increased over time (15/55 = 27.3%; 46/121 = 38%; 
106/210 = 50.5% (chi2 = 11.537, p = 0.003)), as have RT mutations (0/7 = 0%; 2/19 
= 10.5%; 11/22 = 50% (chi2 = 11.088, p = 0.004)).   
Conclusions: Mutations within subtype non-B viruses found within ART-naïve 
patients are no different from subtype B populations in the cohort.  We have found 
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an increasing prevalence of subtype non-B within this cohort, predominantly 
represented by subtype C. 
van de Vijver DAMC, Wensing AMJ, Op de Coul E, Angarano G, Asjo B, Balotta C, 
Boeri E, Camacho R, Chaix ML, Costagliola D, de Luca A, Maljkovic I, de Mendoza 
C, Derdelinck I, Grossman Z, Hamouda O, Hatzakis A, Hoepelman IM, Hemmer R, 
Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Nielsen C, 
Ormaasen V, Perrin L, Paraskevis D, Puchhammer-Stockl E, Ruiz L, Salminen M, 
Schmit JCC, Schneider F, Schurrmann R, Soriano V, Stanczak G, Stanojevic M, 
Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, and Boucher 
CAB on behalf of the SPREAD Programme.  Increasing prevalence of HIV-1 non-
B subtypes across Europe from 1996-1999 to 2000-2002; results from the 
CATCH-study [Abstract].  In 2nd European HIV Drug Resistance Workshop: 2004 
March 11-13; Rome, Italy.  Abstract number 1.3 
Loveday C, MacRae E, Johnson M and on behalf of the ICVC Collaborative 
Research Group.  A Dynamic Analysis that Allows More Accurate Estimates of 
the Prevalence of Mutations in ART-Naïve HIV/AIDS Patients in a UK Cohort 
(January 2001 to Date) [Abstract].  In 11th Conference on Retroviruses and 
Opportunistic Infections; 2004 February 8-11; Moscone West, San Francisco, CA, 
USA.  Abstract number 687.  [ *Awarded Young Investigator Award] 
Background: The ICVC undertakes the virological care of over 7000 patients in 
37 clinical centres across the UK. The annual prevalence of ART mutations in the 
drug-naïve patients submitted for sequencing has been over 20% from 2001 to 
2003. This study uses a sliding dynamic analysis to normalise year on year 
variations and allow more accurate estimations of resistance in ART-naïve patients 
from 2001 to date. 
Methods: All ART-naïve patients who had genotypic resistance tests performed 
as part of their clinical care were included (VGI TRUGENE HIV-1 - Bayer 
Diagnostics). Mutations derived from the rules based algorithm (Genelibrarian 
report) were analysed. Prevalence points were generated for 4 annual quarters 
commencing in 2001 and advancing by 3-month intervals to date to provide 8 
‘annual’ comparisons of resistance prevalence. Data were analysed using SPSS 
11.5 (www.spss.com).  Chi-square tests were used to analyse significant 
differences between major mutations present at the different time-scales. 
Results: 252 ART-naïve patients were included. The majority were male 
(n=184,73%) mean age 36 years (range 18-74). Chronic naïve (n=174,69%), PHI 
(n=58,23%) and pregnant naïve (n=20,8%) were all represented. Patients derived 
from Europe (n=133, 57%), Africa (n=84, 33%) and other developing countries 
(n=35, 10%). 18% (n=45) were subtype NB with representation of most subtypes.  
183/252 ART-naïve patients screened had mutations (excluding 40 with L63P 
only), 29 patients had no mutations. Analysis revealed a gradual and significant 
rising prevalence (24.7%) of all major mutations to 2002 (Q1-4) but a more recent 
decline (16.5%) to date.  
As presented in the graph, major mutations conferring NNRTI resistance increased 
up to end 2002 (from 5.3% at 2001 Q1-4 to 14.6% at 2002 Q1-4), with prevalence 
now declining.   
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Prevalence of NRTI mutations decreased between 2001 Q2 and 2002 Q2 but has 
increased and remained at a steady rate (7.5%).  PI mutations are evident at low 
prevalence rates between 2001 Q3 and 2003 Q2 and are absent at the most 
recent time point. No significant differences in major mutations across the time-
scales were observed.  Of note, our data showed that NB subtypes were over-
represented in patients with major mutations.   
Conclusions: A dynamic analysis of resistance data revealed a rising prevalence 
to 2002 but a more recent decline by end of 2003. This method allows detailed 
temporal analysis of single mutations and subtypes involved. 
2003 
MacRae E, Loveday C, Johnson M and on behalf of the ICVC Collaborative 
Research Group.  The rising prevalence of ART resistance mutations in naïve 
patients with HIV/AIDS in a UK cohort [Abstract].  In 9th European AIDS Conference 
(EACS); 2003 October 25-29; Warsaw, Poland.  Abstract number 3.1/6 
Background: ICVC collaborates with 41 clinical centres across Greater London, 
rural England/Wales (>7000 patients with HIV/AIDS) and recommends the use of 
ART resistance testing for naïve patients, since establishing a significant increase 
in mutations in the cohort between 2000 and 2002.  
Objectives: To audit the prevalence of ART mutations in naïve patients from June 
2002 to June 2003.  
Methods: All ART-naïve patients submitted for genotypic sequencing during this 
period are included.  The VGI TRUGENE HIV-1 (Bayer Diagnostics) test was used 
to determine resistance.  Clinical, virological data, mutations (derived from VGI 
report - GeneLibrarian) and polymorphisms were analysed. 
Results: 129 naïve patients were tested (n = 35 PHI, 83 chronic naïve, 11 pregnant). 
Patient demographics showed majority male (M91:F38); mean age 35.5 years 
(range 18-65); risk groups: MSM (35%), heterosexual (19%), pregnant (9%), 
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bisexual (1%), IDU (1%); country of origin: Europe (44%), Africa (28%), Asia, 
Australasia, North and South America, Middle East (all 1%). 
Eighty-eight presented with mutations associated with ART (excluding 23 with L63P 
only).  From the 88, 19 had at least one major mutation, including: RT – K65R (n:1), 
D67N (n:1), F77L (n:1), A98S (n:1), K101E/Q (n:3), K103N (n:7), Y115F (n:1), 
V179D/E(n:6), Y181C (n:2), K219Q (n:1); PR – D30N (n:1), N88D (n:1). Prevalence 
rate – 22%.    
Minor mutations included RT – V118I (n:4), T215D (n:1); PR – L10I/V/R (n:26), 
K20R/M (n:11), M36I/L/T (n:57), L63P/T (n:61) A71V/T (n:15).  Sixteen presented 
with three or more of these minor mutations.  
Conclusions: Mutations involving all 3 drug classes prior to ART are evident here. 
Surveillance is continuing. 
Kinloch S, MacRae E, Johnson MA and Loveday C.  Horizontal transmission of 
NNRTI resistance between two patients with recent HIV infection [Abstract].  In 
9th European AIDS Conference (EACS); 2003 October 25-29; Warsaw, Poland.  
Abstract number 3.1/7 
Background: NNRTIs have been used increasingly in first-line therapy in recent 
years. Resistance to such antiviral drugs is one of the important factors leading to 
future HAART failure.  
Objectives: To describe horizontal transmission of NNRTI resistance between two 
recently HIV infected patients, naive to HAART. 
Methods: Two patients diagnosed at the ICDC were submitted for routine genotypic 
ART resistance, using the VGI TRUGENE test (Bayer Diagnostics).  Clinical, 
virological data, mutations (derived from VGI report - GeneLibrarian) and 
polymorphisms were analysed. 
Results: Two patients (A and B) with recent HIV infection were diagnosed with a 
K103N mutation. Both partners had been in a relationship during the six months 
preceding HIV seroconversion in patient B. Patient A was diagnosed with primary 
HIV infection (PHI) in June 02 at another London hospital, was naive to HAART, 
and referred himself to our centre in Aug 02. His genotyping assay showed an 
isolated K103N. Patient B was first seen on 27.09.02 with a history of a negative 
HIV test four weeks previously, symptoms consistent with PHI, HIV viraemia > 
750.000 c/mL and CD4 count at 422 cells/mm3 (22%). Genotyping showed a 
similar resistance pattern as Patient A, with only one change observed 
(polymorphism T165T/I).  Sequencing showed there was <1% difference between 
the two strains suggesting a strong epidemiological link between the two patients.  
Conclusions: Horizontal transmission of K103N occurred in these patients naive to 
HAART. Incidence of NNRTI resistance should continue to be routinely monitored 
in recently-infected patients as it has major implications in the choice of first-line 
therapy. 
Wensing A, van de Vijver D, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, 
De Luca A, de Mendoza C, Derdelinck I, Grossman Z, Hamouda O, Hatzakis A, 
Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, 
MacRae E, Maljkovic I, Nielsen C, Ormaasen V, Perrin L, Paraskevis D, 
Puchhammer E, Ruiz L, Salminen M, Schmit J, Schneider F, Schurrmann R, Soriano 
V, Stanczak G, Stanojevic M, Vandamme A, Van Laethem K, Violin M, Wilbe K, 
Yerly S, Zazzi M, Boucher C.  Drug susceptibility patterns in 195 European 
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patients de novo infected with drug resistant virus, implications for Post-
Exposure Prophylaxis [Abstract].  In 9th European AIDS Conference (EACS); 2003 
October 25-29; Warsaw, Poland.  Abstract number LBF 12/1 
 
 
Loveday C, MacRae ED, Johnson M.  A marked increase in prevalence of ART 
mutations in naïve patients with HIV / AIDS in the UK in 2002 – time to 
recommend resistance testing prior to therapy.  [Abstract]  In 10th Conference 
on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, 
Massachusetts, USA.  Abstract number 632. 
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